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ABSTRACT
Cancer metastasis is an important process in cancer progression. This process is
facilitated by proteases that promote degradation of the extracellular matrix, cell migration
and cell invasion. Angiogenesis is important to the metastatic process and also involves
extracellular matrix degradation, endothelial cell migration and invasion. Proteases such as
plasmin and matrix metalloproteinases are responsible for degradation of the extracellular
matrix, facilitating cancer cell invasion and subsequent metastasis. These proteases are also
important in promoting tumour angiogenesis. Therefore, developing methods to target
these proteases may effectively inhibit cancer metastasis and tumour angiogenesis. TAFI
is a plasma zymogen initially known for its role in attenuating fibrinolysis. TAFIa is formed
through cleavage by thrombin, plasmin or, by thrombin in complex with thrombomodulin.
TAFIa is a carboxypeptidase, cleaving carboxyl terminal lysine residues from plasminogen
binding sites on cell surface receptors, which are important in accelerating plasminogen
activation to plasmin. We have demonstrated that TAFIa is able to inhibit metastatic
behaviours, including breast cancer cell invasion, migration and collagen degradation. We
have shown that TAFIa inhibits these metastatic behaviours through attenuation of
plasminogen activation to plasmin. Additionally, we have demonstrated that TAFIa also
acts as an anti-angiogenic factor, inhibiting endothelial cell invasion, migration, tube
formation and collagen degradation. We have also shown that these effects are mediated
by the ability of TAFIa to inhibit plasminogen activation on the endothelial cell surface.
Taken together these results indicate that TAFIa is an anti-metastatic and anti-angiogenic
factor that may represent a novel therapeutic strategy to target cancer metastasis.
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Chapter 1

General Introduction

1

1.1 Cancer
Cancer is characterized as a disease of uncontrolled cell growth. It is the leading
cause of death in Canada, accounting for 30% of deaths [1]. Additionally, breast cancer is
the second leading cause of cancer-related deaths among Canadian women. It is estimated
that in 2015, 5,000 Canadian women died from breast cancer. Furthermore, the Canadian
Cancer Society estimates that 1 in 9 Canadian women will be diagnosed with breast cancer
in their lifetime, making breast cancer the most common type of cancer among Canadian
women [1].
Tumorigenesis is a multi-step process involving the accumulation of genetic
alternations that results in a malignant phenotype. There are many factors that have been
identified that promote tumorigenesis, including environmental factors and familial and
genetic influences. Hanahan and Weinberg described six hallmarks of cancer, which are
acquired characteristics that are attributed to cancer cells [2, 3]. These hallmarks are
alterations to cell physiology that promote tumorigenesis and cancer progression. The six
hallmarks of cancer described by Hanahan and Weinberg are: (i) sustaining proliferative
signals; (ii) resisting cell death; (iii) evading growth suppressors; (iv) enabling replicative
immortality; (v) activating invasion and metastasis; and (vi) inducing angiogenesis [2, 3].
Enhanced understanding of cancer biology has resulted in the proposal of additional
hallmarks of cancer, namely contributions from the immune system, as well as interactions
with the tumour stroma [4, 5]. The majority of cancer-related deaths can be attributed to
metastasis of cancer [6]. Metastasis arises, in part, by activation of cell invasion and
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promotion of angiogenesis. Targeting these events may prove to be a beneficial therapeutic
strategy to prevent the metastatic outcomes of the disease.
1.1.1 Cancer Metastasis
Cancer metastasis is responsible for approximately 90% of cancer-related deaths
[7]. Importantly, it is also the main cause of death in patients with breast cancer. Metastasis
is described as the spread of cancer from the primary tumour site to a secondary location
within the body. Many challenges exist when targeting metastasis and there are currently
no effective therapies to target this process. Therapeutic targeting of metastatic cancers is
problematic due to heterogeneity of metastatic lesions, tumour dormancy and drug
resistance [8, 9]. It is therefore vital to establish effective therapies that inhibit metastatic
growth and also therapies that prevent the metastatic process entirely.
The metastatic cascade is a complex multi-step process that involves: local
invasion; intravasation into the blood stream; survival in the circulation; extravasation; and
colonization of a distinct site [7]. Success at each step within the cascade is vital for the
ultimate goal of cancer metastasis.
Local invasion of cancer is facilitated by physiological processes including
extracellular proteolysis, cell migration and epithelial to mesenchymal transition (EMT)
[10]. Cell invasion is dependent on interactions in the tumour microenvironment between
the cancer cells, basement membrane and stromal cells [11]. The basement membrane is a
specialized extracellular matrix (ECM) that separates epithelial tissue from the stromal
surroundings. It is composed mainly of type IV collagen, laminins, and fibronectin, with
minor contributions from proteoglycans [12]. Physical properties of the ECM can promote

3

or hinder cell migration and regulation of this dynamic structure is important for cancer
progression [13].
Extracellular proteolysis is responsible for degradation of the ECM and basement
membrane, which provides a path for invading cancer cells to enter the stroma and
ultimately the circulation [14]. In normal tissue, extracellular proteolysis is a highly
controlled process; this process, however, is dysregulated in

most tumour

microenvironments due, in part, to increased expression of matrix-degrading proteases in
cancers that proteolytically digest ECM components [15]. There are a large number of
proteases that facilitate degradation of the basement membrane. This includes serine
proteases, such as plasmin and cathepsin G, matrix metalloproteinases (MMPs), and
cysteine proteases, namely cathepsins B and L [13]. Degradation of ECM is predominantly
mediated by plasmin and MMPs (see Section 1.3.2). Additionally, degradation of the ECM
releases sequestered growth factors that were trapped within the structure during ECM
assembly [14].
Cancer cells often acquire a biological program known as EMT, which promotes
local invasion and metastasis [16]. EMT is a complex cellular program in which epithelial
cells lose their adherent phenotype and cell polarity. This process is regulated by cell
signaling, mainly through TGF-β, Notch and Wnt, which results in the downregulation of
epithelial-associated genes (i.e. E-cadherin) and upregulation of mesenchymal-associated
genes (i.e. N-cadherin) [17-19]. Changes in gene expression of cadherins, integrins and
cytoskeletal proteins result in loss of cell-cell attachments and down-regulation of cell
adhesion molecules. This leads to loss of epithelial organization and acquisition of a
mesenchymal phenotype in which cancer cells detach from adjacent epithelial cells and
4

basement membrane, which promotes cell motility [16]. EMT in combination with
enhanced proteolytic activity, promotes cancer cell migration and invasion into the
surrounding stroma.
Intravasation is the process by which invading cancer cells enter the lymphatic
system or bloodstream [7]. While this process requires crosstalk between the cancer cells
and the tumour microenvironment, the underlying mechanisms are not fully understood. In
order for intravasation to occur, cancer cells must cross the endothelial layer by
transendothelial migration. This process is thought to occur in two ways. The cancer cells
can transmigrate through endothelial cell junctions (paracellular) or can cross through the
endothelial cell body (transcellular) [20]. Cytokines and chemokines, secreted from the
tumour and stromal cells, increase the permeability of the endothelium, promoting
transmigration. Specifically, transmigration through endothelial cell junctions can be
accomplished through signalling by TGF-β, TNF-α and Notch, which result in remodelling
of endothelial junctions [21-23]. Proteolysis events mediated by MMPs also facilitate
endothelial junction remodelling, which also contributes to cancer cell transmigration [24].
Transcellular intravasation involves the formation of a pore through cytoskeletal and
membrane remodelling, which allows the cancer cell to cross through the endothelial cell
[25, 26]. Although this route is described in literature, it is thought that transendothelial
migration through cell junctions is the more frequent method of intravasation [20].
Once the cancer cells have intravasated into the bloodstream, circulating tumour
cells (CTCs) must be able to survive a number of stressors encountered in the circulation.
This includes forces of shear stress, the presence of immune cells, and induction of anoikis
[27]. CTCs are required to withstand shear stress caused by the flowing blood; platelets aid
5

in this task by associating with the CTCs [28]. Additionally, association with platelets
protects CTCs from immune cells found in the bloodstream [28]. In the absence of cell
adhesion, epithelial cells normally undergo anoikis, which is a form of programmed cell
death triggered by loss of anchorage [7]. In order for CTCs to survive the circulation, they
must evade anoikis. CTCs are able to escape anoikis by suppressing cell death signals [29].
Additionally, CTCs that have undergone EMT are more likely to survive the circulation,
as the mesenchymal phenotype allows these cells to evade cell death [30].
Surviving CTCs arrest in the capillary bed at a distinct organ site. This is facilitated
in part by platelets, which promote cancer cell adhesion to endothelial cells [31]. The
cancer cells must then exit the bloodstream or lymphatic system, through a process known
as extravasation. It is not expected that mechanisms that drive intravasation are identical
to those driving extravasation, due to stromal contributions during the process of
intravasation [7]. The factors that drive extravasation are dependent on the site of
dissemination. For example, studies have demonstrated that factors that promote
extravasation of breast cancer cells in the lungs are distinct from factors that influence
extravasation in the bone [32]. Padua et al. identified that angiopoietin-like 4 increased
breast cancer transendothelial migration to promote extravasation through lung capillaries
[33]. Additionally, factors such as COX2, MMP-1 and MMP-2 have been shown to
promote pulmonary vascular permeability and extravasation to the lungs [34]. A study by
Kang and coworkers demonstrated that a gene expression signature, including IL-11,
CTGF, CXCR4 and MMP-1, promotes breast cancer metastasis to the bone [35].
Following extravasation, the cancer cells must survive in the foreign
microenvironment and subsequently colonize. Metastatic sites differ depending on the
6

origin of the primary tumour, and therefore it proposed that microenvironment of the
metastatic site is vital for colonization. The seed and soil hypothesis speaks to this concept,
stating that the cancer cells are the “seeds” and the foreign organ is the “soil” and the two
must be compatible for colonization to occur [36]. The metastatic niche model builds on
this hypothesis, emphasizing the importance of the metastatic microenvironment in
facilitating colonization at the secondary site [37]. Others argue that cancer cells are more
important determinants of colonization then the contributions of the metastatic
microenvironment [38]. For colonization to occur, cells entering the new organ must
become resistant to the host organ defences to survive [9]. Disseminated cells often survive
in a state of dormancy which is thought to be induced by the new host microenvironment,
however little is known about the underlying mechanisms responsible for this phenomenon
[39]. Disseminated cells must not only survive this dormant state, but also facilitate
metastatic outgrowth by reinitiating tumour growth and proliferation [9]. Ultimately,
colonization is highly complex and further studies are necessary to delineate factors
influencing contributions of the cancer cells and metastatic microenvironment in this
process.
Understanding mechanisms that promote the metastatic cascade can aid in the
development of therapeutic strategies to combat this phenomenon. Theoretically, there are
a number of factors that can be targeted in the metastatic cascade. Current therapies target
growth of the primary tumour and have limited impact on the metastatic lesion.
Extracellular proteolysis plays a vital in the initial stages of the metastatic cascade and also
promotes metastasis at later stages. Therefore, targeting proteolytic events may be a
beneficial therapeutic strategy. Several clinical trials attempted to target the proteolytic
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activity of MMPs, using MMP inhibitors [40]. However, these trials failed due to sideeffects of the inhibitors. These inhibitors were broad spectrum with resulted in off-target
effects [41]. These trials were also conducted in patients at advanced stages of the disease,
while pre-clinical studies were initiated in animals at early stages [42]. These studies were
conducted in patients with established metastatic lesions and therefore targeting initial
stages of metastasis or studying preventative therapeutics were not possible in these clinical
trials. Additionally, there is redundancy among proteases in the tumour microenvironment
and therefore it may be beneficial to target proteases upstream of MMPs.

1.2 Tumour Angiogenesis
Hanahan and Weinberg described sustained angiogenesis as one of the six
hallmarks of cancer [2, 3]. Angiogenesis is the sprouting of new vessels from pre-existing
blood vessels. Vascular remodelling, through angiogenesis, is an important step in cancer
progression, as it provides the tumour with necessary nutrients and also provides an escape
route for metastatic tumours. An imbalance of angiogenic inhibitors and activators can
stimulate activation of the angiogenic switch, which is point at which tumours transition
from an avascular phase to promote vascularization. Most tumours begin to grow in an
avascular phase, in which they reach a steady-state of proliferation and apoptosis. In the
tumour microenvironment, the angiogenic switch in endothelial cells is triggered when the
tumour growth results in hypoxia and nutrient deprivation [43]. As a consequence, the
effects of angiogenesis activators, such as vascular endothelial growth factor (VEGF),
come to outweigh those of inhibitors, such as thrombospondin-1. Tumours induce
angiogenesis by secreting angiogenic activators, such as VEGF and bFGF. Release of
angiogenic activators stimulates perivascular detachment and vessel dilation [44]. It also
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results in the activation of endothelial cells. Leaky vessels allow plasma proteins to form a
matrix to aid in endothelial cell migration [44]. Basement membrane and ECM degradation
facilitate endothelial cell migration into the stromal surroundings [45]. Angiogenic factors
secreted from the tumour and stromal cells stimulate endothelial cell proliferation and
vessel sprouting through cell migration. Perivascular cells are attracted to the sprouting
vessels, facilitating vascular basal lamina formation around the new vessel [46].
In addition to playing a pivotal role in the metastatic cascade, extracellular
proteolysis promotes angiogenesis by release of sequestered growth factors and by
facilitating cell migration [14]. Proteases such as MMPs and plasmin are able to cleave
matrix components, which results in the release of sequestered VEGF, which further
stimulates the angiogenic switch. Degradation of the ECM also provides a path for
proliferating endothelial cells to sprout into new vessels [44].
Blood vessels formed through tumour angiogenesis are irregular. They are
morphologically distinct from normal blood vessels and often contain irregular branching
patterns [44]. Perivascular cells are often poorly associated with newly formed vessels,
resulting in increased vascular permeability. Blood within the tumour vasculature often
flows bidirectionally and at a much slower rate than in normal blood vessels [47]. Irregular
blood vessel formation results in increased angiogenic activators emanating from leaky
vessels [46]. Angiogenic signals in the tumour microenvironment allow for constant
growth of blood vessels and prevent endothelial cell quiescence [44].
Tumour angiogenesis is important to the metastatic process. It provides the tumour
cells with an escape route. The irregular shape and increased permeability of the tumour
vasculature facilitates the intravasation process [7]. Additionally, angiogenesis is pivotal
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to the colonization step of metastasis [7]. Activation of the angiogenic switch during
colonization allows to the metastatic lesion to transition from the avascular phase to
promote vascularization [48], which is essential for growth of micrometastases [49].

1.3 Plasminogen Activation System
Plasminogen is a 791-amino acid plasma zymogen secreted by the liver [50, 51]. It
circulates at an approximate concentration of 2 µM [52]. Plasminogen consists of an
amino-terminal tail domain, five kringle domains, and a carboxyl-terminal trypsin-like
latent serine protease domain [53]. Native plasminogen has an amino-terminal glutamic
acid and is therefore referred to as Glu-plasminogen. Glu-plasminogen has a closed tight
conformation making it less accessible for activation [54]. Cleavage of Glu-plasminogen
at its Lys77-Lys78 bond by plasmin results in the formation of Lys-plasminogen which has
a more open conformation and is more susceptible to plasminogen activators (Fig. 1.1)
[55]. Cleavage of plasminogen to form plasmin results in a heavy chain consisting of the
kringles, disulfide-bonded to the light chain consisting of the protease domain.
There are two physiological plasminogen activators, urokinase plasminogen
activator (uPA) and tissue-type plasminogen activator (tPA). uPA mediates plasminogen
activation in the pericellular context, while tPA mediates plasminogen activation in the
context of fibrin [56]. uPA is secreted as a zymogen, pro-uPA, and becomes active
following proteolytic cleavage by plasmin. Activation of pro-uPA to uPA by plasmin is
enhanced on the cell surface when pro-uPA is bound to its receptor urokinase plasminogen
activator receptor (uPAR) [57-59]. tPA is secreted as a single-chain protein, that is
proteolytically active. Cleavage of single-chain tPA by plasmin yields two-chain tPA,
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which exhibits 50-fold enhanced activity when compared to single chain tPA [60]. These
plasminogen activators are inhibited by two members of the serine protease inhibitor
superfamily (SERPINS), namely plasminogen activator inhibitors 1 and 2 (PAI-1 and PAI2) [56].
1.3.1

Plasminogen Receptors
Plasminogen activation is under tight control. Plasmin formation does not occur at

a physiologically-relevant rate in the absence of either fibrin or certain cell surfaces.
Accordingly, plasmin activity is only elaborated where it is required. The presence of
excess concentrations of SERPINs such as antiplasmin and α2-macroglobulin ensure that
plasmin activity is not disseminated systemically. In the tumour microenvironment, cell
surface plasminogen activation likely plays a vital role. Indeed, markers of plasminogen
activation on the cell surface are prognostic for cancer progression and metastasis (vide
infra).
Plasminogen receptors play a vital role in activation of plasminogen to plasmin on
the cell surface. They are responsible for localization of plasminogen activation, which is
important in mediating plasmin-dependent processes. Plasminogen receptors are also
important in accelerating plasminogen activation on the cell surface and protecting plasmin
from its natural inhibitor, antiplasmin [61]. Plasminogen receptors are found on a range of
cell types, including endothelial cells, monocytes, macrophages and cancer cells [62-64].
Plasminogen binds to plasminogen receptors most commonly through lysine binding sites
within its kringle domains [65].
The majority of plasminogen receptors mediate their interaction with plasminogen
through lysine binding (Fig. 1.1). Based on the characteristic of lysine binding, there are
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four classes of plasminogen receptors [60, 62]. The first class contains a carboxyl-terminal
lysine residue upon synthesis and promotes plasminogen activation. The second class lacks
a carboxyl-terminal lysine residue when synthesized, but upon proteolytic cleavage a
carboxyl-terminal lysine becomes exposed. The third class of plasminogen receptors do
not possess either a carboxyl-terminal lysine residue or internal lysine residue that can be
exposed, and yet can still accelerate plasminogen activation. The fourth class of receptors
are molecules that bind to plasminogen but do not promote plasminogen activation [60,
62].
The majority of plasminogen receptors possess a carboxyl-terminal lysine or an
internal lysine residue that can be exposed upon cleavage. The importance of lysine binding
in plasminogen activation has been demonstrated using lysine analogs and basic
carboxypeptidase activity. Binding of lysine analogs to plasminogen kringles block
plasminogen binding to the cell surface [66]. Lysine analogs have also been shown to allow
Glu-plasminogen to adopt a more open conformation, making it more accessible to
plasminogen activators in solution [67]. Additionally, studies have shown that
carboxypeptidase B can inhibit plasminogen activation by cleaving carboxyl-terminal
lysine residues from plasminogen receptors [68].
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Figure 1.1: Carboxyl-terminal lysine residues in plasminogen activation on the cell
surface and on fibrin.
Cell surface plasminogen receptors can possess a carboxyl-terminal lysine residue (shown
in red) or an internal lysine residue that can be cleaved to expose a carboxyl-terminal lysine
residue. These residues allow for plasminogen binding to the cell surface and accelerate
plasminogen activation to plasmin. TAFIa cleaves carboxyl-terminal lysine residues from
plasminogen receptors on the cell surface, attenuating plasminogen activation. When fibrin
is cleaved into fibrin degradation products (FDPs) by plasmin, carboxyl-terminal lysine
residues on FDPs are exposed. Plasminogen is able to bind to FDPs, accelerating
plasminogen activation. TAFIa cleaves carboxyl-terminal lysine residues from FDPs,
preventing plasminogen binding and activation. Adapted from reference [69].
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Plasminogen receptors have been shown to enhance cell surface plasminogen
activation, by accelerating conversion of Glu-plasminogen to Lys-plasminogen. Binding
of Glu-plasminogen to plasminogen receptors results in a conformational change that
exposes the plasmin cleavage site on plasminogen, promoting the formation of Lysplasminogen [70-72]. Plasmin generation is dependent on a positive feedback mechanism
that allows for accelerated plasminogen activation. Glu-plasminogen is activated to Gluplasmin by proteolytic cleavage at Arg561-Val562 by plasminogen activators (Fig. 1.2)
[73]. The small amount of Glu-plasmin generated is able to accelerate further activation of
plasminogen, by activation of plasminogen activator and conversion of Glu-plasminogen
to Lys-plasminogen. Plasmin cleaves Glu-plasminogen at Lys77-Lys78 resulting in Lysplasminogen, which has a more open conformation and is more susceptible to plasminogen
activators. Lys-plasminogen is subsequently proteolytically cleaved at Arg561-Val562, by
plasminogen activators resulting in the generation of Lys-plasmin [73]. Plasmin is a broadspectrum specificity serine protease, as it has been shown to cleave a large number of
substrates. Plasmin is important for physiological and pathological functions, including
fibrinolysis, inflammation, angiogenesis, wound healing and cancer metastasis [52, 62, 74].
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Figure 1.2: Activation of Plasminogen to Plasmin.
Native plasminogen circulates as a zymogen with an amino-terminal glutamic acid. Gluplasminogen is converted to Glu-plasmin through proteolytic cleavage at Arg561, by
plasminogen activators (PA), exposing the serine protease active site. Plasmin cleaves Gluplasminogen at Lys77, generating Lys-plasminogen. Lys-plasminogen has a more open
conformation and is more susceptible to cleavage by plasminogen activators. Lysplasminogen is cleaved by plasminogen activators at Arg561 to produce Lys-plasmin.
Used with permission from reference [75].
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1.3.2

Plasminogen Activation System in Metastasis and Angiogenesis
The plasminogen activation system has a well-established role in cancer

progression and metastasis. Factors of the plasminogen activation system are
overexpressed in most cancers and their expression frequently correlates with poor
prognosis. Expression of plasminogen receptors is correlated with invasive breast cancer
[76, 77]. Additionally, elevated levels of plasminogen receptors in breast cancer is
associated with decreased survival [77-79]. Increased uPAR levels in breast cancer is an
independent prognostic marker of shortened relapse-free survival [80-82]. Levels of uPA
and PAI-1 are also prognostic markers in breast cancer and uPA may be an independent
variable used to determine recurrence [83-85].
Plasminogen activation system is involved in several functions related to cancer,
including cell adhesion, cell migration, proliferation, angiogenesis and metastasis [74, 86].
Activation of plasminogen to plasmin promotes metastasis through several mechanisms.
Plasmin itself cleaves extracellular matrix (ECM) components, such as fibronectin,
vitronectin, laminin and collagen, facilitating degradation of the ECM, cell invasion and
ultimately metastasis (Fig. 1.3) [87-89]. Plasmin also activates other proteases and growth
factors that promote ECM degradation, tumour growth and angiogenesis. Specifically, in
vitro plasmin can activate many MMPs, including MMP-1, 2, 3, 9, 13 and 14 [52].
Activation of MMPs in the tumour microenvironment have been shown to be vital in cancer
metastasis and angiogenesis, specifically through ECM degradation, growth factor
activation and cell signalling [74, 90].
By degrading the ECM, plasmin also releases sequestered growth factors, whose
downstream targets facilitate tumour progression. Studies, both in vitro and in vivo, have
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demonstrated that plasmin can liberate basic fibroblast growth factor (bFGF) [91, 92]. This
growth factor mediates cellular processes such as cell proliferation, and studies have
demonstrated its involvement in angiogenesis [93, 94]. Studies have also shown that bFGF
can increase secretion of uPA, suggesting a possible role in mediating positive feedback
for plasminogen activation [95]. Furthermore, release and activation of sequestered VEGF
by plasmin and MMPs stimulates angiogenesis in the tumour microenvironment [74].
Plasmin is also responsible for proteolytic activation of latent TGF-β1 to its active form,
which mediates cancer cell invasion and metastasis through promotion of EMT [96].
Studies have also demonstrated that intravasation is more effective when cancer cells have
high levels of uPAR and uPA and inhibition of plasmin hindered the process of
intravasation [97, 98].
The plasminogen activation system is also able to promote cancer cell invasion and
metastasis through cell signalling by uPAR. Interaction of uPA to uPAR mediates
activation of various signalling pathways that influence cell motility [99]. uPAR does not
possess an intracellular domain and therefore uPAR-mediated intracellular signalling
results from interaction with various integrin and ECM proteins [100]. Overexpression of
uPAR and binding of uPA to its receptor promotes cell migration and adhesion through
binding with integrins and ECM proteins [99]. Specifically, studies have demonstrated that
binding of uPA to uPAR stimulates cell invasion and migration by cell signalling through
Ras/Raf/MEK/ERK pathway [101].
Inhibition of plasminogen activation, by targeting plasminogen activators or
plasminogen receptors, has been thought to be viable therapeutic strategy to inhibit the
effects of the plasminogen activation system on metastasis [62, 102, 103]. Specifically,
17

carboxyl-terminal lysine residues on plasminogen receptors are an attractive target, given
the importance of these residues in plasminogen activation on the cell surface. Targeting
of the plasminogen activation system would impact proteolytic events downstream of
plasmin formation.
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Figure 1.3: Plasminogen activation system in cancer.
Pro-uPA binds to uPAR on the cell surface promoting activation to active uPA through
cleavage by plasmin. Plasminogen (Plg) binds to its cell surface plasminogen receptor (PlgR) which accelerates uPA-mediated Plg activation to plasmin (Pln). Pln activates proMMPs to their active MMP form and together Pln and MMPs degrade the ECM, facilitating
tumour cell invasion and metastasis. This system can be inhibited by PAI-1 and PAI-2,
which inhibit uPA and α2-antiplasmin, which inhibits Pln.
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1.4 Thrombomodulin (TM)
Thrombomodulin (TM) is 557-amino acid long, single-chain type 1 transmembrane
protein [104]. It is found on the surface of endothelial cells, monocytes, smooth muscle
cells, neutrophils and is also expressed in cancer cells, including breast [105-109]. TM is
comprised of five domains, as shown in Figure 1.4. The extracellular domains of TM
include an amino-terminal C-type lectin-like domain, six epidermal growth factor (EGF)like repeats, and a serine/threonine rich domain [104]. TM also contains a transmembrane
domain and a short cytoplasmic tail. This multifaceted glycoprotein is involved in vital
physiological functions such as inflammation and coagulation, and studies have also
demonstrated its involvement in cancer biology [110-112].
The C-type lectin-like domain of TM is 222 amino acids in length and has
homology with other C-type lectins. However, the lectin-like domain of TM does not
contain a calcium binding motif unlike traditional C-type lectins [113, 114]. Additionally,
while conventional C-type lectins bind only to carbohydrates, the lectin-like domain of TM
can also bind protein ligands. Binding of the C-type lectin-like domain of TM to several
ligands mediates inflammation and cell adhesion [115, 116]. The first evidence of the antiinflammatory role of TM was demonstrated by generating mice lacking the lectin-like
domain of TM [115]. These mice were more susceptible to LPS-induced sepsis. It was later
determined that the lectin-like domain of TM can bind the carbohydrate Lewis Y antigen
in LPS found on gram-negative bacteria [117]. Binding to TM prevents LPS binding to
CD14, and therefore decreases the inflammatory response stimulated by LPS. The antiinflammatory effects of TM were further demonstrated when Abeyama et al. reported that
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binding of high mobility group box 1 (HMGB1) protein to the lectin-like domain of TM
sequesters HMGB1, preventing it from eliciting a pro-inflammatory response [118].
The EGF-like domain is responsible for the thrombin cofactor activity of TM.
Thrombin binds to EGF-5 and EGF-6 of TM and this interaction mediates the activation
of both thrombin-activatable fibrinolysis inhibitor (TAFI) and protein C (PC) by thrombin
[119, 120]. Specifically, in the presence of TM, catalytic efficiencies of thrombin-mediated
activation of both TAFI and PC are enhanced by over 1000-fold [121, 122]. Importantly,
domain deletions have identified essential domains necessary for TAFI and PC activation
by thrombin/TM. Specifically, the c-loop of EGF-3 through EGF-6 are required for TAFI
activation, while the interdomain loop connecting EGF-3 to EGF-4 plus EGF4-6 are
required for PC activation. Using site-directed mutagenesis, Wang and coworkers
identified residues within the EGF-like domain of TM that are important for activation of
TAFI and PC by thrombin [123]. Amino acids Val340 and Asp341 within the c-loop of
EGF-3 of TM were found to be vital for activation of TAFI. Amino acid Phe376 in EGF4 was reported to be necessary for protein C activation. Glaser et al. reported that TM can
be oxidized at Met388 in the linker region between EGF-4 and EGF-5 [124]. Interestingly,
oxidation of Met388 drastically reduces thrombin/TM mediated activation of PC, but does
not impact activation of TAFI [123]. This may act as a potential mechanism to support
preferential activation of TAFI over PC at the site of injury, in which neutrophils would
promote TM oxidation [108, 125]. Furthermore, mutagenesis of Gln387 to a proline
abolishes thrombin binding to TM, and therefore results in significant reduction of both
TAFI and protein C activation [123].
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The anti-coagulation function of TM is mediated through binding with thrombin.
Interaction with TM inhibits the pro-coagulant functions of thrombin, by altering its
substrate specificity. This results in inhibition of anion-binding exosite-mediated thrombin
binding to fibrinogen, preventing cleavage of fibrin [122], while promoting activation of
protein C to activated protein C (APC). Structural studies suggest that TM binds to PC,
presenting it optimally as a substrate for thrombin in the ternary complex [126]. APC
possesses anti-coagulant activity by cleaving activated coagulation factors Va and VIIIa,
which attenuates further generation of thrombin [122, 127, 128]. Paradoxically, TM also
acts as an anti-fibrinolytic molecule, through activation of TAFI. As previously mentioned,
the thrombin/TM complex activates TAFI to its active form activated TAFI (TAFIa), which
possesses basic carboxypeptidase activity [121]. TAFIa attenuates fibrinolysis by
removing carboxyl-terminal residues from partially degraded fibrin [129]. These residues
act as cofactors for plasminogen activation to plasmin during fibrinolysis, and are
important in several positive feedback mechanisms in fibrinolysis. The anti-coagulant and
anti-fibrinolytic activities of TM are dependent on not only TM concentrations but also on
complex

interplay between

coagulation

and

fibrinolysis

factors.

Specifically,

concentrations of activators, inhibitors and cofactors involved in coagulation and
fibrinolysis contribute to the anti-coagulant and anti-fibrinolytic functions of TM.
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Figure 1.4: Structure of Thrombomodulin.
Thrombomodulin contains a C-type lectin-like domain, six EGF-like repeats, a
serine/threonine rich domain, a transmembrane domain and cytoplasmic tail. The structure
of an EGF-like repeat is shown, containing three disulfide bonds within the three loop
structure. The EGF-like domain is responsible for the cofactor functions of TM, involving
thrombin-mediated activation of TAFI and protein C. EGF5-6 bind to thrombin, EGF3-6
are necessary for activation of TAFI and EGF4-6 are necessary for activation of protein C.
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1.4.1

Thrombomodulin in Cancer and Angiogenesis
TM is expressed in several cancers, including breast, bladder, cervical, ovarian,

colorectal, melanoma, and prostate [109, 130-136]. Loss of TM expression is associated
with advanced disease stage and metastatic potential. Studies in melanoma and prostate
cancers have demonstrated that loss of TM expression is a result of hypermethylation of
the THBD promoter region [135, 136]. Furthermore, loss of TM has been associated with
poor prognosis in several cancers. Specifically, TM expression was found to be
significantly inversely correlated to survival in non-small cell lung cancer [137]. In
hepatocellular carcinoma, tumours positive for TM expression were associated with higher
recurrence-free survival compared to tumours negative for TM [138]. This study also found
that TM-positive tumours had lower frequencies of intrahepatic metastasis. In addition,
Hamatake et al. reported loss of TM expression in lung squamous cell carcinoma was
associated with decreased survival in patients [139]. They also found decreased TM
expression in metastatic lesions compared to primary tumours. In breast cancer patients,
low TM expression was correlated with high relapse rates [109]. In bladder cancer,
decreased TM expression was found to be correlated with advanced clinical stage [130].
Therefore, the evidence is consistent with the idea that TM is an anti-metastatic factor,
although mechanistic studies are required to demonstrate a direct role for this factor.
Indeed, researchers have sought to understand the role of TM in regulating
metastatic potential. Specifically, a study using murine melanoma cells indicated that TM
is capable of inhibiting cell invasion in vitro and in vivo [134]. Furthermore, overexpression
of TM suppressed migration of both cervical and ovarian cancer cells in vitro [131, 132].
Wu and coworkers reported that TM mediates migratory ability of prostate cancer cells by

24

regulating epithelial to mesenchymal transition (EMT) [140]. Additionally, silencing of
TM increased invasiveness of bladder cancer, both in vitro and in vivo. Decreased TM in
bladder cancer also resulted in increased tumour growth, angiogenesis and EMT. The
mechanisms by which TM suppresses cancer cell invasion and migration are not fully
understood, however several studies have demonstrated an important role for TM in
mediating EMT. Specifically, a study found that TM expression is inversely correlated to
Snail expression in tumour cells [141]. Furthermore, the same study found that decreased
TM expression inhibits trafficking of E-cadherin to the cell membrane [141]. Recently,
Zheng et al. reported that thrombomodulin reduces metastatic potential of lung cancer cells
by up-regulating E-cadherin expression [142]. This is consistent with studies in cervical,
prostate and liver cancer, in which down-regulation of TM decreased E-cadherin
expression [131, 140, 143].
Recently, Horowitz and coworkers demonstrated the importance of the thrombinbinding domain of TM on metastasis in vivo [144]. Lack of thrombin binding to TM
resulted in a metastatic phenotype in nude mice. This indicates a potential role for the
thrombin/TM complex in mediating the anti-metastatic effects of TM. Given that the
thrombin/TM complex is responsible for the activation of TAFI and protein C, this result
suggested a role for one or both of these thrombin/TM substrates in mediating the antimetastatic effects of TM.
Thrombomodulin has been shown to be both pro- and anti-angiogenic. Shi and
coworkers reported that a variant of TM that only included the EGF-like domain and the
serine/threonine rich domain enhanced angiogenic responses, in vitro and in vivo [145].
This was followed up with a more recent study that determined that this variant of TM
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induced angiogenesis by activating Type 1 fibroblast growth factor receptor (FGFR1)
[146]. Using site-directed mutagenesis, this study reported that the effects of TM are
independent of its ability to activate protein C. Conversely, the same group found that the
C-type lectin-like domain of TM acts as an anti-angiogenic factor, by interacting with
Lewis Y antigen [147]. This indicates that depending on the stimulus, TM may act as both
a pro- and anti-angiogenic factor.

1.5 Thrombin-Activatable Fibrinolysis Inhibitor (TAFI)
Since 1989, TAFI has been discovered independently by several different groups,
based on various characteristics. In 1989, Hendricks et al. described basic
carboxypeptidase activity in serum that disappeared following 2-hour incubation at 37°C
[148]. It was determined that this carboxypeptidase activity was unrelated to the
constitutively active plasma carboxypeptidase N. Due to the instability of this newly
described carboxypeptidase, it was named “unstable” carboxypeptidase (or CPU). Also in
1989, in an independent study, Campbell and Okada identified a basic carboxypeptidase in
serum that cleaved carboxyl-terminal arginine residues, preferentially over lysine [149].
Therefore, they it was given the name arginine carboxypeptidase (or CPR). In 1991, a
plasminogen binding protein was isolated from plasma and named procarboxypeptidase B
(proCPB) because cDNA sequence analysis revealed this protein is homologous to
pancreatic carboxypeptidase B [150]. In 1995, Bajzar and coworkers purified a plasma
zymogen that when activated by thrombin, inhibits fibrinolysis. Therefore, they named this
zymogen TAFI [151]. Amino acid sequencing analysis revealed that CPU, CPR, proCPB
and TAFI are identical proteins [150-152].
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Since its initial discovery, the role of TAFI in attenuating fibrinolysis has been well
established. TAFI, when activated to its active form, TAFIa, cleaves carboxyl-terminal
lysine residues from partially degraded fibrin. These lysine residues act as plasminogen
and tPA binding sites on fibrin, which accelerate plasmin generation and ultimately
fibrinolysis. By removing these lysine residues, TAFIa is able to inhibit plasmin formation
and attenuate fibrinolysis. In addition to inhibiting plasminogen activation in the context
of fibrinolysis, TAFIa has also been shown to inhibit cell surface plasminogen activation,
through cleavage of plasminogen receptors [69].
1.5.1

CPB2 Gene Expression and Regulation
CPB2 is the gene encoding TAFI, as designated by the Human Genome

Organization (HUGO), and is located on chromosome 13 (specifically 13q14.11) [152].
The gene contains 11 exons and 10 introns, spanning 48 kilobase pairs of genomic DNA
[153]. There have been no genetic disorders identified in association with CPB2. CPB2 is
mainly transcribed in the liver, however extra-hepatic expression of CPB2 has been
observed. Specifically, CPB2 mRNA has been detected in platelet α-granules,
megakaryocytes, monocytes, monocyte-derived macrophages, adipocytes and endothelial
cells [154-157]. However, our study, using an appropriate method of TAFI detection, failed
to yield evidence of TAFI protein in many of these sites [157]. In our study TAFI protein
was detected in macrophages and megakaryocytes.
Plasma TAFI concentrations vary within the population from approximately 75 to
275 nM; however, genetic factors such as SNPs in CPB2 only account for approximately
25% of the variability [158, 159]. It is thus thought that the majority of variation associated
with plasma TAFI levels arises from gene regulation. Understanding transcriptional and
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post-transcriptional regulation of CPB2 provides important insight into factors influencing
plasma TAFI concentrations, in haemostasis, during inflammation and disease states.
Regulation of CPB2 occurs through different molecular mechanism including regulation
of gene expression, mRNA stability and alternative splicing of transcripts.
The 5’ and 3’ flanking regions of CPB2 have been extensively studied. The 5’
flanking region lacks a TATA box and instead transcription is initiated from multiple
transcription start sites [153]. This feature is common among some proteins with liverspecific expression. Based on the transcription initiation start site used, 5’-untranslated
regions (UTR) of the mRNA transcripts vary in length. Nucleotides -80 to -73 of the 5’
flanking region are important for basal hepatic expression, as deletion of these base pairs
results in an elimination of promoter activity. Several transcription factor binding sites have
been identified in the promoter region of CPB2. A CCAAT/enhancer binding protein
(C/EBP) site [160] may be important in restricting CPB2 expression to certain cells. A
hepatocyte nuclear factor-1α (HNF-1α) binding site was also found in the promoter region
and is important for liver-specific expression of CPB2 [161]. Furthermore, a nuclear factorY (NF-Y) binding site is important for basal promoter activity of CPB2 [161]. Additionally,
a glucocorticoid responsive element (GRE) was identified in the promoter and a synthetic
glucocorticoid hormone analog was able to stimulate CPB2 promoter activity [162].
Glucocorticoid is an important steroid hormone that functions to reduce inflammation, by
up-regulating the expression of anti-inflammatory proteins. The presence of a GRE in the
CPB2 promoter indicates a potential role for TAFI in inflammation. Hori and coworkers
reported that CPB2 gene expression in adipocytes is regulated by insulin through
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phosphatidylinositol-3-kinase (PI3K)/Akt pathway [156], although others studies called
into question whether CPB2 is truly expressed in those cells [155].
The 3’UTR of CPB2 plays an important role in mRNA regulation. Analysis of the
3’ flanking region of CPB2 revealed sequences that correspond to three different
polyadenylation sites [153]. Use of these sites during mRNA processing results in
transcripts with different length 3’ UTR, specifically 390, 423 or 549 nucleotides in length
[153]. Studies have demonstrated that the stability of the mRNA transcript is dependent
the polyadenylation site used [163]. Use of the first polyadenylation site results in the
shortest and most stable transcript. As the length of the transcript increases, there is a
decrease in stability. Hence, use of the third polyadenylation site results in the longest and
least stable transcript.
Studies have identified both cis-elements and trans-acting factors that modulate
transcript stability, polyadenylation site usage and transcript abundance. Inflammatory
cytokines interleukin-1β (IL-1β) and IL-6 were found to decrease the stability of the CPB2
transcript and shift the abundance of the transcript to the longest and least stable [163].
Treatment of IL-1β and IL-6 therefore promote use of the third polyadenylation site.
Progressive deletions of nucleotides within the 3’ flanking region identified one stability
element upstream of the first polyadenylation site, as well as three instability elements, one
located upstream of each polyadenylation site. Mobility shift assay identified tristetraprolin
(TTP) as a trans-acting factor that binds to the third instability element (upstream of the
third polyadenylation site) and causes destabilization of the transcript [164]. A recent study
determined that TNF-α and lipopolysaccharide (LPS) down-regulated CPB2 mRNA and
TAFI protein levels in HepG2 cells [165]. These pro-inflammatory factors effect mRNA
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stability dependent on TTP binding. Furthermore, the same study found that treatment of
HepG2 cells with anti-inflammatory cytokine IL-10 increased mRNA stability and
abundance, independent of TTP binding [165]. This study also identified HuR as a transacting factor that binds to the 3’ UTR and stabilizes the transcript. Masuda and coworkers
reported that the PI3K pathway is important in post-transcriptional regulation of CPB2 in
hepatocytes, as use of a PI3K inhibitor decreased mRNA abundance and stability [166].
Intriguingly, cytokines that influence mRNA regulation in hepatocytes have distinct effects
in macrophages [165]. Specifically, pro-inflammatory factors LPS, TNF-α, IL-8 and IL-6
+ IL-1β all resulted in an increase in mRNA abundance and stability. These results indicate
that post-transcriptional regulation of CPB2 is tissue-specific.
Several single nucleotide polymorphisms (SNPs) have been identified throughout
the CPB2 gene. Specifically, SNPs have been identified in the 5’ flanking region, the
coding region the 3’ flanking region [167, 168]. In addition to SNPs reported in literature,
HapMap and dbSNP databases revealed 72 and 339 SNPs in CPB2, respectively [169].
SNPs within the 5’ flanking region of CPB2 were not found to influence promoter activity,
and indeed they are present between known transcription factor binding sites. Of the SNPs
identified in the coding region, only two result in amino acid substitutions, +505G/A and
+1040C/T [168]. These nucleotide changes correspond to Ala147Thr and Thr325Ile,
respectively. Three SNPs in the 3’ flanking region, +1344 G/A, +1542 C/G and +1583
A/T, all correspond to changes in CPB2 mRNA stability [167] and thus may be causally
related to variation in plasma concentrations of TAFI.
Matsumoto and coworkers identified an alternatively spliced variant of TAFI which
was found in the hippocampus [170]. This TAFI variant is translated from a CPB2
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transcript lacking exon 7 and contains a 52-base pair deletion in exon 11. They reported
that this variant of TAFI can cleave β-amyloid precursor protein (APP) and Aβ1-42, which
is an APP-derived β-amyloid peptide. Further studies identified additional splice variants
in various cell types. Cagliani et al. reported CPB2 mRNA lacking exon 7 in HepG2 cells
[171]. Exon 7 skipping was also reported in Dami megakaryocytes, THP-1-derived
macrophages, peripheral blood mononuclear cells, platelets, testis and cerebellum [172].
Additionally, exon 7 and 8 skipping was detected in liver and megakaryocytes [172]. It
was determined that these spliced transcripts of CPB2 are translated but are retained within
the cell instead of being secreted. Alternative splicing of CPB2 may be a mechanism of
tissue specific down-regulation of CPB2 or may generate intracellular isoforms of TAFI
with novel functions.
1.5.2

Variations and Associations in Plasma TAFI Concentrations
Plasma TAFI concentrations have been shown to be influenced by certain disease

states. Studies have found an increase in plasma TAFI concentrations in patients with
diabetes, renal disease, primary hypothyroidism, Behcet’s disease, and polycystic ovary
syndrome [173-180]. Studies have demonstrated that obesity also influences plasma TAFI
levels, as they have been found to be higher in obese individuals versus non-obese
individuals [155]. On the other hand, patients with cirrhosis or inflammatory bowel disease
had plasma TAFI concentrations that were less than healthy individuals [181-183].
Clinical studies have also examined plasma TAFI concentrations as a potential risk factor
for certain cardiovascular diseases. Specifically, clinical studies have shown that elevated
plasma concentrations of TAFI are associated with increased risk for venous thrombosis,
venous thromboembolism and ischemic stroke [184-187].
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Plasma TAFI levels have been shown to increase with age in women but not men
[188, 189]. Additionally, there is an increase in TAFI levels in postmenopausal women
when compared to premenopausal women. Plasma TAFI concentrations decreased with
administration of selective estrogen receptor modulators, including HMR 3339 and
raloxifene [190, 191]. Additionally, there was a decrease in plasma TAFI levels using
hormone replacement therapy (HRT), specifically, transdermal or oral estradiol or estradiol
in combination with trimegestone [192, 193]. Conversely, studies have found no difference
in plasma TAFI concentrations upon administration of HRT and SERMs [194, 195]. A
study in HepG2 cells aided in the understanding of the role of hormones in CPB2
expression and regulation [196]. This study determine that estrogen and progesterone were
able to decrease expression of CPB2, although the estrogen and progesterone receptors
were not found to bind to the CPB2 promoter. The effects of these hormones were found
to be independent of the estrogen receptor and instead dependent on the PI3K pathway
[196]. Paradoxically, studies have demonstrated that plasma TAFI concentrations are
higher in pregnant women when compared to non-pregnant women [197-199]. Levels of
TAFI increased during the gestation period, peaking at 20-39 weeks and promptly
decreasing following delivery [197-199]. Therefore, though there is a clear role for sex
hormones in regulating plasma TAFI levels, the mechanistic details underlying these
observations and their physiological relevance remains unclear.
1.5.3

Structure and Activation of TAFI
The TAFI protein is synthesized as a 423 amino acid pre-proenzyme. It contains a

22 amino acid signal peptide that is cleaved prior to secretion [150]. The mature protein
therefore contains 401 amino acids, with a predicted molecular mass of 46 kDa. Due to
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glycosylation sites in the amino-terminal domain of the protein, the molecular mass of
TAFI when observed on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDSPAGE) is approximately 60 kDa [151]. TAFI contains two domains, the activation peptide
(spanning from Phe1-Arg92) and the catalytic domain (Ala93-Val401) [200].
The activation peptide of TAFI contains two parts. Phe1-Val76 form an open
sandwich antiparallel α/β-fold with four β-strands and two α-helices [200]. The linker
region, from amino acids Glu77-Arg92, is partially α-helical in structure [200]. There are
four N-linked glycosylation sites within the activation peptide of the protein (at Asn22,
Asn51, Asn63 and Asn86) [201]. Glycosylation of the activation peptide allows for proper
folding and secretion of the zymogen. The activation peptide is also important in
preventing substrates from entering the active site of the zymogen. Furthermore, the
activation peptide plays a vital role in restricting movement of the dynamic flap region,
prior to activation of TAFI. The dynamic flap is a region of the catalytic domain important
for the stability of TAFIa and will be discussed in more detail in section 1.5.4.
TAFI circulates in plasma as the zymogen. It is activated to its active form, TAFIa,
by proteolytic cleavage at Arg92 (Fig. 1.5). TAFI is activated by thrombin, plasmin or most
effectively by thrombin in complex with TM Thrombin and plasmin are both weak
activators of TAFI, therefore large amounts of these enzymes are required for TAFI
activation. The endothelial cofactor TM enhances catalytic efficiency of thrombinmediated TAFI activation by 1,250-fold [121]. Plasmin-mediated activation of TAFI is
enhanced approximately 15-fold by glycosaminoglycans [202]. Compared to plasmin in
the presence of glycosaminoglycans, TM-dependent activation by thrombin is still 10-fold
more efficient [202]. Therefore, the thrombin/TM complex is thought to be a vital
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physiological activator of TAFI. Indeed, a baboon model of sepsis identified thrombin/TM
as the predominant activator of TAFI in this setting in vivo [203]. Mosnier and coworkers
determined that, in plasma, thrombin/TM mediated activation of TAFI is optimal at 5 nM
TM [204]. Concentrations of TM greater then 5 nM decreased TAFI activation in plasma.
This phenomenon was also demonstrated using microvascular endothelial cells [204]. Cell
density (corresponding to an increase in TM concentration) was inversely correlated to
activation of TAFI. This was not observed in plasma deficient of protein C, indicating
competitive binding of these thrombin/TM substrates. Accordingly, it was concluded that
at concentrations of TM greater than 5 nM, activation of protein C inhibits thrombin
generation and subsequent activation of TAFI. Therefore, in vivo activation of TAFI by
thrombin/TM depends on the site of activation, as concentrations of TM vary depending
on blood vessel size [205].
There have been studies aimed at identifying residues important for TM-dependent
TAFI activation. Substitution of three consecutive lysine residues in the activation peptide
(Lys42-44) to alanines, resulted in an 8-fold reduction in thrombomodulin-dependent TAFI
activation [206]. Additionally, a recent study identified Arg12 and Arg377 of TAFI as
important residues in thrombin/TM mediated activation [207]. This is consistent with a
study by Plug and coworkers which demonstrated that mutagenesis of Arg12 to Gln
significantly decreased thrombin/TM mediated activation of TAFI [208]. It is thought that
Arg12 interacts directly with TM, while Arg377 interacts with thrombin in the presence of
TM. Additionally, Zhou et al. also demonstrated the importance of the activation peptide
in thrombomodulin-dependent activation of TAFI [209]. Deletion of amino acids 1-73 of
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the activation peptide abolished the cofactor ability of thrombomodulin, with respect to
thrombin-mediated activation of TAFI [209].
Once activated, TAFIa possesses basic carboxypeptidase activity, cleaving
carboxyl-terminal arginine and lysine residues from protein and peptide substrates. TAFIa
is a member of the metallo-carboxypeptidase family, as it contains a Zn2+ ion in the active
site, which is coordinated by His159, Glu162 and His288 [210, 211]. The Zn2+ ion aids in
the deprotonation of an incoming water molecule [210]. The key catalytic residue in the
active site is Glu363, which is responsible for abstracting the proton from the water
molecule [211]. The oxygen of the carbonyl group of scissile peptide bond in the substrate
is polarized by the presence of Arg217 in the active site. These residues allow for
nucleophilic attack on the carbonyl carbon. Specificity of TAFIa for substrates containing
carboxyl-terminal arginine or lysine residues is mediated by the presence of Asp348 at the
base of an elongated specificity pocket. The Zn2+ ion and Arg217 aid in the stabilization of
the tetrahedral intermediate. The tetrahedral intermediate collapses as the nitrogen of the
peptide bond of the substrate removes the proton from Glu363. The products are released
and the enzyme is able to receive a new substrate [211].
1.5.4

Intrinsic Instability and Inactivation of TAFIa
A distinct characteristic of TAFIa is that it is intrinsically unstable and undergoes

temperature-dependent spontaneous decay. TAFIa therefore possesses a short half-life of
approximately 8-15 minutes at 37°C [212]. The exact mechanism by which TAFIa
spontaneously decays is unknown, however crystal structures have identified a region of
the protein linked to its instability [200, 213]. The instability of TAFIa results from a highly
mobile region, named the dynamic flap (Phe297-Trp350). This region is stabilized in the
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zymogen by hydrophobic interactions with the activation peptide. Specifically, amino acids
Val35 and Leu39 within the activation peptide interact with Tyr341 to stabilize the
dynamic flap [200]. When TAFI is activated, the activation peptide is released causing an
increase in the mobility of the dynamic flap (Fig. 1.6). The mobility of this region
ultimately results in an irreversible conformational change that inactivates TAFIa to form
inactivated TAFI (TAFIai).
In addition to Arg92, other thrombin and plasmin cleavage sites have been
identified (Fig. 1.5). The additional thrombin cleavage site is Arg302, while Arg302,
Lys327 and Arg330 have been identified as plasmin cleavage sites [214-216]. These sites
were originally thought to be responsible for the inactivation of TAFIa. Mutation of the
thrombin cleavage site (Arg302Gln) decreased the stability of TAFIa [214]. Therefore, this
indicated that cleavage at Arg302 was not responsible for the inactivation of TAFIa.
Furthermore, additional plasmin cleavage sites did not prevent inactivation [214-216].
These results confirmed that TAFIa inactivation was not a result of enzymatic cleavage by
thrombin or plasmin [216]. Instead, it is thought that the conformation change exposes
cryptic cleavage sites (viz. Arg302) that make TAFIai more susceptible to proteolytic
cleavage.
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Figure 1.5: Activation, inactivation and proteolytic cleavage of TAFI.
The activation peptide of TAFI is shown in red and the catalytic domain is shown in blue.
Four N-linked glycosylation sites in the activation peptide are depicted. TAFI is activated
to TAFIa by proteolytic cleavage at Arg92 by thrombin, plasmin or thrombin/TM.
Inactivation of TAFIa resulting in TAFIai is caused by an irreversible conformational
change associated with loss of enzymatic activity. TAFI, TAFIa and TAFIai are also
susceptible to proteolytic cleavage at sites distinct from Arg92. In addition to Arg92,
thrombin is able to cleave TAFIai at Arg302. Plasmin cleavages sites in TAFI(a) are
Arg302, Lys327 and Arg330. Adapted from reference [217].
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Figure 1.6: Structure of TAFI and inactivation of TAFIa.
A) TAFI illustrated as a ribbon structure. The activation peptide is shown in blue and 4 Nlinked glycans are illustrated in yellow. When activated to TAFIa (shown in green), the
activation peptide is cleaved. The dynamic flap region (amino acids 296-350) is shown in
orange and the catalytic zinc ion is illustrated as a pink sphere. B) TAFI consists of the
activation peptide (in red), the catalytic domain (in blue) and the dynamic flap region (in
yellow). Activation peptide of TAFI is cleaved by thrombin, plasmin or thrombin/TM
complex to form TAFIa. The dynamic flap region is composed of amino acids 296-350,
which are stabilized by residues within the activation peptide of TAFI. When the activation
peptide is released this region possess high mobility at 37°C, which results in an
irreversible conformational changes that inactivates the enzyme, forming TAFIai. Adapted
from reference [200].
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As previously mentioned, two SNPs within the coding region of CPB2 correspond
to amino acid substitutions. The polymorphism resulting in Thr325Ile causes a change in
the stability of TAFIa; note that residue 325 is within the dynamic flap. While Thr325
possesses a half-life of 8 minutes at 37°C, Ile325 nearly doubles the half-life of TAFIa to
15 minutes [168, 218]. The anti-fibrinolytic potency of the Ile325 variant is
correspondingly greater. Studies have demonstrated that this polymorphism allows for
more favourable interaction between the dynamic flap and the catalytic domain [213].
Intriguingly, individuals with the more stable variant of TAFIa have lower plasma levels
of TAFI [168, 219], perhaps because of linkage disequilibrium between the SNP encoding
the Thr325Ile substitution and other SNPs linked to differences in CPB2 expression.
Several studies have used site-directed mutagenesis to identified key amino acids
within the dynamic flap involved in the stability of TAFIa. Mutagenesis of Ser305 to Cys
and Thr329 to Ile both result in an increase in intrinsic stability of TAFIa. The stabilizing
effect of Cys305 is attributed to a more favourable interaction with aromatic residues in
proximity to amino acid 305 [220]. Molecular modeling demonstrated that while Thr329
is exposed, Ile at this position is buried within the structure, allowing for favourable
hydrophobic interactions with the catalytic domain. When these stabilizing mutations were
combined with the naturally occurring stable isoform (Thr325Ile), the resulting intrinsic
instability increased the half-life to 70 minutes at 37°C [220]. In addition, Knecht et al.
observed that amino acid substitutions His333Tyr and His335Gln together increased the
half-life of TAFIa to 90 minutes at 37°C [221]. When all five stabilizing mutations were
combined (Ser305Cys, Thr325Ile, Thr329Ile His333Tyr and His335Gln – into a variant
known as CIIYQ), the intrinsic instability markedly increased, corresponding to a half-life
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of 1140 minutes at 37°C [222]. Recently, these mutations were combined with deletion of
amino acids 1-73, which further increased the half-life to approximately 1980 minutes at
37°C [209]. This stable deletion mutant of TAFI illustrates the importance of amino acids
Ala74-Arg92 of the activation peptide in stabilization of the catalytic domain, as exposing
this variant to thrombin significantly decreased the stability [209].
To date, there are no known physiological inhibitors of TAFIa. The intrinsic
instability of TAFIa resulting from its spontaneous conformational change is thought to the
be primary regulator of TAFIa activity. Given that TAFIa is a basic carboxypeptidase,
lysine and arginine analogs act as competitive inhibitors of TAFIa. Specifically, the
arginine analogs 2-mercaptomethyl-3-guanindinoethylthiopropanoic acid (MERGEPTA)
and 2-guanindinoethylmercaptosuccinic acid (GEMSA) and the lysine analog εaminocaproic acid (ε-ACA) are effective in inhibiting TAFIa [212, 223]. Unfortunately,
these inhibitors are not specific, inhibiting other basic carboxypeptidases, including
carboxypeptidase N (which, as previously mentioned, is also found in plasma) [224]. In
addition to these analogs, natural carboxypeptidase inhibitors in potato, leech and tick have
been identified [225-227].
Potato tuber carboxypeptidase inhibitor (PTCI) is a 39-amino acid peptide which
has a molecular mass of 4.5 kDa [225]. It is thought that this potato peptide is important in
inhibiting both endogenous and foreign carboxypeptidases. PTCI is a competitive inhibitor
of TAFIa, as well as pancreatic carboxypeptidases A and B [228]. In the context of plasma,
PTCI is specific to TAFIa, as it does not target carboxypeptidase N. PTCI has a 27 amino
acid globular core with a protruding 5-amino acid carboxyl terminal tail, which is important
for its inhibitory effects [229, 230]. The inhibitory mechanism of PTCI has been studied in
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the context of carboxypeptidase A. Based on X-ray crystallography, the Val-38-Gly-39
bond of PTCI is hydrolyzed and the inhibitor remains trapped in the active site of
carboxypeptidase A [229]. The new carboxyl-terminal Val-38 interacts with the zinc in the
active site. Although similar studies have not been done with TAFIa, it is expected that the
inhibitory mechanism is similar, given that the Ki values for TAFIa and carboxypeptidase
A are both within the same nanomolar range [212].
Importantly, the above mentioned competitive inhibitors of TAFIa are problematic
in that in addition to inhibiting the activity of the enzyme, they have all been shown to
increase the stability [212]. Accordingly, these reversible inhibitors also protect TAFIa
from proteolytic cleavage [214]. Studies with these inhibitors have demonstrated that they
have a biphasic effect [231]. This biphasic effect is dependent on the concentration of TAFI
and the inhibitor. At low concentrations these inhibitors enhance the effect of TAFIa, by
increasing the half-life of the enzyme. At high concentrations these inhibitors are able to
effectively inhibit the activity of TAFIa, although the half-life is increased [232]. In
addition to the inhibitors, glycosaminoglycans, such as heparin, have also been shown to
increase the half-life of TAFIa [202]. Based on crystal structure analysis, five sulfate ions
were found bound to the dynamic flap, indicating that stabilization of TAFIa by heparin
may result from direct binding to the dynamic flap region [233].
1.5.5

Biological Functions of TAFIa
TAFIa is a basic carboxypeptidase, cleaving carboxyl-terminal lysine and arginine

residues from protein and peptide substrates, including fibrin degradation products (FDPs),
plasminogen receptors, bradykinin, anaphylatoxins, thrombin-cleaved osteopontin and
plasmin-cleaved chemerin [69, 129, 234-236]. TAFIa cleaves carboxyl-terminal lysines
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from partially degraded fibrin, residues that mediate positive feedback in the fibrinolytic
cascade by (i) accelerating tPA-mediated plasminogen activation; (ii) promoting plasminmediated Glu- to Lys-plasminogen conversion; and (iii) protecting plasmin from inhibition
by antiplasmin [129, 237-239]. Accordingly, TAFIa attenuates fibrinolysis and hence
promotes clot stability. Importantly, TAFIa attenuates fibrinolysis through a thresholddependent mechanism [240]. As long as the concentration of TAFIa remains at or above
the threshold, fibrinolysis is successfully attenuated. If the concentration of TAFIa falls
below the threshold concentration, the number of carboxyl-terminal lysine residues on
fibrin increases, accelerating fibrinolysis. Inhibition of fibrinolysis explains why elevated
concentrations of TAFI have been associated with thrombotic disorders (see above).
However, the antifibrinolytic activity of TAFIa may also be necessary for normal
hemostasis. It has been demonstrated that in hemophilia, premature lysis of clots occurs
because not enough thrombin is produced to activate sufficient TAFI to stabilize the clot
[241-243].
TAFI deficient mice have been used to elucidate potential roles for TAFI in vivo.
TAFI knockout mice do not show any overt abnormalities, developing and reproducing
like their wild-type counterparts [244]. These mice however do show phenotypic
differences when challenged. Several studies were completed to assess the effect of TAFI
on models of fibrinolysis. Specifically, increased fibrinolysis was observed in TAFI
knockout mice using a batroxobin-induced pulmonary embolism model [245].
Furthermore, a thromboembolism model demonstrated increased fibrinolysis in mice with
a TAFI deficient background and double knockout of TAFI and PAI-1 [246]. This study
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attributed the pro-fibrinolytic phenotype predominantly to the TAFI deficiency in mouce
backgrounds.
Along with its role in balancing coagulation and fibrinolysis, TAFI also plays a role
in down regulating inflammation. In vitro, TAFIa cleaves arginine residues from
bradykinin and anaphylatoxins C3a and C5a, which results in inactivation of these
inflammatory mediators [223, 234]. Studies in mice have also shown that they may also be
substrates of TAFIa in vivo [247, 248]. Anaphylatoxins play a role in neutrophil
recruitment and activation during inflammation [249]. Using an E. coli-induced sepsis
model, TAFI deficiency resulted in enhanced neutrophil activity, correlating with elevated
levels of C5a [250]. Additionally, increased levels of C5a were also observed in TAFI
knockout mice with LPS-induced acute lung injury [251]. These results demonstrate a
potential role for TAFI in inflammation.
TAFI deficiency has also been shown to affect wound healing in vivo. Using a
cutaneous wound healing assay, te Velde and coworkers observed a delay in wound healing
in mice with TAFI deficiency [252]. Keratinocyte migration is an important mechanism in
cutaneous healing, which was impaired in TAFI deficient mice. This result may be
attributed to enhanced fibrin clearance due to lack of TAFI, removing the matrix that
provided a scaffold along which the cells migrated [253]. The study also examined the
effect of TAFI deficiency in healing of colonic anastomoses [252]. This form of healing
was also found to be impaired in TAFI deficient mice. Intriguingly, unlike cutaneous
healing, this type of wound healing depends on mechanisms such as angiogenesis and ECM
remodelling, which are mediated in part by the plasminogen activation system [252].
Importantly, TAFIa has been shown to modulate plasminogen activation in vivo [254].
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Taken together, TAFI has several potential roles in mediating fibrinolysis,
inflammation and wound healing. Regulation of fibrinolysis and wound healing are
mediated by the ability of TAFI to attenuate plasminogen activation. Additional biological
roles of TAFI may be identified through its ability to inhibit plasmin formation.

1.5.6

TAFI in Cancer and Angiogenesis
The role of TAFI in cancer has not been well-characterized. The majority of studies

have examined plasma concentrations of TAFI and/or SNPs in patients with different types
of cancer, with a specific focus on the contribution of TAFI to the thromboembolic
complications that frequently accompany cancer. Hataji et al. demonstrated that plasma
TAFI levels were increased in patients with lung cancer compared to healthy individuals
[255]. The same study found that TAFI concentrations were higher in patients with small
cell carcinoma compared to adenocarcinoma or squamous cell carcinoma. Intriguingly,
they also found that plasma TAFI levels were higher in patients that responded to
chemotherapy compared to non-responders. Unfortunately, this study did not examine
TAFI levels in the context of metastasis. Another study also found an increase in plasma
TAFI levels in patients with non-small cell lung cancer [256]. This study did not find any
correlations with TAFI levels and stage of the disease. Eser et al. found no difference in
TAFI concentrations in patients with gastric cancer compared to healthy controls [257].
However, an independent study by Fidan et al. found that TAFI levels were higher in
gastric cancer patients when compared to healthy individuals [258]. Balcik et al. examined
serum levels of TAFI in patients diagnosed with multiple myeloma and found an increase
in patients compared to healthy controls [259]. It is speculated that increased plasma TAFI
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concentrations may contribute to the fibrinolytic deficiency in cancer patients. However,
increased levels may not be the cause but instead a consequence of disease progression, as
there are many factors affecting CPB2 gene expression and regulation that would
ultimately influence TAFI protein levels. Meijers et al. showed that plasma concentrations
of TAFI in patients with acute promyelocytic leukemia were similar to control groups
[260]. However, they also determined that while TAFI levels were the same, there was a
significant reduction in TAFI activity in patient samples.
TAFI levels in breast cancer patients have been examined in several studies. TAFI
levels were found to be increased in breast cancer patients compared to healthy controls
[261]. Unfortunately, this study did not provide information related to disease stage or
metastasis. A study by Chengwei et al. also found an increase in TAFI levels in patients
with breast cancer [262]. Conversely, Kotschy et al. examined plasma TAFI levels in
patients with colorectal and breast cancers and found they were similar to control samples
[263].
Associations with the Thr325Ile TAFI polymorphism have been examined in
different cancer types. A large study of ovarian cancer found no significant association
between the CPB2 +1040C/T SNP and the incidence of ovarian cancer [264]. In contrast,
the prevalence of the CPB2 +1040C/T polymorphism was found to be less in patients with
oral squamous cell carcinoma than in healthy controls [265]. It may be that the presence of
the more stable isoform of TAFI may protect individuals from the onset of oral cancer.
Conversely, two studies in breast cancer patients determined the CPB2 +1040C/T
polymorphism is positively associated with breast cancer [262, 266].
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The lack of consistent results with respect to associations between TAFI levels or
CPB2 genotype and cancer is puzzling. It is possible that no such correlations exist and the
few published studies are outliers. It is also possible that variations in study design, cancer
type under investigation, and methods used to assay TAFI concentrations make it
impossible to mine consensus from the literature. It is also notable that the existing studies
are generally association studies with the occurrence of cancer. As such, they tell us
nothing about whether differences in TAFI levels are the cause or the consequence of
cancer incidence, or whether the differences are causally related or attributable to a chance
association of TAFI levels with something else that is causally related. Finally, these
studies do not provide any mechanistic insights, and do not address the key question of the
role of TAFI in metastasis.
There have been few studies that focus on the biological functions of TAFI in
cancer. A study in HT1080 fibrosarcoma cells found that TM attenuated invasion of these
cells through promotion of TAFI activation [267]. On the other hand, no differences were
seen in TAFI knockout mice compared to controls when observing tumour growth and
metastasis [268]. However, this study was carried out using cell lines that do not support
TAFI activation even in the presence of TAFI and therefore a role for TAFI cannot be ruled
out. Intriguingly, mice with a double knockout background of TAFI and apolipoprotein-E
(apoE) were found to develop hepatic tumours when treated with streptozotocin, a
diabetogenic and carcinogenic agent [269]. Tumours were only observed in double
knockout mice treated with steptozotocin and not in control mice or mice with the single
knockout. Interestingly. apoE knockout mice treated with streptozotocin had increased
plasma TAFI levels. Therefore, in the double knockout system, lack of TAFI may
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contribute to tumourigenesis. This study also found that double knockout mice treated with
streptozotocin has increased plasma concentrations of TGF-β1, which can promote cancer
cell invasion and metastasis [270].
Several studies have also hinted at a potential role for TAFI in angiogenesis. TAFIa
was found to decrease in vitro bFGF-induced endothelial cell tube formation on a plasma
clot matrix, by inhibiting plasminogen activation [271]. This result implies that TAFI may
inhibit tube formation in the tumour microenvironment. Furthermore, studies in vivo have
demonstrated a role for TAFI in regulating plasmin-mediated migration of leukocytes and
keratinocytes during would healing [252, 272]. TAFI may also regulate plasmin-mediated
migration of endothelial cells during tumour angiogenesis.

1.6 Rationale and Objectives
TAFIa has a known biological function of attenuating plasminogen activation in
the context of fibrinolysis and wound healing [129, 252]. Plasmin has a well-understood
function in cancer progression, facilitating cell invasion and metastasis through
degradation of the ECM and basement membrane [99]. Plasmin generation in the tumour
microenvironment is enabled by plasminogen receptors, that accelerate activation of
plasminogen to plasmin [62]. TAFIa has been shown to cleave carboxyl-terminal lysine
residues on these receptors, inhibiting plasminogen activation [69]. The ability of TAFIa
to attenuate plasminogen activation on the cell surface points to a potential role for TAFI
in inhibiting the metastatic functions of plasmin, namely MMP and growth factor
activation, ECM degradation and angiogenesis (Fig. 1.7). Furthermore, the endothelial
cofactor TM is described as an anti-metastatic factor [142]. The anti-metastatic effects of
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TM are attributed to its thrombin-binding domain, which is responsible for the activation
of TAFI and protein C [144]. Studies have not determined which substrate of the
thrombin/TM complex is responsible for the anti-metastatic effects of TM. We therefore
hypothesize that (i) the anti-metastatic effects of TM result from its ability to activate TAFI
and (ii) TAFIa functions as an anti-metastatic and anti-angiogenic factor through inhibition
of plasminogen activation.
To address these hypotheses, the research objectives of this dissertation are:
1) To examine the effect of TAFIa on metastatic behaviours of breast cancer cells.
2) To assess the role of TAFIa on angiogenic potential of endothelial cells and
endothelial-breast cancer cell co-cultures.
3) To determine the effect of thrombomodulin on metastatic and angiogenic
behaviours in breast cancer cells.
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Figure 1.7: Hypothesis of TAFI in the tumour microenvironment.
TAFI is activated to TAFIa on the cancer cell surface by the thrombin/TM complex.
Plasminogen (Plg) is activated to plasmin (Pln) by uPA when bound to plasminogen
receptors (Plg-R) on the cell surface. Pln has pro-metastatic effects, including increased
MMP secretion and activation, increased ECM degradation, increased growth factor
activation and increased angiogenesis. TAFIa cleaves carboxyl-terminal lysine residues
from Plg-R on the cell surface. This inhibits Plg conversion to Pln. This would therefore
inhibit the pro-metastatic effects of Pln.
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Chapter 2

Activated thrombin-activatable fibrinolysis inhibitor (TAFIa)
attenuates breast cancer cell metastatic behaviors through
inhibition of plasminogen activation and extracellular
proteolysis
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2.1 Summary

Background: Thrombin activatable fibrinolysis inhibitor (TAFI) is a plasma zymogen,
which can be converted to activated TAFI (TAFIa) through proteolytic cleavage by
thrombin, plasmin, and most effectively thrombin in complex with the endothelial cofactor
thrombomodulin (TM). TAFIa is a carboxypeptidase that cleaves carboxyl terminal lysine
and arginine residues from protein and peptide substrates, including plasminogen-binding
sites on cell surface receptors. Carboxyl terminal lysine residues play a pivotal role in
enhancing cell surface plasminogen activation to plasmin. Plasmin has many critical
functions including cleaving components of the extracellular matrix (ECM), which
enhances invasion and migration of cancer cells. We therefore hypothesized that TAFIa
could act to attenuate metastasis.
Methods: To assess the role of TAFIa in breast cancer metastasis, in vitro migration and
invasion assays, live cell proteolysis and cell proliferation using MDA-MB-231 and
SUM149 cells were carried out in the presence of a TAFIa inhibitor, recombinant TAFI
variants, or soluble TM.
Results: Inhibition of TAFIa with potato tuber carboxypeptidase inhibitor increased cell
invasion, migration and proteolysis of both cell lines, whereas addition of TM resulted in
a decrease in all these parameters. A stable variant of TAFIa, TAFIa-CIIYQ, showed
enhanced inhibitory effects on cell invasion, migration and proteolysis. Furthermore,
pericellular plasminogen activation was significantly decreased on the surface of MDAMB-231 and SUM149 cells following treatment with various concentrations of TAFIa.
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Conclusions: Taken together, these results indicate a vital role for TAFIa in regulating
pericellular plasminogen activation and ultimately ECM proteolysis in the breast cancer
microenvironment. Enhancement of TAFI activation in this microenvironment may be a
therapeutic strategy to inhibit invasion and prevent metastasis of breast cancer cells.
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2.2 Background
Metastasis is the process by which malignant cells migrate from the site of the
primary tumor to distant parts of the body [1]. This phenomenon is responsible for the
majority of breast cancer related deaths. The breast tumor microenvironment facilitates
metastasis by providing the necessary factors (such as stromal cells, signaling molecules,
and proteolytic enzymes) to initiate the metastatic process. Importantly, metastasis is
mediated by the interaction between the tumor cells, stromal cells and the extracellular
matrix (ECM) [2, 3]. Proteins in the tumor microenvironment influence the progression of
cancer by providing a favourable environment for ECM degradation. Specifically, the
presence of proteases such as plasmin and matrix metalloproteinases (MMPs) mediate
extracellular proteolysis, resulting in ECM degradation [4, 5]. Degradation of the ECM
promotes cell migration and invasion and also releases latent growth factors that stimulate
cell proliferation [1].
The plasminogen activation system (PAS) plays a vital role in extracellular
proteolysis. Plasminogen is a zymogen that is converted to its active form plasmin by
urokinase plasminogen activator (uPA) and tissue-type plasminogen activator (tPA) [4],
with uPA playing the more important role in pericellular plasminogen activation [6].
Plasmin is a serine protease of broad specificity that cleaves multiple substrates, including
ECM proteins, latent growth factors and a number of pro-MMPs [4]. Plasmin therefore is
considered a pro-metastasis enzyme [7]. The PAS is active in many types of cancers,
including breast cancer [4]. Specifically, uPA and its receptor, urokinase plasminogen
activator receptor (uPAR) are expressed in tumor cells, as well as tumor-associated stromal
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cells [4, 8]. Developing methods to target the PAS could be key in inhibiting cancer cell
invasion and metastasis [9].
Thrombin

activatable

fibrinolysis

inhibitor

(TAFI),

also

known

as

carboxypeptidase B, U or R [10], is a plasma zymogen expressed mainly in the liver but
also found in megakaryocytes (leading to a platelet pool of TAFI) and macrophages [11].
TAFI is converted to activated TAFI (TAFIa) by proteolytic cleavage at Arg92 either by
thrombin, plasmin or thrombin in complex with the endothelial cofactor thrombomodulin
(TM). TAFIa is a basic carboxypeptidase, which removes carboxyl-terminal arginine and
lysine residues from peptide and protein substrates, including fibrin degradation products
(FDPs), anaphylatoxins C3a and C5a, thrombin-cleaved osteopontin and cell-surface
plasminogen receptors [12-15].
Intriguingly, TAFIa is intrinsically unstable, with a half-life of 8-15 minutes at
37°C. This instability is considered to be the physiological means of TAFIa inhibition, as
no endogenous inhibitors exist [16]. Ceresa et al. characterized a mutant of TAFIa with a
180-fold enhancement in half-life compared to wildtype TAFIa [17]. This stable mutant of
TAFIa contains five point mutations in the instability region, specifically S305C, T325I,
T329I, H333Y, H335Q and is therefore named TAFI-CIIYQ.
The ability of TAFIa to cleave cell-surface plasminogen receptors raises the
possibility that TAFIa could modulate the PAS in the tumor microenvironment, thereby
attenuating the metastatic potential of the tumor cells. Furthermore, TM, the cofactor
necessary for physiological activation of TAFI has been characterized as an anti-metastatic
factor. In vitro studies have shown that TM can inhibit invasion of fibrosarcoma cells
through activation of TAFI [18]. An important in vivo study demonstrated that the anti73

metastatic potential of TM could be attributed to its thrombin-binding domain [19]. In
addition, expression of TM in breast cancer tumors is inversely correlated to malignancy
[20]. Therefore, we hypothesized that the anti-metastatic potential of TM may be mediated
by its ability to enhance the activation of TAFI. Here, we address this hypothesis using an
in vitro model of the breast tumor microenvironment.
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2.3 Methods

2.3.1 Cell Culture
MDA-MB-231 and HTB-126 cells (ATCC) were grown in Dulbecco’s modified
eagle medium (DMEM/F12) (Invitrogen), containing 10% fetal bovine serum (FBS) and
1% antibiotic-antimycotic (10 units/mL penicillin G sodium, 10 μg/mL streptomycin
sulfate and 25 ng/mL amphotericin B) (Invitrogen). SUM149 cells (a kind gift from Dr.
Stephen Ethier, Karmanos Cancer Institute) were cultured in DMEM/F12 containing 5%
FBS, 1% antibiotic-antimycotic, 10 µg/mL insulin (Sigma) and 0.5 µg/mL hydrocortisone
(Sigma). MCF7 cells (ATCC) were grown in RPMI-1640 medium (Gibco) containing 10%
FBS and 1% antibiotic-antimycotic. MCF10A (ATCC) and MCF10CA1a (obtained from
the Karmanos Biobanking and Correlative Sciences Core) were maintained in DMEM-F12
media containing 0.5 µg/ml hydrocortisone, 10 µg/ml insulin, 20 ng/ml human EGF and
5% (vol/vol) heat inactivated horse serum. Human embryonic kidney (HEK293) cells
(ATCC) were cultured in minimum essential medium (MEM) (Gibco) supplemented with
5% FBS and 1% antibiotic-antimycotic. THP-1 acute monocytic leukemia cells (ATCC)
were cultured in RPMI-1640 medium adjusted to contain 4.5 g/L glucose, 10 mM HEPES
pH 7.4 and 1.0 mM sodium pyruvate, and supplemented with 10% (v/v) fetal bovine serum
(ATCC), 1% (v/v) antibiotic-antimycotic, and 50 μM β-mercaptoethanol. THP-1
monocytes were differentiated by the addition of 100 nM phorbol 12-myristate 13-acetate
to the medium for 72 hours. Human umbilical vein endothelial cells (HUVECs) (Lonza)
were grown in EGM Complete Medium (Lonza). All cells were sub-cultured in 100 mm
cell culture plates and were kept in an incubator maintaining conditions of 37°C, 5% CO2.
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2.3.2 Cloning, Expression and Purification of recombinant TAFI
The full-length TAFI-CIIYQ cDNA sequence [17] present in the pNUT vector [21]
was used as a template for PCR amplification. To insert TAFI-CIIYQ in the pcDNA4A
vector, unique PstI and AgeI restriction sites were engineered at the 5’ and 3’ ends of the
sequence through PCR. PCR amplification was performed with Phusion HF DNA
polymerase (New England Biolabs) as per manufacturer’s protocol, using TAFI-CIIYQpNUT as the template (10 ng/µL) and the following primer pair: sense 5’-AAA CTG CAG
TTG GGA TGA AGC TTT GC-3’ and anti-sense 5’-GGA CCG GTA ACA TTC CTA
ATG ACA TGC CAA G-3’. Using PstI and AgeI, TAFI-CIIYQ cDNA was ligated into the
pcDNA4A plasmid in-frame with a carboxyl-terminal His6-tag-encoding sequence. TAFIWT [21] was cloned into pcDNA4A using the same method.
HEK293 cells were seeded into a 6-well plate at a density of 1.5 x106 cells per well.
Cells were transfected using 1 µg of TAFI-pcDNA4A expression plasmids and Mega Tran
1.0 (OriGene) according to manufacturer’s protocol. Stably-expressing cell lines were
selected by culturing in the presence of 100 µg/mL zeocin (Invitrogen). Stable cell lines
were grown in roller bottle culture for the production of recombinant TAFI in OptiMEM
(Gibco) supplemented with 1% antibiotic/antimycotic.
Recombinant TAFI (rTAFI) was purified using a Ni2+ Sepharose column (GE
Healthcare Life Sciences), utilizing the His6-tag at the carboxyl-terminal of the protein.
Conditioned medium harvested from the cells was supplemented with 50 mM NaH2PO4,
0.5 M NaCl, 1 mM β-ME 10% glycerol, pH 7.9 (buffer A), containing 5 mM imidazole.
The column was washed and eluted with wash and elution buffers, which were buffer A
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containing 10 mM and 400 mM imidazole, respectively. Eluted rTAFI was dialyzed
overnight at 4ºC against HBS (0.02 M HEPES pH 7.4, 0.15 M NaCl) containing 5%
glycerol. Dialyzed rTAFI was then concentrated by ultracentrifugation using Amicon Ultra
Centrifugal Filters (Fisher Scientific) at 4ºC with a buffer exchange using HBS containing
0.01% (v/v) Tween-80 (HBST).

2.3.3 RNA Extraction and Quantitative Real-time PCR
RNA was extracted from various cell lines using RNeasy Plus Mini Kit (Qiagen),
as per the manufacturer’s protocol. Quantitative real-time PCR (qRT-PCR) was completed
using iTaq one-step RT-PCR kit with SYBR® green (BioRad). The following primers were
used for qRT-PCR: TM sense: 5’ CCC TGA ACA AGA ATT GGA AGC T 3’; TM
antisense: 5’ GGA GCC TAG GAT TCT GCA TTT CTA 3’; TAFI sense: 5' GCT GCC
GGA GCG TTA CAT 3’; TAFI antisense: 5' CAT TCC TAA TGA CAT GCC AAG CT
3'; GAPDH sense: 5' GGA GCC AAA AGG GTC ATC ATC 3'; GAPDH antisense: 5'
GTT CAC ACC CAT GAC GAA CAT G 3'.

2.3.4 Plasminogen Activation Assays
Plasminogen activation assays were performed as previously described by
Romagnuolo et al. [22]. Briefly, MDA-MB-231 and SUM149 cells were grown to
confluency in black, clear-bottom 96 well plates. Various TAFI concentrations were
activated in Hank’s buffer saline solution (HBSS) (0.137 M NaCl, 5.4 mM KCl, 0.25 mM
Na2HPO4, 0.44 mM KH2PO4, 1.3 mM CaCl2, 1 mM MgSO4, 4.2 mM NaHCO3, 1 g/L
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glucose and 0.1% BSA) with 25 nM thrombin, 100 nM TM, and 5 mM CaCl2 for 10
minutes at room temperature. Following the 10-minute incubation, thrombin was inhibited
with PPAck. Cells were washed twice with HBSS. Activated TAFI (1-50 nM, final) was
added to cells for 30 minutes at 37°C. Cells were then washed twice with HBSS and a
solution containing 300 nM plasminogen (purified from human plasma by lysine-sepharose
affinity chromatography as previously described [23]), 10 pM uPA (Calbiochem) and 40
mM of the fluorogenic plasmin substrate H-D-Val-Leu-Lys-AMC (Bachem). Hydrolysis
of H-D-Val-Leu-Lys-AMC was monitored for an hour at 37°C at excitation and emission
wavelengths of 370 nm and 470 nm, respectively.

2.3.5 Cell Invasion and Migration Assays
Cell culture inserts (BD Biosciences) with a pore size of 8 µm were coated with 2
mg/mL Cultrex reconstituted basement membrane extract (Trevigen) for 1 hour at room
temperature. MDA-MB-231 and SUM149 cells (1 × 105) in serum-free medium were
seeded into the upper chamber. Complete medium was added to the lower chamber with
either 10 ug/mL potato tuber carboxypeptidase inhibitor (PTCI) (Sigma) or 10 nM rabbit
TM (Haemotologic Technologies). Cells were allowed to invade for 24 hours at 37°C.
Following 24 hours, non-invaded cells in the upper chamber were removed. Invaded cells
were fixed with cold methanol and stained with 0.25% crystal violet. Images were taken of
five fields of view with a 20× objective and cell numbers in each field were determined by
counting.
For TAFIa treatment, recombinant TAFI was activated with 25 nM thrombin
(Haematologic Technologies), 100 nM TM, and 5 mM CaCl2 for 10 minutes at room
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temperature. Thrombin was inhibited with 200 nM H-D-Phe-Pro-Arg chloromethylketone
(PPAck; Calbiochem) and placed on wet ice. The activation mixture was supplemented
with DMEM containing 10% FBS and 1% antibiotic and added to the lower chamber to
achieve final TAFIa concentrations of 1, 5, 25, or 50 nM. Mock activations of rTAFI were
carried out in the same manner but without thrombin.
Cell migration assays were performed using the same protocol as cell invasion
assays, except that the cell culture inserts were not coated with Cultrex and the cells were
seeded in the upper chamber at a lower density (3 × 104 cells/well).

2.3.6 Cell Metabolism Assay
MDA-MB-231 and SUM149 cells (2.5 × 103/well) were seeded into a 96 well plate.
Cells were grown for 24 hours. PTCI or TM was then added to the cells in fresh medium
for 24 hours. Following the 24 hours, WST-1 reagent (Roche) was added and incubated for
2 hours at 37°C. The absorbance was then measured at 450 nm using a plate-reading
spectrophotometer.

2.3.7 Live-cell proteolysis assay
Live-cell proteolysis experiments were carried out as described by Victor et al.
[24]. Round glass-bottom dishes (MatTek) were coated with Cultrex containing 25 µg/mL
dye quenched (DQ)-collagen IV (Invitrogen). MDA-MB-231 cells and SUM149 cells were
labeled with CellTracker Orange (Invitrogen) in serum-free medium for 1 hour. Cells were
allowed to recover in complete medium before 2 × 104 (SUM149) or 1 × 104 cells (MDA79

MB-231) were seeded onto the Cultrex-coated glass. Dishes were then incubated at 37°C
for 45 minutes. Following the incubation, complete growth medium containing 2% Cultrex
was added to the cells, with or without 10 µg/mL PTCI. Cells were incubated at 37°C and
5% CO2 for 48 hours. Following incubation, cells were imaged using an Olympus IX81
confocal microscope.
For TAFIa treatment, activated (50 nM) and mock-activated (50 nM) rTAFI
mixtures were prepared as described above. Glass-bottom dishes were prepared and cells
were seeded as described above. Each plate was supplemented with 2 mL of DMEM
medium containing 10% FBS, 1% antibiotic, 2% Cultrex and the activation mixture with
or without activated TAFI. Cells were incubated at 37°C and 5% CO2 for 48 hours.
Quantitative analysis of the confocal microscopy data was performed using the
following protocol. Each of the images (15- 20 depending on the size of the spheroid) of
the z-stack in the experiment was initially in TIFF RGB format, which were then converted
to 8-bit grayscale prior to processing. The images were then filtered to remove granulation
using a median filter. The brightness curves were trimmed so that areas of high intensity
did not discard other areas of interest when thresholding; the identical trimming method
was conducted for each image. Each image was then filtered and tuned (again using the
same parameters in each case), a threshold based on Otsu’s technique [25] was applied to
the image which converts it to a binary format. The resultant image contains an accurate
depiction of the shape and contour of the areas of interest. At this stage, the areas of each
image were then calculated by matrix summation. The average intensity of an image was
then determined by applying the binary image as a mask to the original grayscale image
and calculating the mean pixel intensity of the resulting matrix. Each pixel is represented
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as an 8-bit grayscale value and therefore represented as a number between 0 and 255. This
algorithm was applied to each image in the same exact manner without any modifications.
The data were represented as a ratio of the intensity of the green fluorescence to the area
of the cells, averaged over the z-stack.

2.3.8 Statistical Analysis
Data from the experiments were presented as means of at least 3 independent
experiments ± standard error of the mean (SEM). Analysis of the data to identify
statistically significant differences amongst experimental conditions was completed using
one-way ANOVA with SPSS software (version 22); pairwise comparisons between
conditions were performed using a Tukey post-hoc analysis. p values < 0.05 were
considered statistically significant.
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2.4 Results

2.4.1 TAFI and TM are expressed in breast cancer cell lines
Expression of CPB2 (the gene encoding TAFI) was assessed in various breast
cancer cell lines, using qRT-PCR (Figure 1). CPB2 mRNA was detectable in all of the
examined breast cancer cell lines, albeit at a lower level in all cases compared to the
positive control THP-1 macrophages (Figure 1), which is correspondingly much lower than
reported in liver or a cultured hepatoma cell line [11]. CPB2 mRNA levels in the highly
malignant and invasive MDA-MB-231, HTB-126, and MCF10ACA1a cell lines were
comparable to mRNA levels in the non-invasive [26] MCF7 cell line. Therefore, levels of
CPB2 mRNA do not appear to show any relationship to the malignancy of the breast cancer
cell lines.
It has been reported that TM expression is inversed correlated with malignancy in
prostate, breast and lung cancer [27-29]. In contrast to CPB2, the expression levels of
THBD (the gene encoding TM) were found to be generally inversely correlated to
malignancy (Figure 1). This relationship is revealed when the cell lines are arranged in
decreasing order of THBD expression from left to right, as the more malignant cell lines
are on the right.
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Figure 2.1: Expression of CPB2 (TAFI) and THBD (thrombomodulin) mRNA in
breast cancer cell lines.
RNA was extracted from various breast cancer cell lines and expression of CPB2 and
THBD was analyzed using qRT-PCR. Expression of CPB2 and THBD were normalized to
GAPDH mRNA levels in all cells. The data are expressed relative to THP-1 macrophages
(CPB2) or HUVECs (THBD) and are the means ± SEM of 3-4 independent experiments,
and are arranged in decreasing order of THBD expression from left to right. *: p < 0.05
versus MCF10A (CPB2) and †: p < 0.05 versus MCF10A (THBD).
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2.4.2 TAFIa inhibits plasminogen activation on both MDA-MB-231 and SUM149
cell lines
Addition of TAFIa resulted in a decrease in plasminogen activation of up to 30%
in both MDA-MB-231 and SUM149 cells (Figure 2). This decrease, however, was not
strictly dose-dependent, as the magnitude of the effect tended to decrease at the highest
concentrations of TAFIa. The ability of TAFIa to decrease cell surface plasminogen
activation is consistent with its ability to decrease extracellular collagen proteolysis.
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Figure 2.2: TAFIa inhibits pericellular plasminogen activation on breast cancer cell
lines.
SUM149 (black bars) and MDA-MB-231 cells (grey bars) were treated with varying
concentrations of TAFIa (1-50 nM) for 30 minutes at 37oC. Plasminogen activation assay
was carried out with 300 nM plasminogen, 10 pM uPA and a fluorescent plasmin substrate.
The rate of formation of plasmin (taken as the slope of the plot of change in fluorescence
versus time squared) was monitored for 1 hour at 37oC. The data represent the means ±
SEM of 4-5 independent experiments and are expressed relative to the control in the
absence of TAFIa. **: p < 0.01 relative to control.
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2.4.3 TAFIa directly inhibits cell invasion and migration of MDA-MB-231 and
SUM149 cell lines
We examined the effect of TAFIa on cell invasion of MDA-MB-231 and SUM149
cell lines by inhibition of TAFIa using the specific competitive inhibitor PTCI. Both cell
lines should be sensitive to the effects of PTCI as they both express TM and therefore
presumably have the capacity to support TAFI activation. Inhibition of TAFIa using 10
μg/mL PTCI resulted in a significant increase in invasion (Figure 3A,B) and migration
(Figure 4A,B) of both MDA-MB-231 and SUM149 cells. In addition, treatment with 10
nM of the cofactor TM resulted in an approximately 30% decrease in invasion in both
SUM149 and MDA-MB-231 cell lines (Figure 3A,B) as well as decreases in migration of
MDA-MB-231 and SUM149 cells by 30% and 20%, respectively (Figure 4A,B). These
results indicate that modulation of TAFI activity can affect invasion and migration
potential of breast cancer cells.
To directly assess the effect of TAFIa on cell invasion we used wild-type TAFI
(TAFI-WT) as well as a stable variant (TAFI-CIIYQ) (Figure 3C,D). While treatment with
activated TAFI-WT (TAFIa-WT) did not affect cell invasion, we observed a dosedependent decrease in MDA-MB-231 cell invasion upon treatment with TAFIa-CIIYQ.
The highest dose of TAFIa-CIIYQ (50 nM) resulted in an approximately 60% decrease in
invasion of MDA-MB-231 cells (Figure 3C,D). Notably, this effect was only observed with
the TAFIa enzyme and not the (non-activated) TAFI zymogen. In addition, we assessed
the effect of TAFI and TAFIa on cell migration. We observed a dose-dependent decrease
in cell migration of MDA-MB-231 cells when treated with either TAFIa-WT or TAFIaCIIYQ (Figure 4C,D), although significance was only reached at 50 nM TAFIa-CIIYQ.
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Treatment with the non-activated TAFI did not have an effect on migration, as we observed
with cell invasion. These results demonstrate directly that TAFIa can inhibit breast cancer
cell invasion and migration in vitro.
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Figure 2.3: The effects of PTCI, TM and TAFIa on breast cancer cell invasion.
(A) SUM149 and MDA-MB-231 cells were subjected to invasion assays in the presence
of 10 µg/mL PTCI or 10 nM TM or in the absence of these additions (Control). The number
of invaded cells were imaged and counted in five fields of view. Images shown were taken
at 4× magnification. Scale bars: 200 µm. (B) Quantification of invaded cells, relative to
control (absence of treatment). The data represent the average cell number per field of view
± SEM from at least 4 independent experiments. *: p < 0.05 and **: p < 0.01 relative to
control. (C) Cells were treated with varying concentrations (1-50 nM) of either TAFIa-WT
or TAFIa-CIIYQ or 50 nM mock-activated TAFI-WT or TAFI-CIIYQ (Non-Activated)
for 24 hours. Invasion was imaged as in (A). (D) Quantification of invaded cells, relative
to control (absence of TAFIa). The data represent the average cell number per field of view
± SEM from at least 3 independent experiments. *: p < 0.05 and **: p < 0.01 relative to
control; #: p < 0.05 and ## p < 0.01 relative to TAFIa-WT. (E) To demonstrate the purity
of the recombinant TAFI proteins, TAFI-WT and TAFI-CIIYQ (500 ng each) was
subjected to SDS-PAGE on a 12% polyacrylamide gel followed by staining with silver.
The positions of migration of molecular weight markers are shown to the left of the gel.
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Figure 2.4: The effects of PTCI, TM and TAFIa on breast cancer cell migration.
(A) SUM149 and MDA-MB-231 cells were subjected to migration assays in the presence
of 10 µg/mL PTCI or 10 nM TM or in the absence of these additions (Control). The number
of migrated cells were imaged and counted in five fields of view. Images shown were taken
at 4× magnification. Scale bars: 200 µm. (B) Quantification of migrated cells, relative to
control (absence of treatment). The data represent the average cell number per field of view
± SEM from at least 4 independent experiments. *: p < 0.05 and **: p < 0.01 relative to
control. (C) Cells were treated with varying concentrations of either TAFIa-WT or TAFIaCIIYQ (1-50 nM) for 24 hours. Cells were also treated with 50 nM mock-activated TAFIWT or TAFI-CIIYQ (Non-Activated). Migration was imaged as in (A). (D) Quantification
of migrated cells, relative to control in the absence of TAFIa. The data represent the
average cell number per field of view ± SEM from at least 3 independent experiments. *:
p < 0.05 relative to control; #: p < 0.05 relative to TAFIa-WT.
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2.4.4 TAFIa does not affect breast cancer cell proliferation
We next wanted to determine whether manipulation of TAFI impacted cell
proliferation. Treatment with 10 μg/mL PTCI had no effect while treatment with 10 nM
TM slightly decreased cell proliferation (as measured by a metabolic assay), albeit to an
extent that was not statistically significant (Figure 5). This result is in keeping with
previous study conducted in melanoma cells [30]. As shown in Figure 5B, treatment of
MDA-MB-231 cells with both variants of TAFI resulted in a slight, albeit again nonsignificant, decrease in cell proliferation. This result was independent of TAFI activation,
as addition of TAFIa gave the same result as addition of the zymogen.
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Figure 2.5: The effects of PTCI and TM on cell proliferation of breast cancer cell
lines.
MDA-MB-231 and SUM149 cells were subjected to the WST-1 assay as an index of
proliferation. (A) Cells were treated with 10 µg/mL PTCI or 10 nM TM, for 24 hours. (B)
MDA-MB-231 cells were treated with 50 nM of the indicated TAFI variants, either with
(Activated) or without (Non-Activated) prior treatment with thrombin-TM. Following the
treatment, the WST-1 assay was conducted and metabolic activity of the cells assessed by
measuring absorbance at 450 nm. The data represent the average cell number per field of
view ± SEM from at least 3 independent experiments and are relative to the control in the
absence of treatment.
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2.4.5 TAFIa inhibits DQ-collagen type IV proteolysis by MDA-MB-231 and
SUM149 cells
We examined the effect of TAFIa on degradation of DQ-collagen type IV by MDAMB-231 and SUM149 cells. Inhibition of TAFIa using 10 μg/mL PTCI resulted in a
significant increase in collagen IV proteolysis by both MDA-MB-231 and SUM149 cells
(Figure 7). DQ-collagen degradation products were localized both intracellularly
(represented by the yellow in the merged images) and extracellularly.
Next, we sought to directly investigate the effect of TAFIa on DQ-collagen type IV
degradation. MDA-MB-231 cells were treated with either activated or mock-activated
TAFI variants, TAFI-WT or TAFI-CIIYQ (Figure 8). Intriguingly, addition of TAFICIIYQ resulted in a decrease in collagen type IV proteolysis of approximately 30%,
irrespective of whether this variant was activated or not (Figure 8B). Addition of wild-type
TAFI or TAFIa had no significant effect on proteolysis. Taken together, these results
demonstrate a role for TAFIa in preventing collagen degradation.
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Figure 2.6: Inhibition of TAFIa increases proteolysis of DQ-collagen type IV by breast
cancer cells.
SUM149 (A) and MDA-MB-231 (B) cells labeled with CellTracker Orange (shown in red)
were grown on reconstituted basement membrane extract containing 25 µg/mL DQcollagen IV. Cells were treated with 10 g/mL PTCI for 48 hours. Confocal images were
taken following the 48-hour treatment. DQ-collagen degradation products were observed
in green. Scale bars: 20 µm. (C) DQ-collagen fluorescence was quantified and normalized
to the area of CellTracker Orange fluorescence. The data are represented as the green
fluorescent intensity per area of the red fluorescence, averaged across the entire z-stack and
expressed relative to untreated cells (Control). The data represent the mean ± SEM of 3
independent experiments, each carried out in triplicate. *: p < 0.05 versus Control. (D)
MDA-MB-231 cells labeled with CellTracker Orange (shown in red) were grown on rBM
containing 25 µg/mL DQ-collagen IV and treated with 50 nM of either TAFIa-WT or
TAFIa-CIIYQ, or with 50 nM mock-activated TAFI-WT or TAFI-CIIYQ. Confocal
images of cells (red) and DQ-collagen IV degradation products (green) were captured after
48 hrs. Scale bars: 20 µm. (E) Degradation of DQ-collagen IV was quantified as in (C).
The data represent the mean ± SEM of 3 independent experiments, each carried out in
triplicate. *: p < 0.05 versus Control.
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2.5 Discussion

TM has been shown to be an anti-metastatic factor in animal studies [19, 31] and
low levels of tumor TM have been shown to be a negative prognostic indicator in breast
cancer [20]. The anti-metastatic function of TM has been shown to reside in its ability to
bind to thrombin [19]. We report here that a molecular target of the thrombin TM complex
– namely, TAFI – can inhibit pro-metastatic behaviours of breast cancer cells in vitro
including invasion, migration, and extracellular proteolysis.
The thrombin-TM complex activates TAFI over 1000-fold more efficiently than
thrombin alone, and 20-fold more efficiently than plasmin [32]. Accordingly, we would
hypothesize thrombin-TM to be a relevant activator of TAFI in the tumor
microenvironment, particularly in the absence of a strong thrombogenic stimulus that
would result in generation of large amounts of thrombin and plasmin. We found that the
more malignant cell lines tended to express less mRNA encoding TM (Figure 1), and hence
these cells would be less able to support TAFI activation. In other words, the more
malignant cell lines are characterized by a relatively low capacity to generate potentially
anti-metastatic TAFIa. Indeed, although Reijerkerk and coworkers found that absence of
TAFI did not affect the growth and metastasis of B16 melanoma or Lewis lung carcinoma
cell lines in mice, these cell lines are unable to support TAFI activation [33].
Although we were able to detect expression of mRNA encoding TAFI in breast
cancer cells, there was no apparent correlation with malignancy (Figure 1). This
observation evokes the concept that the limiting factor in the anti-metastatic TAFI pathway
may not be TAFI itself, but instead the presence of TM that is required for TAFI activation
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in this milieu. Indeed, several studies have shown that plasma TAFI concentrations are
elevated in breast cancer patients and are positively correlated with endpoints such as poor
prognosis and risk of recurrence [34-36]. These findings are the opposite of what would be
expected given the ability of TAFIa to inhibit pro-metastatic behaviours such as invasion
that we have documented in this study. Moreover, a common single nucleotide
polymorphism in CPB2 encoding a more stable TAFIa species was also more frequent in
breast cancer patients than controls [35, 36]. In the breast cancer microenvironment, TM
may be provided by the breast cancer cells and/or by stromal cells such as endothelial cells
and macrophages [37]. TAFI may arise from tumor cells or macrophages, but more likely
from blood plasma present due to leaky tumor microvasculature [38].
We showed that TAFI can inhibit plasminogen activation on the breast cancer cell
surface (Figure 2). Carboxyl-terminal lysine binding sites on cell surface receptors play a
crucial role in plasminogen activation [39]. TAFIa cleaves carboxyl-terminal lysine
residues from various protein and peptide substrates. Plasmin has a series of pro-metastatic
effects including direct proteolysis of ECM and basement membrane proteins, activation
of latent pro-MMPs, and liberation of latent growth factors from the extracellular matrix
[40]. The decrease in plasmin generation in the presence of TAFIa likely results in
decreased activation of latent MMPs in the extracellular milieu, amplifying the effect of
TAFIa. It is notable that inhibition of TAFIa had a greater effect on cell invasion than cell
migration (Figures 3,4). The former requires cells to degrade the matrix while the latter
does not, and is an index merely of how fast cells can move. While the PAS has been shown
to be important for cell movement [40], our data suggest a key role for TAFI in blocking
proteolysis of collagen and other extracellular matrix components.
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TAFIa activity is regulated by the intrinsic instability of the enzyme. While the TAFI
zymogen is stable, the enzyme undergoes a spontaneous conformational change that causes
loss of activity [21, 41]. The half-life of TAFIa at body temperature is 8 – 15 minutes [42].
When we added purified recombinant TAFIa to our invasion assays, we saw no effect
(Figure 3). This is not surprising as the invasion assay is conducted over 24 hours and most
of the TAFIa activity would have disappeared within the first hour. Indeed, when we used
a stable TAFIa variant (TAFIa-CIIYQ) with a much longer half-life (1140 min [43]) we
did observe a dose-dependent decrease in cell invasion (Figure 3). Addition of the nonactivated forms of wild-type TAFI or TAFI-CIIYQ had no effect on invasion (Figure 3),
indicating that TAFI zymogen concentration was not a limiting factor under these
conditions. However, in cell migration assays, both enzymes appeared to have an effect
(Figure 4), although the decreases caused by wild-type TAFIa were non-significant. Again,
addition of the zymogens had no effect (Figure 4). The migration assays may have been
influenced at an early stage by the presence of TAFIa, for example if most of the migration
occurred in the first hours of the 24-hour incubation. Assays of the metabolic activity of
the breast cancer cell lines showed minimal impact of manipulation of TAFIa activity
(Figure 5). These findings suggest that the effect of TAFIa on invasion and migration
cannot be attributed to changes in cell proliferation.
Inhibition of TAFIa enhanced DQ-collagen degradation, indicating an important role
for TAFIa in mediating collagen proteolysis (Figure 6). Unlike cell migration, in the
proteolysis assays both the wild-type and mutant zymogens of TAFI along with their active
counterparts resulted in a decrease in collagen degradation (Figure 6). The 48-hour
incubation for the proteolysis assays may have allowed for ongoing activation of the added
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TAFI to have manifested in less accumulation of degraded DQ-collagen type IV. In the
breast tumor microenvironment, we would expect continuous activation of TAFI through
the action on small amounts of thrombin generated in situ interacting with TM on the
surface of different cell types in this environment. We observed the presence of DQcollagen type IV proteolysis both extracellularly and intracellularly (Figure 6). The
proteases and pathways involved in pericellular proteolysis versus intracellular proteolysis
are distinct [44, 45]. Pericellular proteolysis involves MMPs, serine proteases (including
components of the plasminogen activation system), and cysteine proteases [44, 45].
Intracellular proteolysis involves endocytosis of DQ-collagen IV by the live cells followed
by degradation of the substrate in the lysosome [45-47]. Intracellular proteolysis can also
occur after partial degradation of DQ-collagen type IV by pericellular proteases with
subsequent endocytosis and further degradation in the lysosome [48]. As such, an increase
in intracellular proteolysis also reflects the extent of pericellular proteolysis. We saw
effects of manipulation of TAFIa activity on both pericellular and intracellular proteolysis
(Figure 6), but since TAFIa acts outside the cell, we would argue that TAFIa directly affects
pericellular proteolysis, with an indirect effect on intracellular proteolysis.
In conclusion, we have demonstrated for the first time that activation of TAFI results
in a suppression of breast cancer cell invasion and migration. Our data are consistent with
the idea that TAFIa mediates these effects by inhibiting pericellular plasminogen activation
and by attenuating proteolysis of collagen type IV. Further work will be required to define
the full spectrum of the effects of TAFIa on specific proteases and protease targets in the
breast tumour microenvironment. Our results indicate that promotion of TAFI activation
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in this microenvironment, either by provision of soluble TM or stabilization of TAFIa,
would have anti-metastatic effects.
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Chapter 3

Activated Thrombin-Activatable Fibrinolysis Inhibitor Attenuates the
Angiogenic Potential of Endothelial Cells: Potential Relevance to the
Breast Tumour Microenvironment
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3.1 Summary
Thrombin-activatable fibrinolysis inhibitor (TAFI) is a basic carboxypeptidase
zymogen present in blood plasma. Proteolytic activation of TAFI by thrombin, thrombin
in complex with the endothelial cell cofactor thrombomodulin (TM), or plasmin results in
an enzyme (TAFIa) that removes carboxyl-terminal lysine residues from protein and
peptide substrates, including cell-surface plasminogen receptors. TAFIa is therefore
capable of inhibiting plasminogen activation in the pericellular milieu. Since plasminogen
activation has been linked to angiogenesis, TAFIa could therefore have anti-angiogenic
properties, and indeed TAFIa has been shown to inhibit endothelial tube formation in a
fibrin matrix. In this study, the TAFI pathway was manipulated by providing exogenous
TAFI or TAFIa or by adding a potent and specific inhibitor of TAFIa. We found that TAFIa
elicited a series of anti-angiogenic responses by endothelial cells, including decreased
endothelial cell proliferation, cell invasion, cell migration, tube formation, and collagen
degradation. Moreover, TAFIa decreased tube formation and proteolysis in endothelial cell
culture grown alone and in co-culture with breast cancer cell lines. In accordance with these
findings, inhibition of TAFIa increased secretion of matrix metalloprotease proenzymes by
endothelial and breast cancer cells. Finally, treatment of endothelial cells with TAFIa
significantly inhibited plasminogen activation. Taken together our results suggest a novel
role for TAFI in inhibiting tumour angiogenic behaviours in breast cancer.
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3.2 Background
Sustained angiogenesis is of one the hallmarks of cancer [1, 2] and is necessary for
the growth of a tumour past a dormant avascular stage [3-6]. Tumour angiogenesis provides
nutrients and oxygen to a tumour and also can act as an escape route allowing metastasis
to occur [6, 7]. It is firmly established that highly angiogenic tumours have a higher
metastatic potential than less vascular tumours [8].
The plasminogen activation system (PAS) is an important contributor to the
metastatic process, including angiogenesis [9, 10]. The PAS is an enzymatic cascade
responsible for cleavage and activation of plasminogen to its active form plasmin by
urokinase plasminogen activator (uPA) and tissue-type plasminogen activator (tPA) [11].
Plasminogen activation is enhanced on the cell surface by plasminogen receptors, some of
which possess carboxyl-terminal lysine residues, allowing for plasminogen binding [12].
Plasmin is a serine protease that cleaves a wide range of substrates, including several matrix
metalloproteinases (MMPs) and a variety of extracellular matrix (ECM) proteins [13],
events that stimulate cell invasion, migration, and ultimately sprouting during angiogenesis
[14].
Thrombin-activatable

fibrinolysis

inhibitor

(TAFI),

also

known

as

procarboxypeptidase B2 and procarboxypeptidase U, is a plasma zymogen that plays a role
in attenuating fibrinolysis [15] and in regulating pericellular plasminogen activation [16].
TAFI is activated by thrombin, plasmin and, most efficiently, thrombin in complex with
the endothelial cell cofactor thrombomodulin (TM). TAFIa is a basic carboxypeptidase that
cleaves carboxyl-terminal lysine residues from various protein and peptide substrates,
including fibrin degradation products and plasminogen receptors.
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Recently, we have demonstrated that TAFIa possess anti-metastatic potential,
inhibiting cell invasion, cell migration and collagen degradation of breast cancer cells,
through attenuation of plasminogen activation [17]. Likewise, Higuchi et al. found that
TM-stimulated activation of TAFIa decreased invasion of HT1080 fibrosarcoma cells by
reducing pericellular plasminogen activation [18]. A study by Reijerkerk et al. reported no
difference in metastasis or tumour growth in TAFI knockout mice [19]. However, the cell
lines used in the latter study (Lewis lung carcinoma and B16-BL melanoma) do not support
TM-mediated TAFI activation on their surface; therefore, this study does not clearly rule
out a role for TAFI in cancer. The role of TAFI in tumour angiogenesis has not been
previously explored, although TAFIa has been shown to reduce degradation of ECM [20]
and to inhibit wound healing angiogenesis in plasma clots [21]. Collectively, these findings
suggest that TAFIa has the potential to play an anti-angiogenic and anti-metastatic role in
cancer progression. We therefore set out to further assess the potential of TAFI to regulate
angiogenesis in a setting that, unlike a plasma clot, more closely mimics the breast cancer
tumour microenvironment.
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3.3 Methods

3.3.1 Cell lines and cell culture
SUM149 cell line was a gift from Dr. Stephen Ethier (Barbara Ann Karmanos
Cancer Institute), MDA-MB-231 cell line was purchased from Sigma, and human
umbilical vein endothelial cells (HUVECs) were purchased from Lonza. SUM149 cells
were grown in Dulbecco’s Modified Eagles Medium: Nutrient Mixture F-12 (DMEM/F12) (Gibco) supplemented with 10% fetal bovine serum (FBS) (Gibco), 1%
antibiotic/antimycotic (Gibco), 10 μg/mL insulin (Sigma-Aldrich) and 0.5 μg/mL
hydrocortisone (Sigma-Aldrich). MDA-MB-231 cells were supplemented with DMEM/F12 supplemented with 10% FBS, and 1% antibiotic/antimycotic. HUVECs were
supplemented with Endothelial Cell Basal Medium-2 (EBM-2) (Lonza) completed with
2% FBS (Lonza) and Endothelial Cell Growth Media-2 (EGM-2) SingleQuots Kit (Lonza).
HUVECs were used at passage five for all experiments. Human embryonic kidney (HEK
293) cells were cultured in minimum essential media (MEM) (Gibco), containing 5% FBS
and 1% antibiotic/antimycotic. All cells were maintained at 37°C in a humidified 95%
air/5% CO2 atmosphere.

3.3.2 TAFI purification and activation
TAFI was cloned into a mammalian expression plasmid in-frame with a carboxylterminal 6×His tag encoding sequence, as previously described [17]. This plasmid was
stably transfected into HEK 293 cells and conditioned media (CM) was collected from cell
lines grown in triple flasks (Nunc). Recombinant TAFI (rTAFI) was purified utilizing a
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Ni2+-Sepharose column (GE Healthcare Life Sciences), as previously described [17]. TAFI
(0.8 µM) was activated to TAFIa using 25 nM thrombin (Haematologic Technologies),
100 nM thrombomodulin (Haematologic Technologies) and 5 mM CaCl2 for 10 minutes at
room temperature. Following incubation, thrombin was inhibited using 200 nM H-D-PhePro-Arg chloromethylketone (PPAck; Calbiochem). TAFIa was then used in experimental
procedures as described below, at a final concentration of 50 nM. For experiments using
non-activated TAFI, the activation mixtures were assembled as described above, in the
absence of thrombin. For control experiments, the activation mixtures were assembled in
the absence of TAFI. Therefore, all experiments were conducted with the equivalent
concentrations of added CaCl2, thrombomodulin, and chloromethylketone.

3.3.3 Endothelial cell invasion and migration assays
Transwell invasion assays were used to assess the effect of inhibiting TAFIa on
endothelial cell invasion. BD Falcon cell culture inserts (8 μm pore size; PET track-etched
membranes) (BD Biosciences) were coated with 2 mg/mL Cultrex Basement Membrane
Extract (BME) without Phenol Red (Trevigen) in a 24-well plate for one hour. BME was
diluted to 2 mg/mL from a stock solution with serum and supplement-free EBM-2 medium
(Lonza). Following incubation, the inserts were washed three times with HEPES Buffered
Saline Solution (HBSS) (Lonza). Supplement free EBM-2 containing 0.5% FBS was added
to the bottom of each well in the 24-well plate. Test substances added to this medium were
50 ng/mL vascular endothelial growth factor (VEGF) or 25 µg/mL potato tuber
carboxypeptidase inhibitor (PTCI). For experiments using TAFI, medium in the bottom
chamber contained 50 ng/mL VEGF and 50 nM activated or non-activated TAFI, or no
111

added TAFI. Coated inserts were placed in the wells and 50,000 HUVECs/well in 100 µL
of serum- and supplement-free EBM-2 were added into the coated inserts. Cells were
allowed to invade into the BME for 20 hours, after which non-invaded cells were removed
with a cotton swab, and the invaded cells were fixed in methanol. The invaded cells were
stained with 0.25% (w/v) Crystal Violet (Sigma-Aldrich). The cells in five different fields
of view were counted under a 20× objective using an Olympus CKX415F2 Inverted
Microscope.
Cell migration assays were carried out in the same manner as the cell invasion
assay, except cell culture inserts were not coated with BME.

3.3.4 Cell metabolism assay
Cell proliferation of HUVECs was determined using the WST-1 assay (Roche
Diagnostics), which measures metabolic activity of viable cells. HUVECs were seeded in
a 96-well plate at 10,000 cells/well complete EBM-2 media. Cells were treated in
quadruplicate with either 50 ng/mL VEGF or 25 µg/mL PTCI. For experiments with TAFI,
cells were treated with 50 nM of either activated or non-activated TAFI, in the presence or
absence of 50 ng/mL VEGF. Cells were treated for 24 hours, following which WST-1 was
added to each well and incubated for 2 hours at 37°C. The cleavage of WST-1 to formazan
by metabolically active cells was measured at 450 nm using a SpectraMax Plus384
Absorbance Microplate Reader (Molecular Devices).
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3.3.5 Tube formation assays
In preparation for tube formation assays, 35 mm glass bottom culture dishes
(MatTek) were coated with BME and incubated for 10 minutes at 37°C to allow the BME
to solidify. HUVECs grown in T25 flasks to ~80% confluency were washed four times
with HBSS (Lonza), and labelled with 5 µM Cell Tracker™ Orange CMTMR (Life
Technologies Inc.) in EBM-2 with 0.75% FBS for one hour at 37°C. Labelled cells were
then washed four times with HBSS (Lonza) and incubated in complete EBM-2 for one hour
at 37°C. Following incubation, 20,000 HUVECs in EBM-2 with 0.75% FBS were seeded
on top of the BME-coated glass bottom dishes and allowed to attach for 40 minutes at 37°C.
Subsequently, complete EBM-2 media containing 2% BME with and without treatment
(50 ng/mL VEGF or 25 µg/mL PTCI) was added. For TAFI treatments, 50 nM of either
activated or non-activated TAFI or the control activation mixture was added to complete
EBM-2 containing 2% BME. Cells were incubated at 37°C for 18 hours to allow formation
of tube-like structures [22, 23]. Cells were then imaged using an Olympus IX81 confocal
microscope. Tube formation in eight to ten different fields of view was imaged under a 10×
objective. Relative tube length was measured as the total length of all tubes within the field
of view divided by total number of tubes within the field of view.
For co-culture experiments, SUM149 or MDA-MB-231 cells washed with
phosphate buffered saline (PBS), and labelled with 5 µM CellTrace™ Far Red DDAO-SE
(Life Technologies Inc.) in serum free DMEM/F-12 for one hour at 37°C. Labelled cells
were then washed with PBS, and incubated in complete DMEM/F-12 for one hour at 37°C.
Following incubation, breast cancer cells (20,000 SUM149 cells or 7,000 MDA-MB-231
cells in serum free DMEM/F-12) were seeded on top of BME coated glass bottom dishes,
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and allowed to attach for 40 minutes at 37°C. Complete DMEM/F-12 media containing 2%
BME was added and cells were incubated at 37°C for 24 hours. Thereafter, media was
removed and 20,000 HUVECs pre-labeled with Cell Tracker™ Orange CMTMR were
seeded on top of the embedded breast cancer cells. Cells were treated with either VEGF
(50 ng/mL), PTCI (25 µg/mL) or 50 nM TAFI, as described above. After 18 hours of
incubation at 37°C, tube formation was assessed as described above.

3.3.6 Dye-Quenched (DQ)-collagen IV proteolysis assays
Proteolysis of DQ-collagen IV by HUVECs was assessed as previously described
[24, 25]. Briefly, 35 mm dishes were coated with BME containing 25 µg/ml DQ-collagen
IV (Life Technologies Inc.) and incubated for 10 min at 37 °C. HUVECs were then seeded
on top of the BME/DQ-collagen IV mixture as described above for the tube formation
assay with and without 50 ng/mL VEGF or 25 µg/mL PTCI or 50 nM TAFI/TAFIa
treatments. Cells were incubated at 37°C for 18 hours, and then imaged using an Olympus
IX81 confocal microscope. Three to four z-stacks each containing fourteen 2.5 µm slices
were imaged using a 20× objective with a zoom of three, and three adjacent slices were
selected for analysis (one of which generally including the slice at the equatorial plane).
The amount of proteolysis was determined using ImageJ software by calculating total green
fluorescence of the DQ-collagen type IV degradation products in each the three slices
divided by HUVEC area and averaging over the selected slices.
Proteolysis of DQ-collagen IV by co-cultured HUVECs and breast cancer cells was
assessed as previously described [26]. BME mixed with 25 µg/ml DQ-collagen IV was
used to coat a 35 mm glass bottom culture dish as described above. Breast cancer cells,

114

pre-labeled with CellTrace™ Far Red DDAO-SE, were seeded on top of the BME/DQcollagen IV mixture using the same cell number, procedure and treatments as described for
the co-culture tube formation assay above. Cells were incubated at 37°C for 18 hours. Areas
were HUVEC tube-like structures were in contact with a breast cancer spheroid were
imaged and the extent of proteolysis measured as described above for the HUVEC
monocultures.
3.3.7 Plasminogen activation assay
Plasminogen activation assays were conducted as previously described [17, 27].
Briefly, HUVECs were seeded to confluency in black, clear-bottom 96 well plates. Cells
were washed twice with HBS supplemented with 0.4% (w/v) BSA (HBS-BSA). Activated
TAFI (0, 10, 50 nM) was added to the cells and incubated for 30 minutes at 37˚C. Following
the incubation, cells were washed two times with HBS-BSA. Plasminogen activation on
the cell surface was conducted using both uPA and tPA. Plasminogen was purified from
human plasma using lysine-Sepharose affinity chromatography, as previously described
[28]. For the uPA experiments, a solution containing 500 nM plasminogen, 20 nM uPA
(EDM Millipore) and 40 mM of the fluorogenic plasmin substrate H-D-Val-Leu-Lys-AMC
(Bachem) was added to the cells. For the tPA experiments, 500 nM plasminogen, 5 nM
tPA (Alteplase; Kingston General Hospital) and 40 mM H-D-Val-Leu-Lys-AMC was used.
Hydrolysis of the substrate was monitored for 60 minutes at 37°C, at excitation and
emission wavelengths of 370 nm and 470 nm, respectively.
3.3.8 Gelatin zymography
Subconfluent monocultures of SUM149 cells or HUVECs were treated with or
without 50 ng/mL VEGF or 25 µg/mL PTCI for 24 hours. Following treatment, SUM149
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cells and HUVECs were washed with PBS and then serum starved for 24 hours in serum
free DMEM or EBM-2 with 0.2% FBS media, respectively. CM was collected from both
cell types. Lysates from both cell types were collected by adding lysis buffer (50 mM TrisHCl pH 7.4, 1% Nonidet P-40, 0.25% sodium deoxycholate, 150 mM NaCl, 1 mM EDTA).
Cell lysate protein concentration was determined using a BCA assay (Life Technologies
Inc.) according to the manufacturer’s instructions.
In some experiments, HUVECs grown to 60% confluence were washed with HBSS
(Lonza) and CM from untreated, VEGF, or PTCI treated SUM149 cells (prepared under
conditions as described above) was mixed 1:1 with complete EBM-2 medium and added
to the HUVECs. Control HUVECs were treated with complete EBM-2 medium alone.
Following 24 hours of incubation with SUM149 CM, the HUVECs were washed with
HBSS and placed in EBM-2 media with 0.2% FBS for 24 hours. The supernatant and lysate
were then collected, and lysate protein concentration was determined as described above.
MMP2 and MMP9 enzymatic activities in medium from SUM149, HUVEC, or
HUVEC treated with SUM149-CM were determined by SDS-PAGE gelatin zymography
as described by Mohamed et al. [29]. Samples were mixed with 2× SDS sample buffer and
equal protein amounts (20 µg/lane of SUM149 samples, 6 µg/lane of HUVEC samples)
were loaded, without heating or reducing, and subjected to SDS-PAGE on 10%
polyacrylamide gels containing 1% (w/v) gelatin at 125 V for 2.5 hours at 4°C. Human
recombinant MMP2 (5 ng) and MMP9 (2.5 ng) (R&D Systems) were also loaded as
positive controls. Following electrophoresis, gels were incubated twice in renaturing buffer
(2.5% Triton X-100) for 15 minutes. Thereafter, gels were washed twice with deionized
water for 15 minutes. Gels were then placed in developing buffer (50 mM Tris-HCl pH
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7.8, 5 mM CaCl2, 0.05% Brij 35) and incubated overnight at 37°C. Subsequently, gels were
stained for 1 hour with Coomassie blue (50% methanol, 10% acetic acid, 40% water, 0.5%
Coomassie brilliant blue R-250), and destained (50% methanol, 10% acetic acid, 40%
water) until clear bands of proteolytic activity appeared. Relative proteolytic activity of
each sample was determined by densitometry using FluoroChem® Q imaging system
software (Alpha Innotech Corporation).

3.3.9 Statistical methods
Results are expressed as a mean ± SEM from at least three independent
experiments. Statistical analysis was performed using one-way ANOVA test with post-hoc
Tukey HSD with IBM SPSS Statistics V22.0 software. Statistical significance was
presumed at p < 0.05.
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3.4 Results
3.4.1 TAFIa inhibits endothelial cell invasion and migration
During angiogenesis, endothelial cells locally degrade the vascular basement
membrane and invade into the surrounding stroma [3, 30]. Here, we performed an in vitro
invasion assay by seeding HUVECs in the top chamber of a BME coated Transwell insert,
to assess the effect of TAFIa on endothelial cell invasion. TAFIa was inhibited using a
specific competitive inhibitor, potato tuber carboxypeptidase inhibitor (PTCI). For the
purposes of comparison, we also used vascular endothelial growth factor (VEGF), a known
stimulator of angiogenesis. Our results show that PTCI significantly increased invasion of
HUVECs 4.6-fold relative to the control, while VEGF increased invasion of HUVECs 6fold relative to the control (Fig. 1A,B). We next assessed the direct effect of TAFI on
endothelial cell invasion. Treatment with both activated and non-activated TAFI resulted
in a 2.4-fold decrease in HUVEC invasion compared to the control treated with VEGF
(Fig. 1E).
Cell migration is another important process that occurs during angiogenesis.
Migration assays were conducted in the absence of BME and hence reflect only the motility
of the cells, since there is no BME barrier that must be proteolyzed. To assess the effect of
TAFI on cell migration, TAFIa was inhibited using PTCI or the cells were treated with
TAFI/TAFIa. As shown in Fig. 1C, treatment with PTCI results in a significant increase in
cell migration. Treatment with either activated or non-activated TAFI significantly
decreased endothelial cell migration by 2.1-fold compared to VEGF alone (Fig. 1F).
Together, these results demonstrate a role for TAFIa in mediating endothelial cell invasion
and migration.
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Figure 3.1: TAFI decreases endothelial cell invasion and migration.
(A) HUVECs were added to a Transwell chamber coated with (for invasion), or without
BME (for migration), in the presence and absence of 50 ng/mL VEGF or 25 µg/mL PTCI.
Cells were allowed to invade for 20 hours and then were fixed, stained and imaged. Images
above were obtained at 4× magnification. Scale bar, 200 µm (B) Quantification of HUVEC
invasion. (C) Quantification of HUVEC Migration. For both cell invasion and migration,
cells were counted from 5 different fields of view at 20× magnification, and cell numbers
expressed relative to control. (D) HUVECs were added to a Transwell chamber coated with
(for invasion), or without BME (for migration), in the presence 50 ng/mL VEGF with 50
nM of either activated (TAFIa) or non-activated TAFI. Cells were allowed to invade for
20 hours and then were fixed, stained and imaged. (E) Quantification of HUVEC invasion
Panels B. (F) Quantification of HUVEC migration Panels C. Values are expressed as mean
± SEM from four independent experiments. ## p< 0.01 versus control, * p<0.05, ** p<
0.01 versus control with VEGF.
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3.4.2 Effect of TAFIa on cell proliferation
We investigated whether the effects of PTCI on HUVEC invasion and migration
may have been due to an increase in proliferation. After incubation for 18 hours, both
VEGF and PTCI increased HUVEC metabolic activity, as measured by the WST-1 as an
index of cell proliferation (Fig. 2A). We next examined the effect of TAFI and TAFIa on
HUVEC metabolic activity, in the presence and absence of VEGF. In the absence of VEGF,
neither TAFI nor TAFIa had a significant effect on metabolic activity (Fig. 2B). In the
presence of VEGF, both the TAFI and TAFIa significantly decreased metabolic activity
(Fig 2B). However, the effects of TAFIa or TAFIa inhibition were of a much lower
magnitude than their effects on cell invasion and migration (Fig. 1).
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Figure 3.2: Effect of TAFI on cell proliferation of endothelial cells.
(A) HUVECs were treated for 24 hours with 50 ng/mL VEGF or 25 µg/mL PTCI. The
WST-1 assay was performed as an index of proliferation. Absorbance values for the
formazan product were measured at 450 nm using a plate-reading spectrophotometer. (B)
HUVECs with treated with 50 nM of either activated or non-activated TAFI in the presence
or absence of 50 ng/mL VEGF for 24 hours. Values are expressed as mean ± SEM from
≥3 independent experiments performed in quadruplicate. * p<0.05, ** p< 0.01 versus
control, # p<0.05, versus control with VEGF.
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3.4.3 TAFIa inhibits tube formation of endothelial cells grown alone and in co-culture
with breast cancer cells
Another index of the angiogenic potential of endothelial cells is the formation of
tube-like structures in vitro, in which the cells undergo a process of attachment, migration,
and differentiation of endothelial cells into tube-like structures on a matrix in a manner that
mimics the in vivo process of tube formation [23, 31]. Previous studies have shown that
inhibition of TAFIa increases endothelial tube formation in a 3D plasma clot consisting of
a fibrin matrix [21]. While this result demonstrated a role for TAFI in wound healing
angiogenesis, the role of TAFI in endothelial tube formation during tumour angiogenesis
has yet to be studied. HUVECs were seeded on top of BME, and were treated with either
VEGF or the TAFIa inhibitor PTCI (Fig. 3A). PTCI promoted in vitro tube formation of
HUVECs as observed by the significant increased relative tube length (1.3-fold) compared
to the control, and resembling the effect of VEGF (Fig. 3B). We next examined the direct
effect of TAFI on endothelial tube formation. Likewise, treatment of endothelial cells with
both TAFI and TAFIa significantly decreased tube formation (Fig. 3C) to 0.75-fold of
untreated control (Fig. 3D).
Next, we assessed the effect of TAFIa inhibition on tube formation of HUVECs
grown in co-culture with either SUM149 cells (Fig. 4) or MDA-MB-231 cells
(Supplementary Fig. 1), both of which are highly aggressive triple negative breast cancer
cell lines. The breast cancer cells form spheroid structures on top of the BME, while the
endothelial cells form tube-like structures. This in vitro co-culture model functions to
mimic the in vivo tumour microenvironment, which consists of cancer cells as well as
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stromal cells such as endothelial cells [32]. Interaction between HUVECs and breast cancer
cells can be seen in merged images combining differential interference contrast (DIC),
HUVEC fluorescence, and breast cancer cell fluorescence images (Fig. 4A/C,
Supplementary Fig. 1A). Co-cultures were treated with VEGF, PTCI, TAFI, or TAFIa.
PTCI significantly increased relative tube length compared to the control with a 1.4-fold
increase in both the SUM149:HUVEC co-cultures (Fig. 4B) or the MDA-MB231:HUVEC co-cultures (Supplementary Fig. 1A), and at levels similar to treatment with
VEGF. Treatment with both TAFI and TAFIa decreased endothelial tube length to
approximately 0.75-fold of untreated control (Fig. 4D).
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Figure 3.3: TAFIa decreases endothelial tube formation.
(A) HUVECs labelled with Cell Tracker Orange™ (red) were seeded on top of BME in a
35 mm glass bottom culture dish and treated with either 50 ng/mL VEGF or 25 µg/mL
PTCI. Cells were imaged 18 hours after seeding HUVECs using confocal microscopy.
Images above were obtained at 40× magnification. Scale bar, 200 µm. (B) Quantification
of endothelial tube formation. To quantify tube formation 8-10 images were obtained at
100× magnification. Tube length was determined by measuring total tube length divided
by total tube number, and is expressed relative to that in the control untreated cells. (C)
HUVECs labelled with Cell Tracker Orange™ (red) were seeded on top of BME and
treated with 50 nM of either activated or non-activated TAFI for 18 hours. Cells were
imaged as in Panel A. (D) Quantification of tube length following treatment with TAFIa,
performed as for Panel B. Values are expressed as mean ± SEM from ≥3 independent
experiments. * p<0.05, ** p< 0.01 versus control.
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Figure 3.4: TAFIa decreases endothelial tube formation in a co-cultures of HUVECs
and SUM149 cells.
(A) SUM149 cells labelled with Cell Trace™ Far Red (green) were seeded on top of BME
in a 35 mm glass bottom culture dish. After 24 hours, HUVECs labelled with Cell
Tracker™ Orange (red) were seeded on top of the SUM149 cells and BME. Co-cultures
were treated with either 50 ng/mL VEGF or 25 µg/mL PTCI and imaged after 18 hours
using confocal microscopy at 40× magnification. Scale bar, 200 µm. (B) To quantify tube
formation, 8-10 images were obtained at 100× magnification. Average tube length was
determined by measuring total tube length divided by total tube number, and is expressed
relative to that in the control untreated cells. (C) HUVECs labelled with Cell Tracker™
Orange (red) and SUM149 cells were labelled with Cell Trace™ Far Red (blue) were
seeded on top of BME and treated with 50 nM of either activated or non-activated TAFI
for 18 hours. Cells were imaged as in Panel A. (D) Quantification of tube length following
treatment with TAFI or TAFIa, performed as for Panel B. Values are expressed as mean ±
SEM from ≥3 independent experiments. * p<0.05, ** p< 0.01 versus control.
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3.4.4 TAFIa decreases proteolysis of DQ-collagen IV by endothelial cells grown alone
and in co-culture with breast cancer cells
One of the initial steps of angiogenesis involves the degradation of vascular
basement membrane and ECM by endothelial cells [3, 30]. Pericellular plasminogen
activation has been implicated in angiogenesis and metastasis and associated with the
activation of MMPs, release of growth factors from the ECM, and degradation of the ECM
[33]. VEGF upregulates components of the plasminogen activation system in the leading
edge of migrating endothelial cell [13, 34, 35]. Moreover, tube formation spatially
correlates with ECM proteolysis in vitro [36]. TAFIa inhibits pericellular plasminogen
activation in vitro and in vivo [37-39]. Therefore, we tested the effect of TAFIa on
proteolysis of DQ-collagen IV, since collagen-IV is the most abundant type of collagen
found in the basement membrane [40]. HUVECs were seeded on top of BME mixed with
DQ-collagen IV, and treated with either VEGF or PTCI. Once DQ-collagen IV – a
quenched fluorescent substrate – is cleaved by proteases, fluorescent DQ-collagen IV
degradation products are produced (green) (Fig. 5A). Degradation products of DQ-collagen
IV were localized predominantly intracellularly, although treatment with VEGF did
slightly increase pericellular (outside the cell or on the cell membrane [36]) localization of
DQ-collagen IV degradation products (Fig. 5A). Treatment of HUVECs with PTCI
significantly increased proteolysis of DQ-collagen IV, 2-fold relative to the control (Fig.
5B). We next examined the effect of TAFI and TAFIa on DQ-collagen IV proteolysis of
HUVECs (Fig. 5C). TAFIa decreased DQ-collagen IV proteolysis to 0.7-fold of control
(Fig. 5D). Non-activated TAFI decreased proteolysis to 0.67-fold of control (Fig. 5D).
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To examine the effect of TAFIa on proteolysis of DQ-collagen IV by both
endothelial and breast cancer cells in the same environment, we co-cultured HUVECs with
SUM149 cells (Fig. 6) or MDA-MB-231 cells (Supplementary Fig. 2). Co-cultures were
treated with PTCI, VEGF, TAFI or TAFIa. Although both intracellular and pericellular
proteolysis was observed in the co-cultures (Fig. 6A and Supplementary Fig. 2A),
HUVEC:MDA-MB-231 co-cultures exhibited predominately pericellular proteolysis
(Supplementary Fig. 2C). In both co-cultures, treatment with VEGF or PTCI significantly
increased both pericellular and intracellular proteolysis as compared to the control (Fig. 6B
and Supplementary Fig. 2D). We next examined the effect of TAFI or TAFIa treatment on
proteolysis in the HUVECs: SUM149 co-cultures. Treatment with either TAFI or TAFIa
resulted in a decrease in DQ-collagen proteolysis to 0.7-fold of control.

128

Figure 3.5: TAFIa decreases proteolysis of DQ-collagen IV by endothelial cells.
(A) HUVECs labelled with Cell Tracker™ Orange (red) were seeded on top of BME mixed
with DQ-collagen IV in a 35 mm glass bottom culture dish and treated with either 50 ng/mL
VEGF or 25 µg/mL PTCI. Cells were imaged 18 hours after seeding HUVECs using
confocal microscopy. DQ-collagen IV cleavage products (green) were present
predominantly intracellularly. Merge images show intracellular (yellow) and pericellular
(green) proteolysis. Images were obtained at 600× magnification. Representative images
from the equatorial plane of a Z-stack are shown. Scale bar, 20 µm. (B) To quantify
proteolysis, three equatorial planes from 3-4 different images in each independent
experiment were examined. Total integrated intensity of DQ-collagen IV fluorescence
divided by total combined cell area of HUVECs was averaged across the three planes and
expressed relative to the control. (C) HUVECs labelled with Cell Tracker Orange (red)
were seeded on top of BME mixed with DQ-collagen IV and treated with 50 nM of either
activated or non-activated TAFI for 18 hours. Cells were imaged as in Panel A. (D)
Quantification of DQ-collagen proteolysis following treatment with TAFI or TAFIa,
performed as for Panel B. Values are expressed as mean ± SEM from ≥3 independent
experiments. * p<0.05, ** p< 0.01 versus control.
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Figure 3.6: TAFIa decreases DQ-collagen IV proteolysis by co-cultured HUVECs and
SUM149 cells.
(A) SUM149 cells labelled with Cell Trace Far Red (pseudocoloured blue) were seeded on
top of BME mixed with DQ-collagen IV in a 35 mm glass bottom culture dish. After 24
hours HUVECs labelled with Cell Tracker Orange (red) were seeded on top of the SUM149
cells and BME mixed with DQ-collagen IV. The co-cultures were treated with either 50
ng/mL VEGF or 25 µg/mL PTCI. Cells were imaged 18 hours after HUVECs were seeded
using confocal microscopy. DQ-collagen IV cleavage products (green) were present both
intracellularly and pericellularly. Merged images show pericellular proteolysis (green)
surrounding the co-cultured cells. Images were obtained at 600× magnification.
Representative images from the equatorial plane of a Z-stack are shown. Scale bar, 20 µm.
(B) To quantify proteolysis, three equatorial planes from 3-4 different images in each
independent experiment were examined. Total integrated intensity of DQ-collagen IV
fluorescence divided by total combined cell area of HUVECs and SUM149 cells was
averaged across the three planes and expressed relative to the control. (C) HUVECs
labelled with Cell Tracker Orange (red) and SUM149 cells were labelled with Cell Trace
Far Red (blue) were seeded on top of BME containing DQ-collagen IV and treated with 50
nM of either activated or non-activated TAFI for 18 hours. Cells were imaged as in Panel
A. (D) Quantification of DQ-collagen proteolysis following treatment with TAFIa,
performed as for Panel B. Values are expressed as mean ± SEM from ≥3 independent
experiments. * p<0.05, ** p< 0.01 versus control.
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3.4.5 TAFIa inhibits plasminogen activation on endothelial cells
Plasminogen activation on the cell surface is accelerated by the presence of
carboxyl-terminal lysine residues found on several plasminogen receptors. These lysine
residues represent plasminogen binding sites on the cell surface. As a carboxypeptidase,
TAFIa has been shown to cleave carboxyl-terminal lysine residues from various substrates,
including plasminogen receptors. As shown in Fig. 7, various concentrations of TAFIa can
inhibit both uPA and tPA mediated plasminogen activation on the surface of HUVECs.
uPA-mediated plasminogen activation decreased 33% in the presence of 50 nM TAFIa; 10
nM TAFIa decreased tPA-mediated plasminogen activation 18%.
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Figure 3.7: Inhibition of plasminogen activation by TAFIa on endothelial cells.
HUVECs were treated with various concentrations of TAFIa (1-50 nM) for 30 minutes at
37°C. Plasminogen activation assay was completed with 500 nM plasminogen, 20 nM uPA
or 5 nM tPA and a fluorogenic plasmin substrate. The rate of plasmin generation was
monitored over 1 hour at 37°C. The data are represented as the relative change in
fluorescence versus time squared. The data represent results of 3-4 independent
experiments and are presented as the mean ± SEM. * p<0.05, ** p< 0.01 versus no TAFIa.
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3.4.6 Effect of inhibition of TAFIa on MMP abundance
Since inhibition of TAFIa was shown to increase proteolysis of DQ-collagen IV by
endothelial cells and by endothelial cells co-cultured with breast cancer cells, we next
wanted to assess whether inhibition of TAFIa affected the abundance of MMPs.
Pericellular plasminogen activation is involved in ECM remodeling, as well as the release
and activation of MMPs from the ECM [22]. MMP2 and MMP9 have been shown to be
implicated in tumour angiogenesis [41]. MMP2 and MMP9 are gelatinases, but also
degrade other ECM proteins such as collagen type IV [42]. VEGF has been shown to be in
a positive feedback loop with MMP9 in RPE cells [43], therefore it was used as a positive
control in these experiments.
Gelatin zymography, which allows the gelatinolytic activity of latent and active
MMP2 and MMP9 to be measured [44], was used to determine the effect of inhibition of
TAFIa on the abundance of MMP2 and MMP9 after treatment of SUM149 breast cancer
cells with PTCI or VEGF. Bands from the SUM149 media samples migrated similarly to
recombinant pro-MMP2 and pro-MMP9 controls, which suggests that they are likely proMMP9 and pro-MMP2 (Fig. 8A). It was determined that PTCI significantly increased
abundance of both pro-MMP2 (1.7-fold) and pro-MMP9 (2.6-fold) compared to the control
(Fig. 8A). We could not detect the presence of active MMP2 or MMP9 (Fig. 8A).
Similar experiments were performed to assess the effect of inhibition of TAFIa on
MMP2 and MMP9 abundance in the medium of HUVECs. It was determined that PTCI
does not significantly affect the abundance of pro-MMP2 (Fig. 8B). We could not detect
the presence of pro-MMP9 or MMP9 (Fig. 8B).
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Next, we used CM from PTCI- or VEGF-treated SUM149 cells to treat HUVECs,
to examine if breast cancer cells could mediate the proteolytic activity of HUVECs in a
paracrine manner. Treatment of HUVECs with CM from untreated SUM149 cells resulted
in a 1.2-fold increase in pro-MMP2 abundance compared to the untreated HUVEC control,
although this was not significant (Fig. 8C). Treatment of HUVECs with CM from PTCI
treated SUM149 cells significantly increased the abundance of pro-MMP2, 1.6-fold
relative to the untreated HUVEC control (Fig. 8C).
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Figure 3.8: Inhibition of TAFIa in SUM149 cells increases abundance of pro-MMP2
and pro-MMP9.
(A) Representative zymogram depicting gelatinolytic activity of pro-MMP9 (92 kDa), proMMP2 (72 kDa) present in CM harvested from SUM149 breast cancer cells treated with
either 25 µg/mL PTCI or 50 ng/mL VEGF for 24 hours. Densitometry was performed and
reported as relative intensity as compared to the control. (B) Representative zymogram
depicting gelatinolytic activity of pro-MMP2 (72 kDa) secreted by HUVECs treated with
either either 25 µg/mL PTCI or 50 ng/mL VEGF for 24 hours. Densitometry was performed
and reported as relative intensity as compared to the control. (C) Representative zymogram
depicting gelatinolytic activity of pro-MMP2 (72 kDa) present in CM harvested from
HUVECs treated with CM from SUM149 cells treated with either 25 µg/mL PTCI or 50
ng/mL VEGF. Densitometry was performed and reported as relative intensity as compared
to the untreated control. Data represent results of ≥3 independent experiments and are
presented as mean ± SEM. * p<0.05, ** p<0.01 versus control
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3.5 Discussion
Our current studies examining the role of TAFIa in angiogenic responses of
endothelial cells were prompted by reports that TAFIa is able to inhibit pericellular
plasminogen activation [37] and to reduce endothelial cell tube formation in a fibrin matrix
[21]. We examined the role of TAFIa in angiogenesis in the context of breast cancer
because we recently demonstrated that TAFIa inhibits pro-metastatic behaviours and
pericellular plasminogen activation in both SUM149 and MDA-MB-231 breast cancer
cells [17]. We therefore used SUM149 and MDA-MB-231 cells in co-cultures with
HUVECs because they provide an appropriate cellular model to evaluate tumour
angiogenesis.
Results from our in vitro studies suggest that TAFIa plays a role in inhibition of
tumour angiogenesis. Addition of TAFI or TAFIa resulted in a decrease in crucial
components of angiogenesis: namely, endothelial cell proliferation, invasion, tube
formation, and ECM proteolysis, while the opposite effects were observed when
endogenous TAFIa was inhibited with PTCI. Although TAFIa appeared to have a small
effect on cell proliferation (Fig. 2), this is unlikely to account for the much larger effect of
TAFI on cell migration and invasion, which we ascribe to effects of TAFIa on cell motility
and basement membrane, respectively. Endothelial tube formation and ECM proteolysis
were also decreased by TAFI/TAFIa in co-cultures of endothelial cells with breast cancer
cells. We hypothesize that the ability of TAFIa to inhibit pericellular plasminogen
activation likely underlies these effects, as we have shown in this study – for the first time
– that TAFIa can inhibit plasminogen activation on HUVECs (Fig. 7).
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For angiogenesis to occur the vascular basement membrane must be locally
degraded by proteolytic enzymes [45]. ECM proteolysis promotes the angiogenic process
in part by stimulating cell invasion and migration [46]. Importantly, growth factors, such
as VEGF, stimulate this process [47]. In this current study we have shown that TAFIa
inhibits VEGF-mediated invasion and migration of endothelial cells. Additionally, we
examined the effect of TAFIa on degradation of DQ-collagen IV, a quenched fluorescent
derivative of type IV collagen [48], by HUVECs grown alone and in co-culture breast
cancer cells. The co-culture systems act to better recapitulate a tumour microenvironment
[26]. TAFIa decreased proteolysis of DQ-collagen IV, thus supporting our hypothesis that
TAFIa is able to inhibit extracellular proteolysis potentially through inhibition of plasmin
formation. Indeed, pericellular proteolysis can be caused by components of the
plasminogen activation system [48, 49], and plasmin can liberate and activate MMPs from
the ECM [50].
Although the proteases and pathways involved in pericellular proteolysis compared
to intracellular proteolysis differ in some respects [48, 49], changes in intracellular
proteolysis, as we observed in some cases (Figs. 5,6) can reflect changes in extracellular
proteolysis. Pericellular proteolysis have been shown to involved MMPs, serine proteases
(including components of the plasminogen activation system), and cysteine proteases [48,
49]. Intracellular proteolysis involves endocytosis of DQ-collagen IV by the live cells, and
degradation of the substrate in the lysosome [49-51]. Intracellular proteolysis can also
occur after partial degradation of DQ-collagen IV with pericellular proteases, after which
endocytosis and further degradation in the lysosome can occur [52]. In this manner the
same proteolytic enzymes can be involved in pericellular and intracellular proteolysis [52].
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For example, cysteine proteases degrade the DQ-collagen IV both at the cell surface and
within lysosomes [48, 49].
Treatment of the HUVEC monoculture with PTCI increased intracellular
proteolysis as compared to the control (Fig. 5), whereas treatment with PTCI increased
pericellular proteolysis as compared to the control in both the co-culture systems (Fig. 6;
Supplementary Fig. 2). Likewise, treatment with TAFI or TAFIa resulted in a decrease in
intracellular proteolysis of the HUVEC monoculture, and decreased pericellular
proteolysis in the co-culture system. It is not clear, however, if TAFIa has a greater effect
on the breast cancer cells in terms of inhibition of pericellular proteolysis than it does on
the endothelial cells, since it is unclear which cells are giving rise to the proteolytic activity
in the co-cultures. Interestingly, there was a greater effect of PTCI and TAFIa in HUVEC
invasion, migration and DQ-collagen proteolysis than there was in HUVEC tube formation,
either in the presence or absence of breast cancer cells (compare Figs. 1, 5 and 6 to Figs. 3
and 4). This could suggest that TAFIa plays a larger role in the proteolysis and invasion
aspects of angiogenesis, while other processes involved in tube formation are resistant to
the effects of TAFI, such as intracellular signaling events regulating cytoskeletal
remodeling or differentiation [53].
Our working model is that TAFI inhibits pericellular plasmin generation, with the
consequence that there is reduced matrix and latent growth factor proteolysis by both
plasmin and by plasmin-activated MMPs. Indeed, uPA bound to uPAR can enhance
endothelial cell organization into tubes [54]. We looked for evidence that manipulation of
TAFI did, in fact, alter levels of MMPs, using a zymography approach. We were not able
to detect the cleaved, active MMP2 and MMP9 (Fig. 8), perhaps because these enzymes
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are rapidly bound by inhibitors in the extracellular milieu. Intriguingly, however, we found
that inhibition of TAFIa did increase the levels of pro-MMP2 and pro-MMP9 in breast
cancer cell conditioned medium. Furthermore, our co-culture systems may be reporting
paracrine signaling between breast cancer cells and endothelial cells [55], where CM
harvested from SUM149 cells slightly increased abundance of pro-MMP2 from HUVECs
(Fig. 8). Interestingly, treatment of those SUM149 cells with PTCI to inhibit TAFIa in the
period prior to collection of CM significantly increased the ability of the CM to increase
pro-MMP2 abundance in HUVEC CM. The mechanisms underlying these effects remain
to be explored, but may relate to the effect of TAFIa on the liberation and activation of
growth factors from the extracellular matrix. Whether TAFIa regulates the expression of
MMP genes is also unknown at this time.
Throughout our studies, we found that addition of non-activated TAFI or TAFIa
had virtually identical effects. This is in contrast to our previous study of metastatic
responses by breast cancer cells [17] in which TAFIa was generally more effective than
TAFI. A major difference in these studies is that HUVECs highly express thrombomodulin
which is a highly effective cofactor for TAFI activation. Therefore, in the current study, it
is clear that the concentration of TAFI itself is a limiting factor, whereas thrombomodulin
is limiting in the breast cancer cells. Indeed, reduced tumour thrombomodulin is a negative
predictor of prognosis in metastatic breast cancer [56].
In conclusion, our results show that TAFIa plays a significant role in modulating
several angiogenic process, including cell invasion, migration, proteolysis and endothelial
tube formation. Our findings suggest that stimulation of TAFI activation in the tumour
microenvironment might be a viable strategy to inhibit tumour angiogenesis.
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3.7 Supporting Information

Supplementary Figure 3.1: Inhibition of TAFIa increases endothelial tube formation
in a co-culture system containing HUVECs and MDA-MB-231 cells.
(A) MDA-MB-231 cells labelled with Cell Trace Far Red (green) were seeded on top of
BME in a 35 mm glass bottom culture dish. After 24 hours HUVECs labelled with Cell
Tracker Orange (red) were seeded on top of the MDA-MB-231 cells and BME. The cocultures were treated with either 50 ng/mL VEGF or 25 µg/mL PTCI. Cells were imaged
18 hours after HUVECs were seeded using confocal microscopy. Images above were
obtained at 40× magnification. Scale bar, 200 µm. (B) To quantify tube formation 8-10
images were obtained at 100× magnification. Tube length was determined by measuring
total tube length divided by total tube number, and is expressed relative to that in the control
untreated cells. Treatment with either VEGF or PTCI significantly increased relative tube
length of HUVECs. Values are expressed as mean ± SEM from six independent
experiments. ** p< 0.01 versus control.
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Supplementary Figure 3.2: Inhibition of TAFIa increases DQ-collagen IV proteolysis
by co-cultured HUVECs and MDA-MB-231 cells.
(A) MDA-MB-231 cells labelled with Cell Trace Far Red (blue) were seeded on top of
BME mixed with DQ-collagen IV in a 35 mm glass bottom culture dish. After 24 hours
HUVECs labelled with Cell Tracker Orange (red) were seeded on top of the MDA-MB231 cells and BME mixed with DQ-collagen IV. The co-cultures were treated with either
50 ng/mL VEGF or 25 µg/mL PTCI. Cells were imaged 18 hours after HUVECs were
seeded using confocal microscopy. DQ-collagen IV cleavage products (green) were present
predominately pericellularly. Merge images show pericellular proteolysis (green)
surrounding the co-cultured cells. Images were obtained at 600× magnification.
Representative images from the equatorial plane of a Z-stack are shown. Scale bar, 20 µm.
(B) To quantify proteolysis three equatorial planes from 3-4 different images from one
experiment were quantified. Total integrated intensity of DQ-collagen IV florescence
divided by total combined cell area of HUVECs and MDA-MB-231 cells was averaged
across the three planes and expressed relative to the control. Treatment with either VEGF
or PTCI significantly increased proteolysis of DQ-collagen IV. Values are expressed as
mean ± SEM from six independent experiments. ** p< 0.01 versus control.
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Chapter 4

Thrombomodulin as a cofactor for TAFI and protein C
activation: role in breast cancer metastatic behaviours and
angiogenic potential
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4.1 Summary
Metastasis is an important process in cancer progression. This process is facilitated by
proteases that promote extracellular matrix degradation and cell invasion. Angiogenesis is
important to the metastatic process and also involves degradation of the extracellular
matrix and cell invasion. Thrombomodulin (TM) has been shown to be an anti-metastatic
factor in various cell types. The anti-metastatic effects of TM have been attributed to its
thrombin binding domain, which is responsible for the activation of TAFI and protein C.
We therefore sought to determine which substrate of the thrombin/TM complex is
important for the anti-metastatic functions of TM and what the role of TM is in
angiogenesis. We examined metastatic behaviours using MDA-MB-231 and SUM149
cells. Angiogenic behaviours were tested in HUVECs and in co-culture systems with
HUVECs and either MDA-MB-231 or SUM149 cells. We utilized a truncated variant of
recombinant TM containing EGF-like domains 3-6 (rTM EGF306) and containing
mutations that eliminated the ability of TM to promote either TAFI (V340A/D341A) or
PC (F376A) activation. Treatment with rTM EGF3-6 WT increased breast cancer cell
invasion and DQ-collagen proteolysis of breast cancer cells, but did not effect endothelial
tube formation. Use of rTM EGF3-6 V340A/D341A consistently resulted in an increase in
pro-metastatic and pro-angiogenic behaviours, including cell invasion, DQ-collagen IV
proteolysis and endothelial tube formation, in all systems tested. Conversely, treatment
with rTM EGF3-6 F376A decreased cancer cell invasion and DQ-collagen IV proteolysis
of breast cancer cells compared to rTM EGF3-6 WT. Treatment with rTM EGF3-6 F376A
also decreased endothelial tube formation and DQ-collagen IV proteolysis in HUVECs
alone and in the co-culture systems, compared to control in the absence of treatment. These
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results show that increasing protein C activation (using rTM EGF3-6 V340A/D341A)
promotes metastatic behaviour and angiogenic potential. On the other hand, increasing
TAFI activation inhibits metastatic and angiogenic potential. Together these results
demonstrate that manipulating cofactor ability of TM can promote or inhibit metastatic and
angiogenic behaviours.

148

4.2 Background
Cancer metastasis is the cause of the majority of cancer-related deaths and is
characterized as the spread of cancer from the primary tumour site to a secondary location
[1]. The metastatic cascade is facilitated in part by proteolytic events which degrade the
extracellular matrix (ECM) and basement membrane [2]. Specifically, proteases such as
plasmin and matrix metalloproteinases (MMPs) cleave ECM components, which
ultimately results in cell invasion into the stromal surroundings. Proteolytic events are also
important to the process of angiogenesis, the sprouting of new blood vessels from preexisting vessels [3]. Tumour angiogenesis facilitates metastasis by providing an escape
route for metastasizing cells.
Thrombin-activatable fibrinolysis inhibitor (TAFI) is a plasma zymogen that is
activated to its active form activated TAFI (TAFIa) by cleavage by thrombin, plasmin or
thrombin in complex with thrombomodulin (TM) [4-6]. TAFI activation by the
thrombin/TM complex is over 1000-fold more efficient then thrombin alone, and thus is
thought to represent an important physiological mode of TAFI activation [4]. TAFIa is a
basic carboxypeptidase and a known inhibitor of plasminogen activation to plasmin [7, 8].
TAFIa cleaves carboxyl-terminal lysine residues from protein and peptide substrates
including plasminogen receptors and fibrin degradation products [7, 8]. Carboxyl-terminal
lysine residues are vital in plasminogen activation to plasmin and cleavage by TAFIa of
these residues on plasminogen receptors reflects a key role for TAFI in regulation of
pericellular plasminogen activation [9, 10].
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TM is a transmembrane protein found on the surface of several cell types including
endothelial cells. TM is comprised on a C-type lectin-like domain, 6 epidermal growth
factor (EGF)-like repeats, a serine/threonine-rich domain, a transmembrane domain and a
cytoplasmic tail. TM is involved in several physiological processes including inflammation
and coagulation. TM has also been show to be anti-metastatic factor [11]. Expression of
TM in cancer is inversely correlated to survival [12-14]. Several groups have demonstrated
the important of TM in mediating cell invasion and migration of cancer cells [15-18].
Horowitz and coworkers found that the anti-metastatic effects of TM are attributed to its
thrombin binding domain [19]. Importantly, binding of thrombin to TM is responsible for
the activation of TAFI to TAFIa as well as the activation of protein C to activated protein
C (APC). Horowitz and coworkers did not explicitly determine which substrate of the
thrombin/TM complex is responsible for the anti-metastatic effects of TM. Additional
studies have demonstrated that TM can act either as a pro- and anti-angiogenic factor [20,
21]. We have previously demonstrated that TAFIa inhibits metastatic behaviours of breast
cancer cells by inhibition of plasminogen activation [22]. Additionally, our unpublished
data have shown that TAFIa inhibits angiogenic potential of endothelial cells in breast
cancer through inhibition of plasminogen activation. Conversely, there are conflicting
studies with regard to the role of PC in cancer metastasis [23-26]. While some studies have
demonstrated that APC is metastatic, others have shown it can act as an anti-metastatic
factor. Additionally, studies have shown that APC can act as a pro-angiogenic factor [27,
28]. We therefore sought to determine which substrate of the thrombin/TM complex is
responsible for the anti-metastatic effects of TM and the role of TM in tumour
angiogenesis.
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4.3 Methods

4.3.1 Cell Culture
MDA-MB-231, human embryonic kidney 293 cells (HEK 293) and human
umbilical vein endothelial cells (HUVECs) were purchased from ATCC. SUM149 cells
were a kind gift from Dr. Stephen Ethier (Karmanos Cancer Institute). MDA-MB-231 cells
growth in Dulbecco’s Modified Eagles Medium/ Ham’s F12 (DMEM/F12) (Gibco)
supplemented with 10% fetal bovine serum (FBS) (Gibco), 1% antibiotic/antimycotic
(Gibco). HEK 293 cells were grown in minimum essential medium (MEM) (Gibco)
containing 5% FBS and 1% antibiotic/antimycotic. HUVECs were cultured in Endothelial
Cell Basal Medium-2 (EBM-2) (Lonza) supplemented with 2% FBS (Lonza) and
Endothelial Cell Growth Media-2 (EGM-2) SingleQuots Kit (Lonza). HUVECs were used
at passage five for all experiments. SUM149 cells were grown in DMEM/F12
supplemented with 5% FBS, 1% antibiotic/antimycotic, 10 μg/mL insulin (Sigma-Aldrich)
and 0.5 μg/mL hydrocortisone (Sigma-Aldrich). All cells were maintained at 37°C and 5%
CO2.

4.3.2 Construction of recombinant TM (rTM) EGF3-6
Site directed mutagenesis was completed to generate mutations corresponding to
amino acid substitutions V340A/D341A and F376A within TM. Cloning vector
puc19TM15 (American Type Culture Collection (ATCC)) containing the full-length TM
open reading frame was used as a template and subjected to the QuikChange II SiteDirected Mutagenesis Kit (Agilent Technologies), as per the manufacturer’s protocol. The
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primer sequences that were used for the V340A/D341A and F376A mutations are located
in Table 4.1. The wild-type (WT) TM and mutated TM cDNA in puc19TM15 were then
excised using EcoRI and inserted into pcDNA4/myc-His A (Invitrogen) digested with this
enzyme.
Generation of rTM EGF3-6 was completed sequentially, by first removal of the
serine /threonine rich domain, the transmembrane domain and the cytoplasmic domain. To
do so, WT and mutant variants of TM in pcDNA4/myc-His A were used as a template and
subjected to Q5 high fidelity polymerase (New England BioLabs), as per the
manufacturer’s protocol. The primers (found in Table 4.2) were used to amplify the lectinlike domain and EGF-like repeats 1-6 WT, V340A/D341A, and F376A TM in
pcDNA4/myc-His A and introduced EcoRI and AgeI sites at the 5’ and 3’ ends,
respectively. PCR amplicons were ligated into pcDNA4/myc-His A following digestion
with EcoRI and AgeI, generating soluble TM (sTM) in pcDNA4/myc-His A, in frame with
a 6× His-tag encoding sequence.
Following removal of domains carboxyl-terminal to EGF6, the lectin domain and
EGF1-2 were removed, while maintaining the signal sequence. Briefly, QuikChange II
Site-Directed Mutagenesis Kit was used to introduce EcoRV restrictions sites downstream
of the signal peptide and upstream of EGF3. sTM variants were used as a template and
both restrictions sites were introduced simultaneously, using primer pairs found in Table
4.3. Clones produced from mutagenesis were digested with EcoRV to remove the lectinlike domain and EGF1-2, after which the remainder was reclosed T4 DNA ligase to
generate rTM EGF3-6.
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Table 4.1 Primer sequences for site-directed mutagenesis of TMa
Mutation
V340A/D341A
F376A

Primer Sequence
5’-TAACTACGACCTGGCG GCCGGCGAGTGTGTGG-3’
5’-CTGCGCCGAGGGCGCCGCGCCCATTCCC-3’

a

Only sense strand sequences are shown. Mutated codons are underlined. Mutated
nucleotides are in boldface type
Table 4.2 Primer sequences for generation of sTMb
Primer Name
TM EcoRI 5’
TM AgeI 3’
b

Primer Sequence
5’-GAATTCGGCAGCGCGCAGCGGCAAGAA-3’
5’-ACCGGTACAGTCGGTGCCAATGTGGCG-3’

Restriction sites are underlined.

Table 4.3 Primer sequences for site-directed mutagenesis to introduce EcoRV restriction
sitesc
Primer Name
Signal
Sequence
EGF3

Primer Sequence
5’-CCCCGCACCCGCAGATATCCAGCCGGGTGGCAGC-3’
5’-CCCCGCACCCGCAGATATCCAGCCGGGTGGCAGC-3’

c

Only sense strand sequences are shown. EcoRV site is underlined. Mutated nucleotides
are in boldface type
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4.3.3 Expression and Purification of rTM EGF3-6
rTM EGF3-6 WT, V340/D341A and F376A were stably transfected into HEK 293
cells using polyethylenimine (Sigma-Aldrich). Stably-expressing cells were selected for
using a final concentration of 100 µg/mL zeocin (Life Technologies). Stably-expressing
cells were grown in OPTI-MEM (Life Technologies) containing 1% antibiotic/antimycotic
in roller bottle culture. Conditioned medium was harvested and subjected to Ni2+Sepharose affinity chromatography utilizing the carboxyl-terminal 6× His-tag, as
previously described [22]. Following purification using Ni2+ affinity chromatography,
protein was dialyzed against HEPES-buffered saline (HBS; 20 mM HEPES pH 7.4, 150
mM NaCl) containing 5% (v/v) glycerol and concentrated using polyethylene glycol
(PEG). Following concentration with PEG, rTM EGF3-6 was subjected to further dialysis
against HBS containing 5% glycerol. Protein concentrations were determined using a
Pierce™ BCA Protein Assay Kit (Life Technologies Inc.) as per the manufacturer’s
protocol.

4.3.4 Activation of TAFI
TAFI (200 nM) was activated using 25 nM thrombin (Haematologic Technologies),
10 nM rTM EGF3-6, 5 mM CaCl2 in HBST (HBS containing 0.01% (v/v) Tween 20).
Control experiments were completed with rabbit lung TM (Haematologic Technologies).
This is a solubilized TM that effectively accelerates activation of TAFI by thrombin and
serves as an appropriate control [29]. Activation was also completed in the absence of
thrombin. Activation mixture was incubated for 10 minutes at room temperature.
Following

the

incubate,

a

solution
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containing

TAFIa

substrate

N-(4-

methoxyphenylazoformyl)-Arg-OH · HCl (AAFR) (Bachem) and thrombin inhibitor Dphenylalanyl-prolyl-argininyl chloromethyl ketone (PPACK) (Calbiochem) was added to
the activation mixture. Hydrolysis of AAFR by TAFIa was monitored by absorbance at
350 nm for one hour.

4.3.5 Activation of Protein C
Activation of PC was completing using 100 nM PC (Haematologic Technologies),
25 nM thrombin, 10 nM rTM EGF3-6, 5 nM CaCl2 in HBS with 0.1% bovine serum
albumin (BSA). Activation was also completed in the absence of thrombin. Activation
mixture was incubated for 30 minutes at 37°C. Following the incubate, a solution
containing 200 μM of APC substrate pyroglutamyl-prolyl-argininyl-p-nitroanilide
hydrochloride (S-2366) (Chromogenix, Orangeburg NY, USA), and 200 nM PPACK was
added to the activation mixture. Hydrolysis of S-2366 by APC was monitored by
absorbance at 405 nm for one hour.

4.3.6 Cell Invasion Assay
BD Falcon cell culture inserts (8 μm pore size; PET track-etched membranes) (BD
Biosciences) were coated with 2 mg/mL Cultrex Basement Membrane Extract (BME)
without Phenol Red (Trevigen), for one hour at room temperature. BME was diluted in
serum-free DMEM before coating inserts. DMEM/F12 with 10% FBS containing 10 nM
rTM EGF3-6 WT, V340A/D41A or F376A was added the lower chamber of a 24-well
plate. MDA-MDA-231 cell and SUM149 cells were diluted to a concentration of 1 × 10 5
cells/mL in serum-free DMEM/F12 and 5 × 104 cells were added to the upper chamber.
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Cells were allowed to invade for 24 hours at 37°C. Following the incubation, non-invaded
cells were removed from the upper chamber and invade cells were fixed with methanol and
stained with 0.25% (w/v) crystal violet (Sigma-Aldrich). Images were taken of five fields
of view and number of invaded cells were counted using ImageJ.

4.3.7 Tube Formation Assay
For tube formation assays, 35 mm glass bottom culture dishes (MatTek) were
coated with BME and incubated for 10 minutes at 37°C allowing the BME to solidify.
HUVECs were labelled with 5 µM Cell Tracker™ Orange CMTMR (Life Technologies
Inc.) in EBM-2 with 0.75% FBS for one hour at 37°C. Following the incubation, HUVECs
were washed three times with HBSS (Lonza) and allowed to recover in complete media for
one hour. HUVECs were then diluted in EBM-2 with 0.75% FBS and 2 × 104 cells were
added to the BME-coated culture dishes. Cells were incubated for 40 minutes to allow
adhesion. Complete EBM-2 media containing 10 nM of either rTM EGF3-6 WT,
V340A/D341A or F376A was then added to the dish. Cells were incubated for 18 hours to
allow for tube formation. Images were taken of 8-10 fields of view using an Olympus IX81
confocal microscope. CellTracker™ Orange CMTMR was imaged at an excitation
wavelength of 540 nm and an emission wavelength of 565 nm. Relative tube length was
measured as the total length of all tubes within the field of view divided by total number
of tubes within the field of view.
For co-culture experiments, SUM149 or MDA-MB-231 cells were labelled with 5
µM CellTrace™ Far Red DDAO-SE (Life Technologies Inc.) in serum-free DMEM/F-12
for one hour at 37°C. Following incubation, labelled cells were washed three times with
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phosphate buffered saline (PBS) and allowed to recover for one hour at 37°C. Glass bottom
culture dishes were coated as previously described. SUM149 or MDA-MB231 cells were
diluted in serum-free DMEM/F12 and 2 × 104 cells (SUM149) or 5 × 103 cells (MDA-MB231) were added to the BME-coated dishes. The cells were incubated for 40 minutes before
complete media was added. The cells were then incubated for 24 hours, following which
the tube formation protocol was carried out as previously described, with additional images
taken of CellTrace™ Far Red DDAO-SE labelled cells. CellTrace™ Far Red DDAO-SE
was imaged using an excitation wavelength of 630 nm and an emission wavelength of 660
nm.

4.3.8 Dye-Quenched (DQ)-Collagen IV Proteolysis Assay
MDA-MB-231 cells, SUM149 cells and HUVECs were fluorescently labelled as
described above. Glass bottom dishes were coated with BME containing 25 µg/ml DQcollagen IV (Life Technologies) for 10 minutes at 37°C. SUM149 or MDA-MB-231 cells
were diluted in serum-free DMEM/F12 and 2 × 104 cells (SUM149) or 5 x ×103 cells
(MDA-MB-231) were added to the BME-coated dishes. HUVECs were diluted in EBM-2
with 0.75% FBS and 2 × 104 cells were added to the BME-coated culture dishes. Cells
were allowed to adhere to the BME for 40 minutes at 37°C. Complete media containing 10
nM of either rTM EGF3-6 WT, V340A/D341A or F376A were added to the dishes.
SUM149 and MDA-MB-231 cells were incubated for 48 hours at 37°C before being
subjected to confocal microscopy. HUVECs were incubated for 18 hours at 37°C prior to
imaging. Stacked images were taken of 3-4 fields of view. The fluorescent intensity of DQcollagen IV (green) per cell area (red) was calculated. For experiments with HUVECs,
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amount of proteolysis was determined using ImageJ software by calculating total
fluorescence of the DQ-collagen type IV divided by HUVEC area for three adjacent slices
(one slice at the equatorial plane and one below and above). Values of the fluorescent
intensity per cell area were averaged across the three slices. For co-culture experiments,
amount of proteolysis was determined using ImageJ software by calculating total
fluorescence of the DQ-collagen type IV divided by the combined area of breast cancer
cells and HUVECs. Three adjacent slices were used for these experiments and averaged,
as mentioned above. For experiments with breast cancer cells, analysis was completed as
previously described [22].

4.3.9 Statistical Methods
Results are expressed as a mean ± SEM from at least three independent experiments.
Statistical analysis was performed using one-way ANOVA test with post-hoc Tukey HSD
with IBM SPSS Statistics V22.0 software. Statistical significance was assumed at p < 0.05.
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4.4 Results

4.4.1 Effect of rTM EGF3-6 mutants on breast cancer cell invasion
We sought to determine which substrate of the thrombin/TM complex is
responsible for the anti-metastatic effects of TM. To do so we generated mutants of TM
that can either support only TAFI activation or only PC activation. Using site-directed
mutagenesis, Wang et al. previously determined residues of TM that are crucial for
thrombin/TM-mediated activation of TAFI and PC. Mutagenesis of V340/D341A
abolishes TM cofactor activity for TAFI activation. Mutagenesis of F376A inhibits
activation of PC by thrombin/TM. We generated these mutants in the context of a truncated
variants of rTM, EGF3-6, since the minimum essential structure of TM necessary for
activation of TAFI is the c-loop of EGF-3 to EGF6 (shown in Figure 4.1). To verify the
effects of the mutations in these novel rTM constructs, TAFI and PC were activated by
thrombin in the presence of the rTM variants and activity assays were completed to assess
activity of each enzyme. The mutants behaved as previously published and rTM EGF3-6
(Fig. 4.2) behaved similar to the TM control (data not shown).
Cell invasion is a measure of pro-metastatic behaviour and therefore we examined
the effect of the rTM EGF3-6 mutants on breast cancer cell invasion. Treatment of MDAMB-231 cells with rTM EGF3-6 resulted in a significant increase in cell invasion
(Fig.4.3A, B). Conversely, treatment of SUM149 cells with rTM EGF3-6 did not affect
cell invasion (Fig. 4.3C, D). Treatment of both MDA-MB-231 and SUM149 cells with
rTM EGF3-6 V340A/D341A (the mutant that does not support TAFI activation) increased
cell invasion (Fig. 4.3). Furthermore, rTM EGF3-6 F376A (the mutant that does not
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support PC activation) significantly decreased MDA-MB-231 invasion when compared to
rTM EGF3-6 WT (Fig. 4.3A, B). However, this effect was not observed in SUM149 cells
(Fig. 4.3C, D). These results suggest that the thrombin cofactor ability of TM affects cell
invasion.
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Figure 4.1: Domain structure of thrombomodulin.
Thrombomodulin contains a C-type lectin-like domain, six EGF-like repeats, a
serine/threonine rich domain, a transmembrane domain and cytoplasmic tail. The EGF-like
domain is responsible for the cofactor functions of TM, involving thrombin-mediated
activation of TAFI and protein C. Illustrated is EGF3-6 which is the minimum necessary
structure for activation of TAFI and which corresponds to the soluble TM variant employed
in this study.
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Figure 4.2: Characterization of cofactor ability of rTM EGF3-6 mutants
(A) TAFI was activated in the presence and absence of 25 nM thrombin (IIa) and in the
presence of 10 nM of the rTM EGF3-6 mutants, for 10 minutes at room temperature.
Following activation, thrombin was inhibited with PPACK and TAFI activity was
measured by initial rate of AAFR hydrolysis. (B) PC was activated in the presence and
absence of thrombin and in the presence of 10 nM of the rTM EGF3-6 mutants, for 30
minutes at 37°C. Following activation, thrombin was inhibited using PPACK and PC
activity was measured by the initial rate of S-2366 hydrolysis. The data represent the mean
± SEM from 3-5 independent experiments. ** p< 0.01 relative to rTM EGF3-6.

162

Figure 4.3: The effect of rTM EGF3-6 mutants on breast cancer cell invasion.
(A) MDA-MB-231 cells and (C) SUM149 cells were subjected to invasion assays in the
presence of 10 nM rTM EGF3-6 mutants. The number of invaded cells were imaged and
counted in five fields of view. Images shown were taken at 4× magnification. (B)
Quantification of invaded MDA-MB-231 cells relative to control (absence of treatment).
The data represent the mean cell number per field of view ± SEM from 3 independent
experiments. *: p < 0.05 relative to control and #: p < 0.05, relative to rTM EGF3-6 WT.
(D) Quantification of invaded SUM149 cells relative to control in the absence of treatment.
The data represent the mean cell number per field of view 2 independent experiments.
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4.4.2 Effect of rTM EGF3-6 mutants on tube formation in endothelial cells and in coculture systems containing endothelial and breast cancer cells

There are conflicting studies on the effect of TM in angiogenesis [20, 21]. We
therefore examined the effect of the rTM EGF3-6 mutants on angiogenesis, we performed
an in vitro tube formation assay. Endothelial cells are able to form tube-like structures in
the presence of BME, which mimics in vivo tube formation. Endothelial cells were treated
with rTM EGF3-6 WT and both mutants. There was no difference in tube formation upon
treatment with rTM EGF3-6 (Fig. 4.4). Treatment with rTM EGF3-6 V340A/D341A
resulted in a significant increase in tube formation, when compared to the control in the
absence of treatment and rTM EGF3-6 WT (Fig. 4.4). Conversely, rTM EGF3-6 F376A
significantly decreased endothelial tube formation, when compared to the control in the
absence of treatment and rTM EGF3-6 WT (Fig. 4.4).
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Figure 4.4: The effect of rTM EGF3-6 mutants on endothelial tube formation.
(A) HUVECs labelled with Cell Tracker Orange (red) were seeded on BME and treated
with 10 nM of the rTM EGF3-6 mutants. Cells were incubated for 18 hours at 37°C and
then imaged using confocal microscopy, at 40× magnification. Scale bar, 500 µm. (B)
Quantification of endothelial tube formation. Images were taken of 8-10 fields of view.
Relative tube length was obtained by measuring the total tube length per field of view
divided by the total tube number per field of view. The data are represented as mean ±
SEM from 6-10 independent experiments. **p< 0.01 versus control, ## p< 0.01 relative to
rTM EGF3-6.
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We next examined the effect of the rTM EGF3-6 mutants on endothelial tube
formation in the presence of SUM149 or MDA-MB-231 breast cancer cell lines. There was
no difference in tube formation in the presence of rTM EGF3-6 when compared to the
control, for both MDA-MB-231 (Fig. 4.5) and SUM149 (Fig. 4.6) cells. The variant of TM
that does not support activation of TAFI (rTM EGF3-6 V340A/D341A) stimulated tube
formation, compared to the control in the absence of treatment and rTM EGF3-6 WT.
Similar results were observed for both MDA-MB-231 (Fig. 4.5) and SUM149 (Fig. 4.6)
cells. Furthermore, the variant of TM that only supports TAFI activation (rTM EGF3-6
F376A) significantly hindered endothelial tube formation, for both MDA-MB-231 (Fig.
4.5) and SUM149 (Fig. 4.6) breast cancer cell lines.
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Figure 4.5: The effect of rTM EGF3-6 mutants on endothelial tube formation in a coculture system containing HUVECs and MDA-MB-231 cells.
(A) MDA-MB-231 cells, labeled with Cell Trace Far Red (green), were seeded on BME
and incubated for 24 hours before HUVECs labeled with CellTracker Orange (red) were
on top of the MDA-MB-231 cells. Cells were treated with 10 nM of each of the rTM EGF36 variants and incubated for 18 hours prior to confocal microscopy. Images were obtained
at 40× magnification. Scale bar, 500 µm. (B) Quantification of endothelial tube formation.
Images were taken of 8-10 fields of view. Relative tube length was obtained by measuring
the total tube length per field of view divided by the total tube number per field of view.
The data are represented as mean ± SEM from 8-10 independent experiments. **p< 0.01
versus control, ## p< 0.01 versus rTM EGF3-6.
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Figure 4.6: The effect of rTM EGF3-6 mutants on endothelial tube formation in a coculture system containing HUVECs and SUM149 cells.
(A) SUM149 cells, labeled with Cell Trace Far Red (green), were seeded on BME and
incubated for 24 hours before HUVECs labeled with CellTracker Orange (red) were on top
of the SUM149 cells. Cells were treated with 10 nM of each of the rTM EGF3-6 variants
and incubated for 18 hours prior to confocal microscopy. Images were obtained at 40×
magnification. Scale bar, 500 µm. (B) Quantification of endothelial tube formation. Images
were taken of 8-10 fields of view. Relative tube length was obtained by measuring the total
tube length per field of view divided by the total tube number per field of view. The data
are represented as mean ± SEM from 5-8 independent experiments. **p< 0.01 versus
control, ## p< 0.01 versus rTM EGF3-6.
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4.4.3 Effect of Effect of rTM EGF3-6 mutants on DQ-collagen IV proteolysis in breast
cancer cells, endothelial cells and in co-culture systems containing endothelial and
breast cancer cells
Extracellular proteolysis is an important step in cancer metastasis [2]. We sought
to examine the effect of the TM mutants on proteolysis of DQ-collagen IV in MDA-MB231 and SUM149 cells. Treatment with rTM EGF3-6 WT increased DQ-collagen IV
proteolysis, compared to control, in MDA-MB-231 (Fig. 4.7) and SUM149 (Fig. 4.8) cells.
DQ-collagen IV proteolysis also increased upon treatment with rTM EGF3-6
V340A/D341A in both MDA-MB-231 (Fig. 4.7) and SUM149 (Fig 4.8) cells. The mutant
that only supports TAFI activation decreased DQ-collagen IV proteolysis in both breast
cancer cell lines, when compared to rTM EGF3-6 WT (Fig. 4.7, 4.8).
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Figure 4.7: The effect of rTM EGF3-6 mutants on DQ-collagen IV proteolysis in
MDA-MB-231 cells.
(A) MDA-MB-231 cells labeled with CellTracker Orange (shown in red) were grown on
BME containing 25 µg/mL DQ-collagen IV. Cells were treated with 10 nM rTM EGF3-6
mutants for 48 hours. Confocal images were taken following the 48 hour incubation. DQcollagen degradation products were observed in green. (B) DQ-collagen fluorescence was
quantified and normalized to the area of CellTracker Orange fluorescence. The data are
represented as the green fluorescent intensity per area of the red fluorescence, averaged
across the entire z-stack and expressed relative to untreated cells (Control). The data
represent the mean ± SEM of 3 independent experiments, each carried out in triplicate. *:
p < 0.05 versus Control.
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Figure 4.8: The effect of rTM EGF3-6 mutants on DQ-collagen IV proteolysis in
SUM149 cells.
(A) SUM149 cells labeled with CellTracker Orange (shown in red) were grown on BME
containing 25 µg/mL DQ-collagen IV. Cells were treated with 10 nM rTM EGF3-6 mutants
for 48 hours. Confocal images were taken following the 48-hour incubation. DQ-collagen
degradation products were observed in green. (B) DQ-collagen fluorescence was quantified
and normalized to the area of CellTracker Orange fluorescence. The data are represented
as the green fluorescent intensity per area of the red fluorescence, averaged across the entire
z-stack and expressed relative to untreated cells (Control). The data represent 1 experiment,
carried out in triplicate.
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Extracellular proteolysis is also important in tumour angiogenesis [3]. We
examined the effect of the TM mutants on proteolysis of DQ-collagen IV in endothelial
cells. We observed a significant decrease in proteolysis of DQ-collagen IV upon treatment
with rTM EGF3-6, when compared to the control (Fig. 4.9). Conversely, endothelial cell
DQ-collagen IV proteolysis significantly increased following treatment with rTM EGF3-6
V340A/D341A, compared to control and rTM EGF3-6 WT (Fig. 4.9). Additionally,
treatment with rTM EGF3-6 F376A resulted in a significant decrease in DQ-collagen
proteolysis when compared to the control (Fig. 4.9).
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Figure 4.9: The effect of rTM EGF3-6 mutants on DQ-collagen IV proteolysis in
endothelial cells.
(A) HUVECs labelled with Cell Tracker Orange (red) were seeded on BME containing 25
µg/mL DQ-collagen IV (green) and treated with 10 nM of the rTM EGF3-6 mutants. Cells
were incubated for 18 hours at 37°C and then imaged using confocal microscopy, at 600×
magnification. Scale bar, 30 µm. (B) DQ-collagen IV fluorescence was quantified and
normalized to the area of CellTracker Orange fluorescence. The data are represented as the
green fluorescent intensity per area of the red fluorescence, averaged over three slices of
the z-stacks and expressed relative to untreated cells (Control). The data are represented as
mean ± SEM from 5 independent experiments. **p< 0.01 versus control, ## p< 0.01 versus
rTM EGF3-6.
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Next we assessed the effect of the TM mutants on proteolysis in co-culture systems
containing endothelial cells and either SUM149 or MDA-MB-231 cells. Addition of rTM
EGF3-6 did not effect DQ-collagen IV proteolysis the in co-culture system, using either
MDA-MB-231 (Fig. 4.10) and SUM149 (Fig. 4.11) cells. We observed a significant
increase in DQ-collagen IV proteolysis in both co-culture systems when treated with rTM
EGF3-6 V340A/D341A (Fig. 4.10, 4.11). We also observed an non-significant decrease in
DQ-collagen IV proteolysis upon treatment with rTM EGF3-6 F376A in the HUVECsMDA-MB-231 co-culture system, when compared to control and rTM EGF3-6 WT (Fig.
4.10). Furthermore, we observed a significant decrease in DQ-collagen IV proteolysis
upon treatment with rTM EGF3-6 F376A in the HUVECs-SUM149 co-culture system
(Fig. 4.11).
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Figure 4.10: The effect of of rTM EGF3-6 mutants on DQ-collagen IV proteolysis in
a co-culture system with HUVECs and MDA-MB-231 cells.
(A) MDA-MB-231 cells, labeled with Cell Trace Far Red (blue), were seeded on BME
containing 25 µg/mL DQ-collagen IV (green) and incubated for 24 hours. Following the
24-hour incubation HUVECs labeled with CellTracker Orange (red) were on top of the
MDA-MB-231 cells. Cells were treated with 10 nM of each of the rTM EGF3-6 variants
and incubated for 18 hours prior to confocal microscopy. Images were obtained at 600×
magnification. Scale bar, 30 µm. (B) DQ-collagen IV fluorescence was quantified and
normalized to the combined area of CellTracker Orange and Cell Tracer Far Red
fluorescence. The data are represented as the green fluorescent intensity per combined area
of the blue and red fluorescence, averaged three slides of the z-stacks and expressed relative
to untreated cells (Control). The data are represented as mean ± SEM from 6 independent
experiments. **p< 0.01 versus control, ## p< 0.01 versus rTM EGF3-6.
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Figure 4.11: The effect of rTM EGF3-6 mutants on DQ-collagen IV proteolysis in a
co-culture system with HUVECs and SUM149 cells.
(A) SUM149 cells, labeled with Cell Trace Far Red (blue), were seeded on BME
containing 25 µg/mL DQ-collagen IV (green) and incubated for 24 hours. Following the
24-hour incubation HUVECs labeled with CellTracker Orange (red) were on top of the
SUM149 cells. Cells were treated with 10 nM of each of the rTM EGF3-6 variants and
incubated for 18 hours prior to confocal microscopy. Images were obtained at 600×
magnification. Scale bar, 30 µm. (B) DQ-collagen IV fluorescence was quantified and
normalized to the combined area of CellTracker Orange and Cell Tracer Far Red
fluorescence. The data are represented as the green fluorescent intensity per combined area
of the blue and red fluorescence, averaged three slices of the z-stacks and expressed relative
to untreated cells (Control). The data are represented as mean ± SEM from 3-7 independent
experiments. **p< 0.01 versus control, ## p< 0.01 versus rTM EGF3-6.
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4.5 Discussion
Several groups have identified TM as an anti-metastatic factor in various cancer
types. Horowitz and coworkers attributed the anti-metastatic effect of TM to its thrombin
binding domain. Given that this domain is responsible for the activation of TAFI and PC,
we sought to determine which substrates is important for the anti-metastatic effects of TM.
Studies have demonstrated that the minimum unit of TM necessary for activation of TAFI
is the c-loop of EGF-3 to EGF-6, while PC requires the interdomain loop connecting EGF3 to EGF-4 plus EGF4-6[30]. We generated mutants of TM that differ in their ability to
support TAFI and PC activation in the context of rTM EGF3-6, based on previously
published mutations [30].
We measured metastatic potential of breast cancer cells based on two pro-metastatic
behaviours, cell invasion and collagen degradation. While we had expected that rTM
EGF3-6 would decrease these pro-metastatic behaviours, we observed an increase in both
cell invasion and DQ-collagen IV proteolysis, suggesting that this variant of TM may be
acting as a pro-metastatic factor. We also observed an increase in cell invasion and DQcollagen IV proteolysis upon treatment with rTM EGF3-6 V340A/D341A. These results
suggest that PC activation may promote metastatic behaviours. On the other hand, the rTM
EGF3-6 F376A variant, which supports TAFI but not PC activation, did not show increases
in these pro-metastatic behaviours, and in some cases decreased them to a level below that
of the control. It could be that loss of ability to support PC activation abolishes the prometastatic effects observed with rTM EGF3-6 V340A/D341A. These results correlate with
a previous study that reported an increase in breast cancer cell invasion and migration upon
treatment with APC [25]. However, these also results correlate with our previous study in
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which we demonstrated that addition of TAFIa decreased pro-metastatic behaviours, such
as cell invasion, migration and collagen proteolysis [22]. Taken together these results
suggest that TAFIa and APC may have opposing roles in cancer metastasis, where TAFIa
inhibits metastatic behaviours and APC promotes cancer metastasis.
We measured angiogenic potential of endothelial cells based on tube formation and
collagen proteolysis. Treatment with rTM EGF3-6 WT did not effect tube formation in any
of the systems used. Treatment with rTM EGF3-6 WT significantly decreased DQ-collagen
IV proteolysis in endothelial cells alone, but did not effect DQ-collagen proteolysis in the
co-culture systems with endothelial cells and breast cancer cells. This contradicts a study
that found use of a TM variant that included EGF1-6 and the serine/threonine domain
increased endothelial tube formation [21]. Our study used a variant that lacks EGF1-2 and
the serine/threonine domain, indicating a potential role for these domains in promoting
angiogenesis. When we assessed cofactor ability of TM, we found that treatment with rTM
EGF3-6 V340A/D341A (mutant that does not support TAFI activation) increased both
endothelial tube formation and DQ-collagen IV proteolysis in all system that were tested.
This indicates that manipulating the cofactor ability of TM to support PC activation may
promote pro-angiogenic behaviours. Specifically, these results suggest that increasing
activation of PC and decreasing activation of TAFI promotes pro-angiogenic behaviours.
This is in keeping with a studies that have shown that APC can increase angiogenesis [27,
28]. Treatment with rTM EGF3-6 F376A decreased endothelial tube formation and DQcollagen IV proteolysis in all cultured systems tested, when compared to rTM EGF3-6 WT.
In general, these results suggest that stimulating of TAFI activation inhibits DQ-collagen
IV proteolysis, while promoting PC activation enhances DQ-collagen IV. However, in
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some cases, either rTM EGF3-6 WT had no effect, or that the effect of rTM EGF3-6 F376A
was not different from control, which suggests that that in some cases TAFI activation is
not playing a role, but instead the observed effect is from lack of PC activation. This is in
keeping with cell invasion and tube formation results which suggest that TAFI may act as
an anti-metastatic and anti-angiogenic factor, while PC is a pro-metastatic and proangiogenic factor. However, these results are still consistent with the idea that TAFI
activation by thrombin/TM is an anti-metastatic and anti-angiogenic pathway. This is in
keeping with our unpublished data that show that TAFIa is able to inhibit pro-angiogenic
effects of endothelial cells. These results also suggest that, although rTM EGF3-6 WT did
not effect angiogenic potential, it may be acting to both promote and inhibit angiogenesis
and therefore these effects counteract each other. Therefore, TAFI and PC may have
opposing roles in angiogenesis, where TAFIa acts as an anti-angiogenic factor and APC
acts as a pro-angiogenic factor.
It is not surprising that TAFI and PC may have opposing roles in angiogenesis and
metastasis. This is similar to their opposing functions in blood coagulation. TAFI is an antifibrinolytic factor, attenuating blood clot breakdown [7]. APC on the other hand is an anticoagulant factor, inhibiting factors Va and VIIIa of the coagulation cascade, which
attenuates thrombin generation [31]. Given their opposing roles and the fact that they are
substrates of the same complex, the ability to modulate activation of TAFI and PC, by the
thrombin/TM may be a method regulate angiogenic and metastatic behaviours.
Specifically, enhancing thrombin/TM-mediated activation of TAFI, while decreasing
thrombin/TM-mediated PC activation may inhibit metastatic and angiogenic behaviours.
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Concentration of TM is an important regulator of TAFI and PC activation. It has
been demonstrated that TM concentrations dictate which substrate would be favour for
activation by the thrombin/TM complex [32]. TAFI activation is favoured at lower
concentrations of TM, while PC is favoured at higher concentrations. While TM is an
known anti-metastatic factor, the rTM EGF3-6 did not exhibit anti-metastatic potential, as
expected. This may be due to the concentration used for these experiments. The
concentration used is likely to favour activation of PC over activation of TAFI. Hence, if
PC is acting as a pro-metastatic and pro-angiogenic factor, increased activation of PC may
counteract the anti-metastatic and anti-angiogenic functions of TAFI. This hypothesis is
supported by the fact that treatment with the mutant that only supports TAFI activation
inhibits metastatic and angiogenic behaviours when compared to rTM EGF3-6 WT. This
is also supported by a previous study that reported that TM increases endothelial tube
length [33]. This study used much higher concentrations of TM then the current study,
possibility suggesting preferential activation of PC. This suggests that promoting activation
of TAFI over PC by decreasing rTM EGF3-6 WT concentrations may result in an observed
anti-metastatic and anti-angiogenic response. It also cannot be overlooked that APC
decreases thrombin generation which in turn decreases TAFI activation. Therefore, results
observed with rTM EGF3-6 WT and rTM EGF3-6 V340A/D341A could be a combined
effect of increased APC and decreased TAFIa.
Thrombin has also been implicated in cancer metastasis and tumour angiogenesis.
It could be that TM acts as a thrombin sink in the tumour microenvironment, inhibiting the
pro-metastatic and pro-angiogenic effects of thrombin. This is similar to the role of TM in
coagulation, in which binding of thrombin to TM decreases the affinity of thrombin from
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fibrinogen to PC and TAFI. Importantly, all variants of TM used in this study are able to
bind to thrombin, despite having differential effects on pro-metastatic and pro-angiogenic
behaviours, suggesting that this mechanism is not predominant in this model system.
Together these results indicate that manipulating cofactor ability of TM impacts
both metastatic and angiogenic behaviours of breast cancer and endothelial cells,
respectively. Promoting activation of TAFI over PC, using variants of TM that are
specifically able to activate TAFI, may be a beneficial therapeutic approach to target both
cancer metastasis and tumour angiogenesis.
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Chapter 5

General Discussion
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Cancer metastasis is responsible for the majority of cancer-related deaths. The
initial stages of cancer metastatic are facilitated in part by proteolytic events in the tumour
microenvironment. Specifically, degradation of the ECM and cancer cell invasion, enables
cancer cells to enter the surrounding stroma and ultimately metastasize. Proteolytic events
are also important for the process of tumour angiogenesis, which also promotes cancer
metastasis. In the current study we have demonstrated that TAFIa acts as an anti-metastatic
and anti-angiogenic factor, inhibiting both metastatic and angiogenic behaviours in breast
cancer and endothelial cells, respectively. We have demonstrated that TAFIa mediates its
anti-metastatic and anti-angiogenic functions through inhibition of plasminogen activation.

5.1 Sources of TAFI in the tumour microenvironment
TAFI is synthesized predominantly in the liver, however CPB2 mRNA and TAFI
protein have been detected in other cell types, including macrophages [1]. In our work, we
have detected CPB2 mRNA in several breast cancer cell lines, with differing mRNA
abundance (Fig. 2.1). Previous studies have demonstrated that CPB2 mRNA is regulated
through several mechanisms [2-4]. For example, the mRNA binding protein tristetraprolin
(TTP) plays an important role in mediating the stability of CPB2 mRNA [3] by binding to
a specific cis-acting element in the 3’-unntranslated region of the transcript and promoting
its degradation. Al-Souhibani and coworkers reported that TTP levels decreased in more
invasive breast cancer cell lines, such as MDA-MB-231 [5]. We have shown that CPB2
mRNA levels are higher in MDA-MB-231 cells (Fig. 2.1) which may be attributable to the
decrease in TTP in this cell line.
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We were unable to detect TAFI protein in conditioned media of any of the breast
cancer cell lines tested, although this may be due to lack of assay sensitivity [6]. It is
unlikely that the breast cancer cells themselves provide the major source of TAFI in the
tumour microenvironment, given the low mRNA abundance in these cell lines. It is more
likely that the major source of TAFI is blood plasma, with some contributions from stromal
cells in the tumour microenvironment. There is an increased vascular permeability in
tumour blood vessels, which results in leakage of plasma proteins from the blood vessels
into the tumour microenvironment [7]. Therefore, plasma TAFI, synthesized by the liver,
is able to enters the tumour microenvironment from leaky blood vessels. Stromal cells may
provide another source of TAFI in the tumour microenvironment. Previous results from
our laboratory have shown that macrophages express and secrete TAFI [1]. Macrophages
may also be involved in modulating localized TAFI expression during inflammation, which
is associated with the development and progression of cancer. Tumour-associated
macrophages (TAMs) express both pro-inflammatory and anti-inflammatory mediators,
both of which have been shown to increase CPB2 mRNA and TAFI protein levels in
macrophages [4, 8]. It is therefore possible that TAMs may have increased TAFI levels,
though autocrine regulation, when compared to macrophages in the absence of stimulus.
Other stromal cells may contribute to TAFI levels in the breast cancer microenvironment,
including endothelial cell and adipocytes [1, 9]. However, while both cell types have been
found to express CPB2 mRNA, TAFI protein has not been detected in either cell type.
Genetic and phenotypic changes to the stromal surroundings is a characteristic of cancer
progression [10]. It is therefore possible that these changes can alter the expression of
CPB2 in stromal endothelial cells and adipocytes. Further studies will be needed to
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determine the extent of stromal contribution TAFI levels in the tumour microenvironment
and whether the plasma is in fact the major source of TAFI the breast cancer
microenvironment.
Results from our mRNA expression studies in Chapter 2 demonstrate that CPB2
expression did not show any relationship with malignancy in breast cancer cells. Several
clinical studies have assessed plasma concentrations of TAFI and these studies have
generally found an increase in patient samples [11-14]. While these studies did not assess
relationships between TAFI concentrations and metastatic disease, it could be argued that
increases in plasma TAFI concentrations in patient samples contradicts the idea of TAFI
as an anti-metastatic factor. However, it is necessary to point out that while TAFI
concentrations may be higher in plasma, it is unknown how this influences the tumour
microenvironment. We have demonstrated that THBD expression was generally inversely
correlated to malignancy in the breast cancer cells examined, and in fact this phenomenon
has been observed in several cancer types [15-17]. Therefore, it is likely that the key
determinant of TAFIa action is not local concentrations of TAFI, but rather the TAFIagenerating capacity of the tumour environment, namely TM concentration, which has been
shown to be inversely correlated to metastatic disease.

5.2 Activation of TAFI in the tumour microenvironment
TAFI is activated to TAFIa by thrombin, plasmin or thrombin in complex TM [1820]. Thrombin and plasmin are both weak activators of TAFI. Thrombin-mediated
activation of TAFI is dramatically accelerated when thrombin is in complex with TM [18],
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leading to suggestions that the thrombin/TM complex is the physiological activator of
TAFI. While we have observed decreased expression of TM in more invasive breast cancer
cell lines, these levels may be sufficient to support TAFI activation. This is evident based
on results we have obtained with PTCI, in (Fig. 2.3, 2.4, 2.6). We have observed prometastatic effects in SUM149 and MDA-MB-231 cells upon treatment with PTCI, as a
result of inhibition of TAFIa. This indicates the ability of these cells to support TAFI
activation, given the specificity of PTCI in this context. It is likely, however, that TAFI
activation is saturated these breast cancer cells. This is evident by lack of effect in cell
invasion, migration and proteolysis upon the addition of non-activated TAFI in (Fig. 2.3,
2.4, 2.6). It is expected that if these breast cancer cells activated the exogenous TAFI, there
would be a decrease in pro-metastatic behaviours, as observed upon the addition of TAFIa.
It is also evident that HUVECs support TAFI activation. We observed an increase in proangiogenic behaviours upon treatment with PTCI (Fig. 3.1, 3.4, 3.5, 3.6). This indicates
that HUVECs are able to activate TAFI and inhibition of TAFIa promotes angiogenic
potential (Fig. 3.1, 3.4, 3.5, 3.6). This is consistent with previous studies that have
demonstrated that HUVECs support TAFI activation [21, 22]. Furthermore, unlike in
breast cancer cells where non-activated TAFI did not have an effect on metastatic
behaviours (Fig. 2.3, 2.4, 2.6), in endothelial cells non-activated TAFI did in fact inhibit
angiogenic potential (Fig. 3.1, 3.4, 3.5, 3.6). This indicates that TAFI activation is not
saturated in this cell type and the cells are able to activate exogenous TAFI. The differences
observed in HUVECs compared to the breast cancer cell lines can be attributed to the levels
of TM on the cell surface. It is therefore evident that TM concentrations play a role in
mediating TAFI activation on the cell surface.
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In patients, TM levels are inversely correlated to clinical stage and therefore
thrombin/TM mediated TAFI activation in cancer would be in part dependent on
expression of TM in the cancer cell [15, 16, 23]. An abolishment of TM expression would
likely prevent thrombin-mediated activation of TAFI on the surface of cancer cells.
However, contributions from the stromal cells in the tumour microenvironment must be
considered. The influence of the tumour microenvironment on TM expression in stromal
cells has not been assessed. TM is expressed in endothelial cells and macrophages [24, 25].
Inflammatory mediators have been shown to increase TM expression in macrophages, and
decrease expression in endothelial cells [26]. This suggests that chronic inflammation in
the tumour microenvironment may down-regulate TM in endothelial stromal cells while
upregulating TM in TAMs. Decreased thrombomodulin expression in endothelial cells
may results in decreased TAFI activation, however an increase in TM expression in TAMs
may promote TAFI activation on these cells. Therefore, additional studies should be aimed
at delineating the contributions of cancer cells and stromal cells in regulating
thrombin/TM-mediated activation of TAFI in the tumour microenvironment.
In Chapter 4 we examined the role of TM in mediating pro-metastatic and proangiogenic behaviours. Several studies have illustrated a potential anti-metastatic role for
TM. Our results demonstrated the complexity of this pathway. Unexpectedly, our soluble
variant of TM (rTM EGF3-6) exhibited neither anti-metastatic potential nor antiangiogenic potential, with the exception of DQ-collagen proteolysis of HUVEC
monocultures. While both TAFI and protein C were able to be effectively activated in
solution by this variant, it is unknown whether one of these substrates would be favoured
upon treatment of breast cancer cells. Our results demonstrate stimulating protein C
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activation, using a variant of TM that does not support TAFI activation (rTM EGF3-6
V340A/D341A), increases pro-metastatic and pro-angiogenic behaviours. This points to a
role for APC in promoting pro-metastatic and pro-angiogenic behaviours. Importantly, this
variant of TM, by facilitating protein C activation, inhibits thrombin formation through the
intrinsic pathway of coagulation, which ultimately inhibits TAFI activation. The variant of
TM that does not support protein C activation (rTM EGF3-6 F376A) demonstrated antiangiogenic behaviour, but overall failed to inhibit pro-metastatic behaviour. Generally, this
variant exhibited similar results to rTM EGF3-6 WT, indicating effects are likely due to
inhibition of protein C activation. However, activity assays demonstrated that this variant
was able to slightly activate protein C and it is not known what effect this would have on
activation on the cell surface. Therefore, it is necessary to generate an additional variant
that better inhibits protein C activation, while retaining its ability to activate TAFI.
Additionally, a necessary control for these experiments should involve generation of a
variant of TM that does not bind to thrombin, namely rTM EGF3-6 Q387P [27]. It would
also be important to directly measure the extent of activation of protein C and TAFI, both
in our in vitro experiments as well as in the the tumour microenvironment in vivo. Overall,
the underlying mechanisms that facilitate thrombin/TM mediated activation of TAFI and
protein C require further examination. Understanding the intricate mechanism of regulation
may give insight into potential therapeutic options to promote activation of TAFI.
Binette and colleagues identified the thrombin/TM complex as the predominant
activator of TAFI in a baboon model of sepsis [28]. However, it is likely that physiological
activation of TAFI is dependent on the context. Plasmin-mediated activation of TAFI is
accelerated in the presence of glycosaminoglycans [29]. ECM components, such as
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heparan sulfate proteoglycan, are frequently overexpressed in cancers [30]. Abundance of
heparan sulfate in cancer may provide an additional mechanism for TAFI activation in the
tumour microenvironment. Further investigation is necessary to delineate mechanisms for
TAFI activation in vivo, specifically in the tumour microenvironment.

5.3 Influence of TAFIa Stability
TAFIa is intrinsically unstable, possessing a half-life of approximately 8-15
minutes at 37°C [31]. With no physiological inhibitors, the spontaneous conformational
change is thought to the physiological method of down-regulation of TAFIa in vivo. We
assessed the effect of TAFIa-WT and TAFIa-CIIYQ on pro-metastatic behaviours of breast
cancer cells. While TAFIa-WT was unable to inhibit pro-metastatic behaviours in breast
cancer cells, we did observe a significant decrease in pro-metastatic behaviours upon
treatment with TAFIa-CIIYQ (Fig. 2.3, 2.4, 2.6). These results indicate that sustained
TAFIa activity over the time course of the experiment is necessary to TAFIa to effectively
inhibit metastatic behaviours. Therefore, increased stability of TAFIa in vivo may
potentially influence its anti-metastatic function. This is important as an SNP within the
population, yields a variant of TAFIa (Ile325) with increased stability. In keeping with this
idea, we did examine the effect of the Ile325 variant on pro-metastatic behaviours,
however, like with TAFIa-WT, we did not observe an anti-metastatic effect. Our results
suggest that prolonged presence of TAFIa in breast cancer inhibits metastatic potential, and
therefore increasing activation or stability of TAFIa may promote its anti-metastatic
behaviour.

196

By contrast, the dramatic differences in stability between TAFIa-WT and TAFIaCIIYQ did not alter their effects on angiogenic potential in HUVECs. Wild-type TAFIa
was equally able to significantly decrease pro-angiogenic behaviours, such as cell invasion,
migration, tube formation and DQ-collagen IV proteolysis (Fig. 3.1, 3.4, 3.5, 3.6). This
could be due to the presence of heparin in the HUVEC media, which increases the stability
of TAFIa [29]. Importantly, the endothelium is rich in proteoglycans. Specifically,
endothelial cells express glycoproteins and proteoglycans which covered the luminal
surface of the cells, to form a structure called the glycocalyx [32]. Therefore, the large
presence of proteoglycans on the endothelial cell surface may contribute to stabilization of
TAFIa. It is also possible that the effects of TAFIa early in the time course ultimately
affect the outcome of the experiment, which may not be the case for the analogous
experiments using the breast cancer cell lines. Further experiments will be needed to assess
the contribution of glycosaminoglycans to the stability of TAFIa in endothelial cells and
breast cancer cells. Use of a variant of TAFIa with low or no affinity to heparin will give
insight into whether stabilization of TAFIa by heparin does in fact enhance anti-metastatic
and anti-angiogenic functions of TAFIa.

5.4 Regulation of Plasminogen Activation by TAFIa
The importance of the plasminogen activation system in cancer progression has
been well-documented. The metastatic cell line MDA-MB-231 has been shown to bind and
activate plasminogen more readily than the non-metastatic MCF-7 cell line [33]. This is
due to an increased abundance of plasminogen receptors on the surface of these cells.
Endothelial cells have also been identified to have a high capacity for plasminogen binding
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on the cell surface [34]. TAFIa functions as an inhibitor of plasminogen activation, through
cleavage of carboxyl-terminal lysine residues on fibrin and plasminogen receptors [35, 36].
We have directly demonstrated that TAFIa is able to attenuate plasminogen activation on
the surface of breast cancer cell lines, SUM149 and MDA-MB-231, and on HUVECs (Fig.
2.2, 3.7). However, we do not know if plasmin activity itself was altered during our in vitro
experiments. This is a difficult question to address as quantities of active enzyme are
usually maintained at very low levels in biological systems due to the excess of zymogen
and of specific inhibitors. Hence overcoming limits of detection using substrate assays is a
significant technical hurdle. Indeed, in our zymograms for MMPs, we were not able to
detect any active (cleaved) MMPs (Fig 3.8), while the DQ-collagen cleavage assays clearly
showed the presence of collagenase activity in this milieu (Fig. 2.6, 3.5, 3.6).
Binding of Glu-plasminogen to plasminogen receptors gives plasminogen a more
open conformation, making it more available to plasmin for cleavage into Lys-plasminogen
[37-39]. This suggests that, by inhibiting plasminogen binding to plasminogen receptors,
TAFIa inhibits conversion of Glu-plasminogen to Lys-plasminogen. An important
characteristic of many cancers is overexpression of uPAR, which is important in
accelerating plasminogen activation on the cell surface [40]. Binding of pro-uPA to uPAR
promotes activation of uPA by plasmin, which is important for positive feedback
mechanism in plasminogen activation. Given that TAFIa inhibits plasmin formation, this
suggests that TAFIa is also able to decrease uPA activation in breast cancer, which would
inhibit conversion of both Glu-plasminogen and Lys-plasminogen to Glu-plasmin and Lysplasmin, respectively. Therefore, through cleavage of plasminogen receptors, TAFIa is
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able to inhibit the positive feedback associated with acceleration of plasminogen activation,
which attenuates plasmin formation on the cell surface.
The ability of TAFIa to inhibit uPA activation may also affect uPA-uPAR
signaling. This signaling complex promotes cell motility through interaction with integrins
on the cell surface [41]. Additionally, uPA-uPAR induces expression of pro-MMPs which
facilitate ECM degradation [42, 43]. Evaluation of the effect of TAFIa on uPA-uPAR
signaling is an important future goal.
As a basic carboxypeptidase, TAFIa targets carboxyl-terminal lysine residues on
plasminogen receptors and therefore any plasminogen receptor with a carboxyl-terminal
lysine residue is a potential substrate for TAFIa. α-Enolase, S100A10 and cytokeratin 8 are
plasminogen receptors with carboxyl-terminal lysine residues [44]. They have been shown
to be overexpressed in breast cancer tissue, and are therefore likely targets for TAFIa in
breast cancer [45, 46]. Annexin II is an additional plasminogen receptor overexpressed in
breast cancer [47]. Annexin II can be cleaved to expose a carboxyl-terminal lysine residue,
which would result in it becoming a substrate for TAFIa [44]. Additionally, Annexin II can
form a heterotetramer with S100A10, increasing its susceptibility to cleavage by TAFIa
[48]. Therefore, there are several plasminogen receptors that are targets of TAFIa on breast
cancer cells.
Stromal cells also express plasminogen receptors that can contribute to
plasminogen activation in the tumour microenvironment. Plasminogen receptors such as
Annexin II, Histone 2B and S100A10 are found on endothelial cells and have been shown
to bind plasminogen and accelerate its activation [49, 50]. We have demonstrated that
TAFIa is able to attenuate plasminogen activation on the surface of HUVECs (Fig. 3.7).

199

Macrophages have also been shown to express plasminogen receptors, including Plg-RKT
and Histone 2B [50, 51]. Both of these receptors possess carboxyl-terminal lysine residues
and

represent

potential

TAFIa

substrates

on

macrophages.

In

the

tumour

microenvironment, it is expected that TAFIa cleaves carboxyl-terminal lysine residues
from plasminogen receptors on breast cancer cells, endothelial cells and macrophages,
thereby inhibiting plasminogen activation.

5.5 Role of TAFIa in Breast Cancer Metastasis
The metastatic cascade is a multi-step process that includes: (i) local invasion; (ii)
intravasation; (iii) survival of the circulation; (iv) extravasation; and (v) colonization [52].
Tumour angiogenesis is important in facilitating cancer progression and promoting the
metastatic process [53, 54]. Both tumour angiogenesis and cancer metastasis require
proteolytic activity during multiple steps of these processes [55, 56].
Local invasion requires proteolytic events that degrade the ECM and basement
membrane, facilitating cell invasion and migration into the surrounding stroma [57]. In
Chapter 2, we examined the effect of TAFIa on pro-metastatic behaviours, namely local
invasion, in breast cancer cells. We demonstrated that TAFIa is able to inhibit DQ-collagen
IV proteolysis, cell invasion and cell migration in MDA-MB-231 cells, by attenuating
plasminogen activation. We have used DQ-collagen IV proteolysis as a measure of ECM
degradation. In addition to collagen IV, plasmin and MMPs have been shown to cleave
other basement membrane and ECM components, including laminin, fibronectin and
vitronectin. This suggests that the inhibitory effects of TAFIa on plasmin formation prevent
cleavage of other ECM components that are targets of plasmin and MMPs. Therefore, it
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would be advantageous to assess the effect of TAFIa on other components of the basement
membrane. Importantly, in the DQ-collagen proteolysis assay cells form three-dimensional
(3D) spheroids because they are grown on BME. Therefore, this assay better mimics in
vivo conditions, since cells form 3D structures and are morphologically distinct from cells
grown in a monolayer [58]. Gene expression profiles differ in cell lines grown in 3D culture
compared to 2D cultures. In general, cells grown in 3D have increased expression of genes
involved in cell invasion, migration and angiogenesis [59]. Given that use of 3D cultures
are more representative of in vivo conditions, the ability of TAFIa to inhibit DQ-collagen
IV proteolysis in 3D culture indicates that TAFIa can mediate proteolytic events in an
environment that better mimics in vivo conditions.
TAFIa may also inhibit local invasion and metastasis by targeting EMT. EMT is an
important phenomenon, in which cells undergo genotypic and phenotypic changes, which
facilitates cell motility [60]. This process is regulated by several mediators including TGFβ1, which is known to be activated by plasmin [61]. Therefore, attenuation of plasmin
formation by TAFIa may inhibit EMT by preventing TGF-β1 activation. Further studies
will be needed to assess the direct effect of TAFIa on EMT, by specifically assessing
whether TAFIa can inhibit TGF-β1-mediated EMT. This can be assessed by examining
expression and localization of E-cadherin and N-cadherin, as well as actin cytoskeletal
remodelling, all of which change during EMT. Furthermore, TM has been shown to inhibit
EMT and therefore future experiment could focus on whether thrombin/TM-mediated
activation of TAFI affects TM [62]. Use of mutants of TM, that support or do not support
TAFIa activation, as in Chapter 3, will give insight into whether increased activation of
TAFI can hinder EMT.

Together, the ability of TAFIa to inhibit DQ-collagen IV
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degradation, cell invasion and cell migration of MDA-MB-231 cells, suggests a role for
TAFIa in mediating initial stages of the metastatic cascade, namely local invasion.
Results obtained in Chapter 3 also point to roles of TAFIa in cancer metastasis
beyond local invasion. Inhibition of TAFIa, using PTCI, resulted in an increase in proMMP-2 and pro-MMP-9 abundance in breast cancer cells (Fig. 3.8). This points to a role
for TAFIa in mediating pro-MMP-2 and pro-MMP-9 secretion, however our studies
assessed the effect of TAFIa inhibition. Therefore, future experiments should assess the
direct effect of TAFIa on secretion of these proteins. It would be beneficial to determine
extent of activation using a more sensitive activity assay. Additionally, we should assess
the mechanisms influencing TAFIa-mediated inhibition of pro-MMP-2 and pro-MMP-9
secretion. The mechanism could involve uPA-uPAR signalling, as interaction of uPAuPAR with α5β1 has been shown to induce pro-MMP-1 and pro-MMP-9 expression in lung
cancer, by signalling through the ERK pathway [42, 43]. It would therefore be important
to also assess the effect of TAFIa on mRNA abundance to determine if TAFIa can
effectively inhibit pro-MMP expression. MMPs are important for the intravasation step
during the metastatic process [63]. MMPs are responsible for cleaving cell-junctions to
promote transendothelial migration and ultimately intravasation. Studies have also found
that MMPs are important for the process of extravasation. Proteolytic events facilitate
transendothelial migration from the blood vessel and promote degradation of the basement
membrane, allowing the cell to enter the adjacent stroma [64]. Additionally, the
plasminogen activation system plays an important role in intravasation, as inhibition of
plasmin activity significantly hinders this process [65, 66]. Therefore, the ability of TAFIa
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to inhibit plasminogen activation and mediate pro-MMP-2 and pro-MMP-9 secretion
indicates potential roles for TAFIa in inhibiting cancer cell intravasation and extravasation.
Colonization is a key step within the metastatic cascade. To allow for propagation
of a metastatic lesion, environment factors need to support metastatic growth. The effects
of TAFIa on proteolysis may also influence cancer colonization. Kroger and coworkers
found that treatment of mice with soluble uPAR resulted in scavenging for uPA, which
decreased breast cancer metastasis to the lung by inhibiting plasminogen activation [67].
Furthermore, MMP inhibitors reduced lung colonization following intravenous injections
of melanoma cells in mice [68]. The underlying mechanisms that are responsible for
increased colonization with the plasminogen activation system and MMPs are largely
unknown. It is likely that ECM degradation, facilitated by these proteases, promotes
angiogenesis at the metastatic site. Additionally, ECM degradation at the metastatic site,
similar to the primary site, releases sequestered growth factors, which promote cell growth
and proliferation at the new organ [69]. Together, this suggests that TAFIa may reduce
colonization, by inhibiting proteolytic events that promote the process.
Our in vitro studies are subject to the limitation that they do not consider tumour
cell interactions with the stroma, with the exception of endothelial cells. The influences of
the stromal cells have been documented in many studies [70]. Fibroblasts and TAMs
release chemokines and cytokines that promote various aspects of cancer progression,
including tumour growth and metastasis [70]. It would therefore be necessary to determine
the effect of TAFIa on stromal interactions, specifically assessing role of fibroblasts and
TAMs.

203

We have demonstrated a role for TAFIa in mediating breast cancer metastatic
behaviours, however further experiments need to be done. Future experiments should be
aimed at assessing the role of TAFIa in breast cancer metastasis in vivo. It will be necessary
to examine the effect of TAFIa using animal models of metastasis. Syngeneic mouse
models allow for assessment of metastasis in mice with an intact immune system [71]. This
will allow usage of TAFI-deficient mice to understand the importance of the presence of
TAFI in the tumour microenvironment. Additionally, human breast cancer cell lines
implanted in immunocompromised mice are able to colonize bone, liver, lung and brain,
and represent a model for assessing metastasis in vivo [71]. Zebrafish have also been used
to assess metastasis in vivo [72]. Use of zebrafish is advantageous due to experiments being
short, inexpensive and high throughput. Zebrafish embryos are transparent, which allows
for easy visualization of cancer cells when labeled with a fluorescent dye and also allows
for real-time detection. In addition, experiments can be carried out without a compromised
immune system, as in many traditional in vivo cancer models. Finally, zebrafish expressed
orthologues corresponding to TAFI, TM, and prothrombin and therefore represent a viable
method to examine anti-metastatic potential of TAFIa.

5.6 Role of TAFIa in Modulating Tumour Angiogenesis
In Chapter 3, we examined the effects of TAFIa on pro-angiogenic behaviours in
endothelial cells and in co-culture systems with endothelial cells and breast cancer cells.
TAFIa has been previously shown to inhibit tube formation on a fibrin matrix, through
inhibition of plasminogen activation [73]. In the current study we demonstrate the ability
of TAFIa to inhibit tube formation on BME. TAFIa was able to decrease tube formation
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both in monoculture and in co-culture systems with breast cancer cells. Importantly, our in
vitro tube formation assays utilized BME to mimic in vivo conditions, in which endothelial
cells are able to proliferate, migration and differentiate to form tube-like structures.
However, cancer cells play an important role in facilitating tumour angiogenesis through
paracrine signaling [74]. Secretion of pro-angiogenic factors by cancer cells, such as
VEGF, promotes endothelial cell activation and subsequent angiogenesis [74]. Therefore,
our co-culture experiments allowed for examination of tube formation in an environment
that better mimic in vivo tumour angiogenesis. Endothelial cells formed tube-like networks
that connected individual breast cancer spheroids grown on BME, which indicates that the
breast cancer cells are able to modulate the angiogenic behaviours of the endothelial cells.
However, we did not observe any differences in the effects of TAFIa in co-culture
experiments when compared to monoculture experiments. It could be that the high levels
of TM on the endothelial cells dominate in this system and therefore the ability of the breast
cancer cells to promote TAFI activation is inferior to promotion of activation by the
endothelial cells. This could be examined by knockdown of TM expression in endothelial
cells to determine whether the breast cancer cells alone can promote TAFI activation to
inhibit tube formation.
ECM degradation facilitates endothelial cell invasion into the surrounding stroma
during angiogenesis. We observed inhibitory effects of TAFIa on VEGF-mediated cell
invasion and migration, as well as DQ-collagen IV proteolysis. Endothelial cells require
angiogenic stimulation, such as VEGF to promote cell invasion and migration. VEGF is a
potent activator of angiogenesis, inducing endothelial cell migration and proliferation and
was therefore used to induce cell invasion and migration. These results indicate a potential
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role for TAFIa in mediating ECM degradation and subsequent cell invasion required during
the process of angiogenesis. We also used co-culture experiments to demonstrate that
TAFIa is able to inhibit DQ-collagen IV proteolysis in an environment that better mimics
tumour angiogenesis. Furthermore, we observed a decrease in VEGF-mediated migration
of endothelial cells, which is an important in vessel sprouting. Overall, we demonstrated
that TAFIa is able to inhibit pro-angiogenic behaviours, although further studies are needed
to assess whether TAFIa can exhibit similar functions in vivo. The Matrigel plug assay is
considered one of the best methods to screen pro-angiogenic and anti-angiogenic factors
[75]. Additionally, the chick choriollantoic membrane (CAM) assay is an effective method
to study tumour angiogenesis, as cross-species xenografts are tolerated [76]. This would
allow xenotransplantation of human breast cancer cells to assess tumour angiogenesis.
Zebrafish are also used to study angiogenesis in vivo. Transparency of zebrafish embryos
allow for convenient visualization of blood vessel formation. Use of animal models will
give insight into the ability of TAFIa to exhibit anti-angiogenic functions in vivo.

5.7 Alternative Mechanisms of Inhibition of Metastasis by TAFIa
In addition to cleaving plasminogen receptors, TAFIa cleaves carboxyl-terminal
lysine and arginine residues from inflammatory mediators, including thrombin-cleaved
osteopontin, bradykinin, anaphylatoxins C3a and C5a and plasmin-cleaved chemerin. In
addition to their roles in inflammation, these TAFIa substrates have also been shown to be
involved in cancer.
Osteopontin levels have been correlated with an invasive phenotype in several
cancer types, including breast cancer [77-80]. Studies have demonstrated that osteopontin
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is functionally important in cancer progression and metastasis. Specifically, osteopontin
upregulates expression of uPA, pro-MMP-2 and pro-MMP-9, increasing matrix
degradation, cell invasion and cell migration [81-83]. Thrombin has been shown to cleave
osteopontin, resulting in exposure of a carboxyl-terminal lysine residue. This form of
osteopontin has also been found to promote cell invasion and metastasis [84]. Furthermore,
overexpression of osteopontin was found to induce angiogenesis in glioma [85]. Liaw and
coworkers demonstrated that osteopontin stimulates angiogenesis through binding to αvβ3
integrin [86]. Interaction of osteopontin with this integrin has been shown to induce VEGF
expression, ultimately stimulating angiogenesis [87]. However, Beausoleil and coworkers
observed increased metastatic lesions in mice upon deletion of the thrombin-cleavage
domain of osteopontin [88]. Thrombin-cleaved osteopontin possesses a carboxyl-terminal
lysine and therefore can be cleaved by TAFIa. It is possible that cleavage by TAFIa
represents a mechanism of regulation of osteopontin function on the cell surface and
therefore removal of the thrombin-cleavage domain would result in the inability of TAFIa
to regulate the invasive and metastatic functions of osteopontin.
Bradykinin activates several signaling pathways involved in cancers, specifically
MAPK, ERK, PKC and NF-κB [89-92]. Bradykinin has been shown to increase prostate
cancer cell migration and expression of pro-MMP-9 [93]. Montana and coworkers reported
that bradykinin also promotes cell invasion in glioma [94]. They found that bradykinin
upregulates IL-6 expression, which has been previous shown to increase cancer cell
invasion and metastasis [95-97]. Yu et al. found that bradykinin was able to stimulate
VEGF expression in prostate cancer cells and also promote endothelial tube formation [98].
Together these studies suggest functions for bradykinin in cancer metastasis and
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angiogenesis. Basic carboxypeptidase cleavage of bradykinin has been found to inactivate
this ligand and therefore illustrates a method of regulation [99]. TAFIa has been shown to
inactivate bradykinin by cleaving its carboxyl-terminal lysine residue [100]. Therefore, in
addition to regulating plasminogen activation, TAFIa may regulate bradykinin in the
tumour microenvironment. This would result in a decrease in bradykinin-mediated cell
invasion and migration.
Studies have shown that the complement system is active in cancer cells, both in
vitro and in vivo [101, 102]. Nitta and coworkers have demonstrated that C5a enhances
cancer cell invasion and promotes secretion of pro-MMPs in cancer cells [103]. C5a has
also been found to stimulate MMP production in macrophages [104]. Piao et al. reported
that colon cancer cells secrete elevated levels of C5a and that blocking of C5a decreased
hepatic metastases of colon cancer in mice [105]. C5a also promotes endothelial cell
migration, proliferation and vessel formation, both in vitro and in vivo [106]. Both C3a and
C5a have been shown to induce VEGF expression, which stimulated neovascularization
[107]. Inactivation of complement factors by TAFIa may therefore decrease complementmediated metastatic and angiogenic functions.
Future experiments should also be aimed at identifying additional mechanisms of
TAFIa function in cancer metastasis. Experiments should be aimed at examining the role
of TAFIa in mediating the pro-metastatic and pro-angiogenic effect of osteopontin,
bradykinin and anaphylatoxin C5a. It is reasonable to expect that these non-plasminogen
activation-mediated events are occurring in our in vitro system and may have contributed
to the effects observed in the current study. It would therefore be important to discern the
contribution of these mechanisms on the anti-metastatic and anti-angiogenic effects
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observed by TAFIa compared to the effects-mediated by inhibition of plasminogen
activation. These contributions could be examined in a system deficient of plasminogen,
through depletion of plasminogen from serum. Metastatic and angiogenic assays can be
carried out using plasminogen-deficient serum to assess whether TAFIa can inhibit
metastatic and angiogenic behaviours independent of plasminogen activation, in vitro.

5.8 Therapeutic Potential of the TAFI pathway
The work in this thesis has, for the first time, identified TAFIa as a potential antimetastatic factor in breast cancer. We have demonstrated that attenuating plasminogen
activation by targeting plasminogen receptors, which may be the mechanism by which
TAFIa inhibits metastatic and angiogenic behaviours. Given that plasminogen receptors
are overexpressed in a number of cancers, they represent a vital therapeutic target. Plasmin
formation is upstream of MMP activation and therefore targeting plasminogen activation
may have more beneficial clinical outcomes than trials with MMP inhibitors.
Targeting the TAFI pathway in the breast cancer microenvironment either by
promoting activation of TAFI, or by increasing TAFIa stability may represent therapeutic
strategies. Promoting TAFI activation can be accomplished using a variant of TM that only
supports activation of TAFI and not of protein C. It would be advantageous to use TM as
a therapeutic, given that soluble TM (Solulin) is currently in clinical trials for treatment as
an anti-coagulant. A phase I clinical trial indicated that Solulin is safe and tolerated with
no reports of bleeding complications [108]. Use of TM as a therapeutic may also be
beneficial with regards to thrombin in the tumour microenvironment. Given that thrombin
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has metastatic functions, TM may act as a thrombin sink and change its substrate specificity
away from its metastatic functions.
Increasing the stability of TAFIa may also be a beneficial therapeutic strategy. We
have shown that increasing the stability of TAFIa resulted in inhibition of pro-metastatic
behaviours in breast cancer cell lines. A stabilizing agent such as an antibody that binds to
the dynamic flap, which prolongs the activity of TAFIa, may have similar inhibitory
effects. Whether utilizing a TAFIa stabilizing agent or a variant of soluble TM, it would be
necessary to establish localized therapies to avoid side effects related to bleeding or
thrombosis. It is well known that agents introduced directly into the vascular system do
preferentially accumulate at tumour sites due to the leaky nature of the tumour vasculature
[63]. Alternatively, liposomes are an attractive method for providing localized therapies
[109]. Use of liposomes conjugated to a selective marker enables drug delivery directly to
the tumour site and may represent a method to provide localized TAFIa treatment in breast
cancer patients. Taken together, we have demonstrated that TAFIa plays an inhibitory role
in breast cancer metastatic and angiogenic behaviours and this pathway may represent a
therapeutic strategy.

5.9 Concluding Remarks
The process of cancer metastasis relies on elaborate interactions within the tumour
microenvironment. Proteolytic events mediated by cancer cells, stromal cells and the ECM
promote the metastatic process. Specifically, proteases such as plasmin and MMPs,
stimulate cancer progression by facilitating ECM degradation, cell invasion and ultimately
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cancer metastasis. The ability to control and down-regulate these proteolytic events may
represent a therapeutic strategy to inhibit the metastatic process. In this current study we
have demonstrated, for the first time, a direct effect of TAFIa in inhibiting metastatic and
angiogenic behaviours in breast cancer, in vitro. We have shown that TAFIa regulating
plasminogen activation on the cell surface, in vitro. TAFIa is able to inhibit breast cancer
and endothelial cell invasion, migration and ECM proteolysis, likely through inhibition of
plasminogen activation. Our studies have also found that TAFIa can inhibit endothelial
tube formation, which is an indicator of angiogenic potential. Taken together, our results
have demonstrated a role for TAFIa in regulating metastatic and angiogenic processes in
vitro. Further studies will be needed to assess the role of TAFIa on metastasis and
angiogenesis in vivo. TAFIa may represent a novel therapeutic strategy aimed at inhibiting
breast cancer metastasis and tumour angiogenesis.
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